https://trial.medpath.com/news/dcd6a388c58e030c/alvotech-and-teva-secure-u-s-settlement-for-eylea-biosimilar-avt06-launch-in-q4-2026 2025-12-19T13:30:38+00:00 hourly 0.9 https://trial.medpath.com/news/ea975c12b19f83cb/ema-committee-recommends-vueway-for-pediatric-patients-under-2-years-addressing-critical-unmet-need-in-neonatal-imaging 2025-12-19T13:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/659af8290db78b4d/university-of-st-andrews-develops-revolutionary-method-to-convert-plastic-waste-into-cancer-drug-building-blocks 2025-12-19T13:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/dad6ccc196159fc5/athira-pharma-acquires-late-stage-breast-cancer-drug-lasofoxifene-in-90-million-deal 2025-12-19T09:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/dbdb6fd47fb0c20a/syneron-bio-secures-nearly-100m-series-a-funding-for-macrocyclic-peptide-platform 2025-12-19T09:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/476755e39ebe9554/rezubio-secures-20-million-series-a-to-advance-novel-membrane-anchored-drug-platform-for-obesity-and-diabetes 2025-12-19T09:30:26+00:00 hourly 0.9 https://trial.medpath.com/news/f8d0087835f4d9a6/ipsen-s-phase-ii-falkon-trial-for-ultra-rare-bone-disease-fop-fails-to-meet-primary-endpoint 2025-12-19T09:29:46+00:00 hourly 0.9 https://trial.medpath.com/news/0324bb4461589e48/fda-approves-subcutaneous-pembrolizumab-formulation-developed-through-space-station-research 2025-12-19T09:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/a88c82e615ded887/northwestern-s-nu-9-drug-prevents-alzheimer-s-pathology-in-pre-symptomatic-animal-model 2025-12-19T09:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/631490a6e24a24d9/home-based-gamma-brain-stimulation-shows-promise-for-early-alzheimer-s-disease-in-randomized-trial 2025-12-19T05:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/f9bf006f161353c2/trump-executive-order-accelerates-medical-cannabis-research-as-mmj-international-holdings-prepares-fda-ready-pharmaceutical-formulations 2025-12-19T05:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/a41a28cca4a22558/telo-genomics-launches-blood-based-mrd-study-for-multiple-myeloma-with-university-of-athens 2025-12-19T05:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/4173c70040595741/meiji-seika-pharma-partners-with-mbc-biolabs-to-accelerate-drug-discovery-innovation 2025-12-19T05:28:43+00:00 hourly 0.9 https://trial.medpath.com/news/5649628a3277588a/clinical-research-embraces-patient-centric-innovation-through-agile-cro-partnerships-and-digital-transformation 2025-12-19T01:51:59+00:00 hourly 0.9 https://trial.medpath.com/news/f1cc5e271e1597b4/annovis-bio-launches-36-month-open-label-extension-study-for-buntanetap-in-parkinson-s-disease 2025-12-19T01:34:41+00:00 hourly 0.9 https://trial.medpath.com/news/6bf184ee86d5fa02/neuraworx-secures-oversubscribed-seed-funding-to-advance-first-in-class-cerebrovascular-pacing-system-for-cns-disorders 2025-12-19T01:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/a64a199a131dc7ed/gsk-partners-with-camp4-therapeutics-in-440m-rna-deal-for-neurodegenerative-and-kidney-diseases 2025-12-19T01:32:44+00:00 hourly 0.9 https://trial.medpath.com/news/6dbd5e2979736279/galapagos-tyk2-inhibitor-glpg3667-meets-primary-endpoint-in-dermatomyositis-phase-3-enabling-study 2025-12-19T01:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/b2edce5fee456b4b/cartesian-therapeutics-appoints-car-t-pioneer-adrian-bot-to-board-of-directors 2025-12-19T01:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/4cc43521115046f5/larimar-therapeutics-advances-toward-q2-2026-bla-submission-for-friedreich-s-ataxia-treatment 2025-12-19T01:30:47+00:00 hourly 0.9 https://trial.medpath.com/news/699251d9936150f2/neoadjuvant-radiation-therapy-shows-promise-for-high-risk-renal-cell-carcinoma-with-vascular-invasion 2025-12-19T01:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/903b43a861aa2c5e/cdc-awards-1-6-million-grant-for-controversial-hepatitis-b-vaccine-study-in-guinea-bissau 2025-12-19T01:29:13+00:00 hourly 0.9 https://trial.medpath.com/news/59ea1c4857926f3b/abbott-s-amplatzer-piccolo-delivery-system-receives-fda-clearance-for-treating-heart-defects-in-premature-infants 2025-12-19T01:28:33+00:00 hourly 0.9 https://trial.medpath.com/news/055867be990a9d83/werewolf-therapeutics-reports-promising-clinical-data-for-cancer-immunotherapies-advances-t-cell-engager-pipeline 2025-12-18T21:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/2b27062ee703078f/oncozenge-submits-phase-iii-clinical-trial-application-for-bupizenge-in-cancer-related-oral-pain 2025-12-18T21:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/647327edc92a2753/minaris-and-cell-and-gene-therapy-catapult-form-strategic-partnership-to-advance-viral-vector-manufacturing 2025-12-18T21:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/6da13578a9529699/ocugen-ceo-s-9-36-million-performance-award-tied-to-gene-therapy-regulatory-milestones 2025-12-18T21:31:10+00:00 hourly 0.9 https://trial.medpath.com/news/3a3f226d85177ec6/almirall-advances-lad603-from-phase-1-completion-to-phase-2-trial-for-severe-alopecia-areata 2025-12-18T21:30:33+00:00 hourly 0.9 https://trial.medpath.com/news/19fabb5ce0d2cd2f/fda-approves-gsk-s-exdensur-as-first-ultra-long-acting-biologic-for-severe-asthma 2025-12-18T21:29:30+00:00 hourly 0.9 https://trial.medpath.com/news/2f7c74ce650985d6/cocrystal-pharma-advances-first-oral-norovirus-antiviral-cdi-988-into-phase-1b-human-challenge-study 2025-12-18T17:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/696f8317ac329f55/cybin-transitions-to-nasdaq-with-new-help-ticker-as-helus-pharma-advancing-phase-3-depression-treatment 2025-12-18T17:47:35+00:00 hourly 0.9 https://trial.medpath.com/news/b8ac7b076fe41893/exelixis-and-natera-launch-phase-3-trial-testing-zanzalintinib-in-mrd-positive-colorectal-cancer-patients 2025-12-18T17:44:20+00:00 hourly 0.9 https://trial.medpath.com/news/7a4ea7625a895902/actinogen-completes-enrollment-in-pivotal-alzheimer-s-trial-with-247-participants 2025-12-18T17:40:53+00:00 hourly 0.9 https://trial.medpath.com/news/0b2576c552c9f3aa/aztreonam-avibactam-shows-noninferior-efficacy-against-carbapenem-resistant-infections-in-open-label-trial 2025-12-18T17:40:24+00:00 hourly 0.9 https://trial.medpath.com/news/f21d92c3c5be903c/novel-zwitterionic-lipids-reduce-mrna-vaccine-inflammation-while-boosting-antigen-expression 2025-12-18T17:38:49+00:00 hourly 0.9 https://trial.medpath.com/news/23c75c978caa6d21/very-low-dose-oral-immunotherapy-shows-promise-for-children-with-multiple-food-allergies 2025-12-18T17:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/1e6be6ba843cc15e/bd-partners-with-penn-institute-to-advance-immunotherapy-research-through-high-parameter-flow-cytometry 2025-12-18T17:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/38f302eea74a3fe9/moderna-secures-54-3-million-cepi-funding-for-first-mrna-bird-flu-vaccine-pivotal-trial 2025-12-18T17:37:48+00:00 hourly 0.9 https://trial.medpath.com/news/98b63bf106c72818/phase-2-trial-of-azathioprine-fails-to-meet-primary-endpoint-in-early-parkinson-s-disease 2025-12-18T17:37:45+00:00 hourly 0.9 https://trial.medpath.com/news/5c5ae13c8b025f96/salarius-pharmaceuticals-rebrands-as-decoy-therapeutics-pivots-to-ai-driven-antiviral-platform 2025-12-18T17:36:56+00:00 hourly 0.9 https://trial.medpath.com/news/33ffb8194ff0360b/liom-achieves-breakthrough-in-non-invasive-glucose-monitoring-technology-extends-series-a-to-chf-38-million 2025-12-18T17:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/12c8200bfa85e061/pulmatrix-and-cullgen-mutually-waive-no-solicitation-clause-while-awaiting-chinese-regulatory-approval-for-merger 2025-12-18T17:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/5971bf6cea46338d/ucla-receives-7-5-million-grant-to-lead-international-autism-clinical-trials-network 2025-12-18T17:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/ba4be34bd2959942/pyxis-oncology-reports-promising-phase-1-results-for-novel-adc-micvo-in-head-and-neck-cancer 2025-12-18T17:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/ce0f5a28a2b8ebc8/astrazeneca-india-receives-cdsco-approval-for-datopotamab-deruxtecan-in-hr-positive-her2-negative-breast-cancer 2025-12-18T17:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/3d10c811f901df09/takeda-s-zasocitinib-achieves-phase-3-success-in-moderate-to-severe-plaque-psoriasis 2025-12-18T17:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/453cc43297f63ffc/avadel-completes-enrollment-in-phase-3-trial-of-lumryz-for-idiopathic-hypersomnia 2025-12-18T17:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/b2b0b7bca2d0d10f/athira-pharma-secures-236-million-financing-and-exclusive-rights-to-lasofoxifene-for-esr1-mutant-metastatic-breast-cancer 2025-12-18T17:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/86ea59d30d91d6df/viatris-achieves-four-major-regulatory-milestones-across-diverse-pipeline-including-gene-therapy-and-generic-approvals 2025-12-18T17:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/e4aa59331c0ec776/memo-therapeutics-potravitug-receives-eu-orphan-designation-for-bk-polyomavirus-infection-in-kidney-transplant-patients 2025-12-18T17:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/1ebc15c02d53b8fe/century-health-and-tessel-biosciences-partner-to-leverage-ai-curated-real-world-data-for-copd-drug-development 2025-12-18T17:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/451dffc281b545e7/havih-envirosciences-partners-with-andhra-pradesh-government-to-establish-bsl-4-anti-infective-drug-development-facility 2025-12-18T17:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/65810ea7d9f39106/lixte-biotechnology-raises-4-3-million-to-advance-cancer-treatment-development 2025-12-18T17:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/751e51c1d590cb34/tislelizumab-plus-chemoradiotherapy-shows-superior-response-rates-in-gastric-cancer-trial 2025-12-18T17:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/64af87fda87c4d5e/beone-medicines-receives-fda-fast-track-designation-for-novel-bispecific-antibody-in-hepatocellular-carcinoma 2025-12-18T17:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/4aa0c0894479f979/fda-approves-ind-and-grants-fast-track-designation-for-cbi-1214-t-cell-engager-in-colorectal-cancer 2025-12-18T17:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/6a9b93fd07fb280c/fda-approves-expanded-indication-for-johnson-johnson-s-trufill-n-bca-system-in-chronic-subdural-hematoma-treatment 2025-12-18T17:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/f829cf4ef4c5646a/syremis-therapeutics-launches-with-165m-series-a-to-advance-novel-mental-health-therapies 2025-12-18T17:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/0a5b4553c5c7a7a5/usc-launches-phase-2b-trial-of-stem-cell-retinal-implant-for-advanced-dry-age-related-macular-degeneration 2025-12-18T13:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/091c529914210927/forx-therapeutics-secures-50m-series-a-to-advance-parg-inhibitor-for-parp-resistant-cancers 2025-12-18T09:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/9b2a79cfc44f7f52/sequana-medical-secures-key-u-s-patent-for-dsr-heart-failure-therapy 2025-12-18T09:28:42+00:00 hourly 0.9 https://trial.medpath.com/news/27c57cebe0559a13/cormedix-reports-72-reduction-in-bloodstream-infections-with-defencath-in-real-world-study 2025-12-18T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/69055d72d4481086/circle-pharma-nominates-cid-165-as-second-oncology-program-targeting-cyclin-d1-driven-cancers 2025-12-18T05:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/16caf27e67789eca/abivax-presents-breakthrough-anti-fibrotic-data-for-obefazimod-at-ecco-2026-alongside-comprehensive-ulcerative-colitis-results 2025-12-18T05:30:01+00:00 hourly 0.9 https://trial.medpath.com/news/80bc85dc7e53d565/prism-biolab-and-talus-bioscience-partner-to-target-previously-undruggable-protein-interactions-using-ai-guided-drug-discovery 2025-12-18T05:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/cbcee87898bb9930/processa-pharmaceuticals-reports-promising-phase-2-data-for-ngc-cap-in-advanced-breast-cancer 2025-12-18T05:29:39+00:00 hourly 0.9 https://trial.medpath.com/news/ae392c9857b31f3c/alphamab-oncology-receives-ind-approval-for-first-in-class-pd-l1-vegfr2-bispecific-adc-jskn027 2025-12-18T05:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/61cf8640ed65b6ba/tirzepatide-shows-consistent-cardiovascular-benefits-regardless-of-heart-failure-status-in-surpass-cvot-trial 2025-12-18T05:28:51+00:00 hourly 0.9 https://trial.medpath.com/news/5b1f638539d759f8/heart-failure-pipeline-shows-strong-activity-with-70-companies-developing-75-therapeutic-candidates 2025-12-18T05:27:59+00:00 hourly 0.9 https://trial.medpath.com/news/1f2a72fc710b8ad5/trump-signs-executive-order-reclassifying-cannabis-to-schedule-iii-opening-new-pathways-for-medical-research 2025-12-18T05:27:44+00:00 hourly 0.9 https://trial.medpath.com/news/6052d01d6b6228a0/cancervax-advances-universal-cancer-platform-with-successful-nanoparticle-and-smart-mrna-validation 2025-12-18T01:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/e031df7c08b24e5e/personalis-next-personal-test-demonstrates-ultrasensitive-ctdna-monitoring-capabilities-across-multiple-cancer-types 2025-12-18T01:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/1a49297a40c8f0b9/hutchmed-s-hmpl-a251-becomes-first-antibody-targeted-therapy-conjugate-to-enter-clinical-development 2025-12-18T01:27:46+00:00 hourly 0.9 https://trial.medpath.com/news/f3f0cdd61d85609c/university-of-chicago-and-abbvie-extend-cancer-research-partnership-through-2027 2025-12-18T01:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/7c9993a859a50a94/insmed-discontinues-brensocatib-development-in-chronic-rhinosinusitis-after-phase-2b-trial-failure 2025-12-18T01:27:35+00:00 hourly 0.9 https://trial.medpath.com/news/c0e5ac59442d45ef/beyond-air-expands-lungfit-ph-global-reach-to-39-countries-appoints-new-cfo 2025-12-17T21:37:37+00:00 hourly 0.9 https://trial.medpath.com/news/77785f2ca63982ca/ustekinumab-demonstrates-superior-drug-survival-among-biologic-naive-psoriasis-patients-in-large-danish-registry-study 2025-12-17T21:35:46+00:00 hourly 0.9 https://trial.medpath.com/news/0383e527a80f7f2a/alnylam-pharmaceuticals-announces-250m-manufacturing-expansion-to-scale-rna-interference-therapeutics-production 2025-12-17T21:35:25+00:00 hourly 0.9 https://trial.medpath.com/news/f84fa1a6a61b7b27/nuvectis-pharma-initiates-phase-1b-combination-study-of-nxp900-with-osimertinib-for-resistant-egfr-mutated-nsclc 2025-12-17T21:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/94cc43d8b51d31f3/veru-receives-fda-clarity-on-enobosarm-glp-1-combination-for-obesity-treatment-plans-phase-2b-plateau-study 2025-12-17T21:34:07+00:00 hourly 0.9 https://trial.medpath.com/news/a0718c2e4553d28c/mrna-therapy-rejuvenates-aging-immune-systems-in-mice-boosting-vaccine-and-cancer-treatment-response 2025-12-17T21:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/16aa6add34cb3a9b/biovaxys-reports-positive-phase-1-results-for-cancer-immunotherapies-in-breast-and-bladder-cancer 2025-12-17T21:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/c79273f8b0ed032c/dna-nanobots-raises-3-5m-to-advance-non-viral-gene-therapy-platform-using-dna-origami-technology 2025-12-17T21:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/0f3a562bc99b805d/insightec-spins-out-lotus-neuro-to-advance-focused-ultrasound-brain-therapies 2025-12-17T21:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/8d8c195fa7dc3498/fda-approves-ferumoxytol-as-novel-brain-cancer-imaging-agent-after-30-years-of-ohsu-research 2025-12-17T21:28:30+00:00 hourly 0.9 https://trial.medpath.com/news/bd93198dddfa3f88/huxley-medical-receives-fda-clearance-for-ai-powered-central-sleep-apnea-detection-in-home-testing-device 2025-12-17T21:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/df8725ee5d00730a/fda-places-clinical-hold-on-merck-daiichi-sankyo-adc-after-fatal-lung-toxicity-events 2025-12-17T21:27:22+00:00 hourly 0.9 https://trial.medpath.com/news/7086ac6bfa258f18/processa-pharmaceuticals-reports-promising-phase-2-data-for-ngc-cap-combination-in-metastatic-breast-cancer 2025-12-17T17:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/8a0eb817512d78b3/enveda-receives-fda-clearance-for-first-in-class-oral-obesity-therapy-env-308-doses-first-patient-in-phase-1-trial 2025-12-17T17:43:22+00:00 hourly 0.9 https://trial.medpath.com/news/66ea5dafb5e48e07/traws-pharma-s-ratutrelvir-shows-promise-as-ritonavir-free-covid-19-treatment-in-phase-2-trial 2025-12-17T17:42:18+00:00 hourly 0.9 https://trial.medpath.com/news/9b6eb10dc47444d7/university-of-hawaii-researchers-identify-strategy-to-overcome-antibody-drug-conjugate-resistance-in-breast-cancer 2025-12-17T17:39:54+00:00 hourly 0.9 https://trial.medpath.com/news/2edc4fc34905afad/short-course-tb-prevention-shows-promise-in-high-risk-populations-as-global-trials-advance 2025-12-17T17:39:32+00:00 hourly 0.9 https://trial.medpath.com/news/f1c6ac09daeaae51/soligenix-reports-positive-phase-2a-results-for-sgx302-gel-formulation-in-mild-to-moderate-psoriasis 2025-12-17T17:37:30+00:00 hourly 0.9 https://trial.medpath.com/news/0cd9a1168752cc1d/moleculin-s-wp1066-shows-promise-in-first-pediatric-brain-tumor-trial-warrants-phase-2-study 2025-12-17T17:37:25+00:00 hourly 0.9 https://trial.medpath.com/news/21c5acec690e5a5d/fda-accelerated-cancer-drug-approvals-deliver-limited-survival-benefits-despite-20-billion-medicare-investment 2025-12-17T17:36:16+00:00 hourly 0.9 https://trial.medpath.com/news/ebe3d4c1749c1b74/half-dose-chemotherapy-proves-equally-effective-for-elderly-lymphoma-patients-in-real-world-study 2025-12-17T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/ab710f873e5e99b7/decode-age-secures-1-7-million-pre-series-a-funding-to-advance-longevity-science-and-gut-microbiome-research 2025-12-17T17:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/b7c9db9f1b70f187/health-canada-approves-tnkase-for-acute-ischemic-stroke-first-new-stroke-treatment-in-nearly-27-years 2025-12-17T17:35:22+00:00 hourly 0.9 https://trial.medpath.com/news/7d4a4711ce8bed5e/4dmt-reports-positive-phase-1-data-for-gene-therapy-4d-710-in-cystic-fibrosis 2025-12-17T17:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/5dcbda413dda5d62/protalix-and-secarna-partner-to-develop-ai-powered-antisense-therapies-for-rare-kidney-diseases 2025-12-17T17:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/71f97a4ac0b3b472/northstrive-biosciences-advances-ai-driven-drug-discovery-to-phase-iii-for-muscle-preservation-in-obesity-treatment 2025-12-17T17:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/bec0f4408fb13d34/pathmaker-neurosystems-receives-fda-breakthrough-device-designation-for-myoregulator-r-als-treatment 2025-12-17T17:30:54+00:00 hourly 0.9 https://trial.medpath.com/news/04642505b61ea13b/peptinovo-biopharma-achieves-manufacturing-breakthrough-for-vitamin-e-based-cancer-prodrug-platform 2025-12-17T17:30:31+00:00 hourly 0.9 https://trial.medpath.com/news/a174dcf08efbb06a/updated-survival-data-from-flaura2-and-mariposa-trials-reshape-treatment-selection-in-egfr-mutated-advanced-nsclc 2025-12-17T17:28:33+00:00 hourly 0.9 https://trial.medpath.com/news/944adc185c1abe76/cuhk-launches-world-s-first-ai-powered-gut-microbiome-test-for-early-autism-detection 2025-12-17T17:28:04+00:00 hourly 0.9 https://trial.medpath.com/news/30417c140ae0a673/sol-gel-discontinues-sgt-210-development-for-darier-disease-after-phase-1b-trial-fails-to-show-efficacy 2025-12-17T13:35:48+00:00 hourly 0.9 https://trial.medpath.com/news/5a38d185acd012ef/mrm-health-partners-with-netherlands-cancer-institute-to-develop-microbiome-therapies-for-cancer-immunotherapy 2025-12-17T13:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/3646c66ac5449a20/japanese-tree-frog-gut-bacterium-achieves-complete-tumor-elimination-in-mice-with-single-dose 2025-12-17T13:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/01ae1256ca88b523/asg-s-beta1-becomes-first-inhaled-erectile-dysfunction-therapy-to-receive-fda-ind-approval 2025-12-17T13:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/fa96628064d9c8b3/crbn-gene-mutations-show-variable-impact-on-myeloma-drug-response-enabling-precision-treatment-selection 2025-12-17T13:28:34+00:00 hourly 0.9 https://trial.medpath.com/news/36ad2a8c6c1fe376/pharmaceutical-m-a-activity-surges-as-companies-brace-for-2026-patent-cliff 2025-12-17T09:29:19+00:00 hourly 0.9 https://trial.medpath.com/news/4cb990632687c235/lupin-s-biosimilar-ranibizumab-ranluspec-receives-positive-ema-committee-opinion-for-multiple-eye-conditions 2025-12-17T09:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/86824cb3751c8467/sanofi-s-efdoralprin-alfa-receives-eu-orphan-designation-for-rare-lung-disease-treatment 2025-12-17T09:28:07+00:00 hourly 0.9 https://trial.medpath.com/news/c2946539ac72b050/kane-biotech-receives-health-canada-approval-for-revyve-antimicrobial-wound-gel-spray-presents-clinical-data-at-wound-healing-conference 2025-12-17T07:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/a9dfa7e60b6d1884/cosette-pharmaceuticals-launches-first-generic-cipro-hc-with-180-day-market-exclusivity 2025-12-17T05:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/f8cf81b679814960/harbour-biomed-partners-with-bristol-myers-squibb-in-1-1-billion-multi-specific-antibody-deal 2025-12-17T05:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/12b12a40b5ddf317/hansa-biopharma-s-phase-3-trial-for-anti-gbm-disease-fails-primary-endpoint-despite-improved-dialysis-free-outcomes 2025-12-17T05:27:25+00:00 hourly 0.9 https://trial.medpath.com/news/a4e494cbb4f7e052/pfizer-s-2026-outlook-falls-short-of-expectations-amid-patent-cliff-and-post-pandemic-transition 2025-12-17T03:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/a77fdbeb4ee2042c/beacon-therapeutics-initiates-landscape-trial-for-x-linked-retinitis-pigmentosa-gene-therapy 2025-12-17T01:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/61699a2bd2cc0e28/cms-reconsiders-medicare-coverage-for-tavr-in-asymptomatic-aortic-stenosis-patients-following-edwards-request 2025-12-17T01:32:28+00:00 hourly 0.9 https://trial.medpath.com/news/892bc75fb38ae3d0/aktis-oncology-pursues-200-million-ipo-to-advance-early-stage-cancer-therapies 2025-12-17T01:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/0d2a41908c794c73/cms-narrows-medicare-coverage-for-skin-substitutes-to-18-products-impacting-wound-care-market 2025-12-17T01:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/ef12d5abe5ab7433/pelareorep-shows-33-response-rate-in-kras-mutant-colorectal-cancer-tripling-standard-of-care-outcomes 2025-12-17T01:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/cad35373dfef45ad/aav-gene-therapy-shows-promise-for-inherited-retinal-disease-and-cardiac-dysfunction-in-preclinical-studies 2025-12-17T01:30:05+00:00 hourly 0.9 https://trial.medpath.com/news/eeda5c089b894d22/inhibrx-biosciences-advances-two-oncology-programs-with-key-enrollment-milestones-and-upcoming-data-readouts 2025-12-17T01:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/db60ef245f0b65ed/dompe-initiates-phase-3-trial-of-dual-mechanism-isocyclosporin-for-atopic-keratoconjunctivitis 2025-12-17T01:28:05+00:00 hourly 0.9 https://trial.medpath.com/news/a3115dc2c98777fb/vir-biotechnology-secures-eur550-million-licensing-deal-with-norgine-for-hepatitis-delta-combination-therapy 2025-12-17T01:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/aedd8ca33949266e/exozymes-achieves-100-fold-scale-up-of-nct-production-with-99-conversion-efficiency-using-cell-free-enzyme-platform 2025-12-17T01:27:32+00:00 hourly 0.9 https://trial.medpath.com/news/03306de18f5b92f8/fda-approves-brain-tumor-warning-for-depo-provera-after-pfizer-lawsuit-pressure 2025-12-17T01:27:27+00:00 hourly 0.9 https://trial.medpath.com/news/099b643fb0a1f255/vyriad-s-vv169-in-vivo-car-t-therapy-achieves-100-tumor-clearance-in-multiple-myeloma-preclinical-studies 2025-12-16T21:36:54+00:00 hourly 0.9 https://trial.medpath.com/news/1afb9c770dac0a58/regenerative-medicine-advances-promise-functional-diabetes-cures-as-multiple-companies-report-clinical-progress 2025-12-16T21:33:59+00:00 hourly 0.9 https://trial.medpath.com/news/67c4c091988abb05/trethera-secures-2-7-million-nih-grant-to-evaluate-tre-515-combination-therapy-for-kras-inhibitor-resistant-lung-cancer 2025-12-16T21:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/9ea86d170e6ea3db/caris-life-sciences-partners-with-genentech-in-1-1-billion-oncology-target-discovery-collaboration 2025-12-16T21:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/fa38739a9e46ddb5/biotech-stocks-rally-after-hours-on-fda-designations-and-clinical-trial-progress 2025-12-16T21:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/2332538684441938/alvotech-raises-100-million-through-convertible-bond-offering-to-fund-biosimilar-pipeline-expansion 2025-12-16T21:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/37a7c9a13d3cec5a/nephrology-advances-in-2025-fda-approvals-and-clinical-breakthroughs-transform-kidney-disease-treatment 2025-12-16T21:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/63eaf44258373eb0/fda-approves-once-monthly-mirikizumab-regimen-for-ulcerative-colitis-as-real-world-data-shows-early-treatment-benefits 2025-12-16T21:28:59+00:00 hourly 0.9 https://trial.medpath.com/news/9d3d88633818d110/profocal-cooled-laser-therapy-demonstrates-84-local-control-rate-in-prostate-cancer-phase-2-trial 2025-12-16T21:28:54+00:00 hourly 0.9 https://trial.medpath.com/news/69e90f1322cec6eb/nektar-therapeutics-advances-rezpegaldesleukin-despite-mixed-phase-2b-results-in-alopecia-areata 2025-12-16T21:28:05+00:00 hourly 0.9 https://trial.medpath.com/news/549720199e147392/cellectar-biosciences-secures-multi-year-supply-agreement-for-alpha-emitting-radioisotopes-to-advance-targeted-cancer-therapies 2025-12-16T17:42:57+00:00 hourly 0.9 https://trial.medpath.com/news/40a9da8c40c98718/immuneering-receives-fda-and-ema-alignment-for-phase-3-atebimetinib-trial-in-first-line-pancreatic-cancer 2025-12-16T17:41:20+00:00 hourly 0.9 https://trial.medpath.com/news/122323803ceed9ce/aeovian-pharmaceuticals-secures-55-million-series-b-to-advance-first-in-class-mtorc1-inhibitor-for-rare-epilepsy 2025-12-16T17:41:17+00:00 hourly 0.9 https://trial.medpath.com/news/04e42b717fca6085/verastem-oncology-restructures-leadership-to-advance-kras-targeted-cancer-pipeline 2025-12-16T17:39:49+00:00 hourly 0.9 https://trial.medpath.com/news/fc1afb3895b556cb/glenmark-secures-global-rights-to-third-generation-egfr-tki-aumolertinib-for-lung-cancer-treatment 2025-12-16T17:38:40+00:00 hourly 0.9 https://trial.medpath.com/news/967aab30bbd60934/beacon-biosignals-partners-with-harmony-biosciences-to-integrate-ai-driven-eeg-technology-in-phase-3-hypersomnia-trials 2025-12-16T17:36:26+00:00 hourly 0.9 https://trial.medpath.com/news/8bc96dc9db826050/university-of-toronto-and-moderna-partner-on-next-generation-mucosal-vaccines-and-ai-driven-mrna-therapeutics 2025-12-16T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/9e5fcad968cbded2/uk-partners-with-nobel-prize-winner-s-biotech-to-produce-cancer-therapies-from-nuclear-waste 2025-12-16T17:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/8f01fd9d2ec7f9f0/genflow-completes-dosing-phase-of-sirt6-gene-therapy-trial-in-dogs-with-no-adverse-events 2025-12-16T17:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/4afb0e7204289aa1/ratio-therapeutics-doses-first-patients-in-phase-1-2-trial-of-fap-targeted-radiopharmaceutical-for-aggressive-sarcomas 2025-12-16T17:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/8a104df26712b019/affibody-s-aby-271-radioligand-therapy-advances-to-phase-i-part-b-following-positive-safety-data-in-her2-positive-breast-cancer 2025-12-16T17:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/f2ffabc7e43fb437/evolveimmune-therapeutics-initiates-first-in-human-trial-of-evolve104-trispecific-t-cell-engager 2025-12-16T17:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/bcd530fb9d6d1499/recludix-pharma-receives-fda-clearance-for-first-in-class-oral-stat6-inhibitor-rex-8756-to-enter-phase-1-testing 2025-12-16T17:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/48eea698c97a8bc3/xoma-royalty-acquires-gene-therapy-developer-generation-bio-for-4-29-per-share 2025-12-16T17:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/c829a9d007516ef5/ember-lifesciences-raises-16-5m-series-a-to-address-35b-cold-chain-crisis-in-pharmaceutical-distribution 2025-12-16T17:34:03+00:00 hourly 0.9 https://trial.medpath.com/news/f602ee13875d86a5/health-canada-approves-elfabrio-for-fabry-disease-treatment-expanding-access-to-pegylated-enzyme-replacement-therapy 2025-12-16T17:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/465045cf517644bf/humacyte-secures-77-5-million-credit-facility-to-support-bioengineered-tissue-platform-expansion 2025-12-16T17:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/4148e97e80851bf1/checkmate-7dx-trial-shows-no-survival-benefit-for-nivolumab-plus-docetaxel-in-metastatic-prostate-cancer 2025-12-16T17:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/ec2c86ead84d7ad6/can-fite-biopharma-advances-dual-phase-iii-programs-with-namodenoson-and-piclidenoson 2025-12-16T17:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/552a85e289604ab4/arch-biopartners-expands-phase-ii-trial-for-lsalt-peptide-with-st-michael-s-hospital-ethics-approval 2025-12-16T17:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/74812d6b0467abf5/ambros-therapeutics-launches-with-125m-to-advance-non-opioid-pain-drug-neridronate-for-rare-disease-crps-1 2025-12-16T17:31:07+00:00 hourly 0.9 https://trial.medpath.com/news/6bbf93ae7c83ae00/adagene-s-muzastotug-receives-fda-fast-track-designation-for-mss-colorectal-cancer 2025-12-16T17:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/975bbe2349f0836a/tonix-pharmaceuticals-licenses-tnx-4900-novel-sigma-1-receptor-antagonist-for-chronic-neuropathic-pain 2025-12-16T17:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/b6827ac5c0aa902b/takeda-joins-baselaunch-as-sixth-pharmaceutical-partner-in-basel-biotech-incubator 2025-12-16T17:28:54+00:00 hourly 0.9 https://trial.medpath.com/news/e2a8dcb750e99a25/baseline-blood-parameters-predict-bcma-car-t-therapy-outcomes-in-multiple-myeloma-patients 2025-12-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bf08031a77f83e57/multi-target-nanoparticle-therapy-achieves-90-neuron-survival-in-alzheimer-s-models 2025-12-16T15:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/5d23b1f53bfb2a2c/metis-techbio-advances-mrna-cancer-therapeutics-with-dual-publications-in-nature-communications-and-jitc 2025-12-16T13:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/cfa65a338a677bc5/atom-therapeutics-launches-phase-2-trial-of-abp-745-for-atherosclerotic-cardiovascular-disease 2025-12-16T13:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/cdc0cb6d48db1868/allogene-secures-full-control-of-car-t-therapy-following-favorable-arbitration-ruling 2025-12-16T13:30:49+00:00 hourly 0.9 https://trial.medpath.com/news/323ba15a071f1ba5/nicox-completes-key-data-generation-for-ncx-470-glaucoma-drug-nda-submission-planned-for-h1-2026 2025-12-16T13:30:05+00:00 hourly 0.9 https://trial.medpath.com/news/aea95261b463723d/ab-science-s-ab8939-shows-promise-against-refractory-acute-myeloid-leukemia-with-novel-dual-target-mechanism 2025-12-16T09:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/61775b94b21066db/manifold-bio-strengthens-leadership-team-with-coo-appointment-to-scale-ai-driven-drug-discovery-platform 2025-12-16T09:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/1035d0194c25bc00/allergy-therapeutics-secures-first-german-approval-for-grassmuno-grass-pollen-immunotherapy 2025-12-16T09:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/4d6945fa93161af8/psychedelic-therapies-advance-through-clinical-trials-as-hmnc-s-novel-ketamine-formulation-shows-promise 2025-12-16T09:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/70b1b48bb9e3727e/biostar-pharma-initiates-pivotal-u-s-trial-for-utidelone-in-her2-negative-breast-cancer-brain-metastases 2025-12-16T09:26:46+00:00 hourly 0.9 https://trial.medpath.com/news/7b632e174ebbd622/major-pharma-companies-push-fda-to-modernize-manufacturing-regulations-to-support-us-drug-production 2025-12-16T09:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/d1d298ed860114ef/allink-biotherapeutics-raises-47m-to-advance-two-adc-programs-in-global-phase-i-trials 2025-12-16T05:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/6eb11633ea46f8de/fda-extends-review-timeline-for-aldeyra-s-reproxalap-dry-eye-treatment-to-march-2026 2025-12-16T05:26:50+00:00 hourly 0.9 https://trial.medpath.com/news/bd9e660dbb728a95/astrazeneca-voluntarily-withdraws-andexxa-from-us-market-following-fatal-thromboembolic-events 2025-12-16T05:26:44+00:00 hourly 0.9 https://trial.medpath.com/news/36d2bdd28022594d/apac-region-emerges-as-global-clinical-trial-powerhouse-with-50000-expected-studies 2025-12-16T03:27:24+00:00 hourly 0.9 https://trial.medpath.com/news/f5c74dc829fa5ab4/sanofi-secures-1-04-billion-license-for-adel-y01-novel-tau-targeting-alzheimer-s-therapy 2025-12-16T01:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/7fb87d700be8c93a/pharmaessentia-reports-strong-besremi-growth-and-advances-pipeline-for-rare-blood-cancer-treatment 2025-12-16T01:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/f7d9371cc6fa0894/attivare-therapeutics-secures-6-6-million-gates-foundation-grant-for-next-generation-malaria-vaccine 2025-12-16T01:34:20+00:00 hourly 0.9 https://trial.medpath.com/news/d7a0cdd4b6005667/gensci-partners-with-rtw-investments-in-1-365-billion-deal-for-first-in-class-thyroid-autoimmune-disease-therapy 2025-12-16T01:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/e3d323f03317b7d1/fda-eliminates-patient-data-requirements-for-real-world-evidence-in-medical-device-applications 2025-12-16T01:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/d9a869ad485b154a/tempramed-secures-south-korean-patent-for-vivi-box-temperature-controlled-medication-storage-system 2025-12-16T01:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/5e4336799b640603/mount-sinai-researchers-develop-cell-selective-mrna-therapy-platform-for-precision-cancer-treatment 2025-12-16T01:30:54+00:00 hourly 0.9 https://trial.medpath.com/news/b8ae9cf66333a43d/novel-apd-1-conjugated-nanodrugs-show-promise-for-overcoming-pancreatic-cancer-immunotherapy-barriers 2025-12-16T01:30:43+00:00 hourly 0.9 https://trial.medpath.com/news/a087f2944606d144/nektar-therapeutics-to-report-phase-2b-results-for-alopecia-areata-treatment-rezpegaldesleukin 2025-12-16T01:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/29677247b55739f7/io-biotech-s-cancer-vaccine-shows-25-5-month-median-progression-free-survival-in-five-year-melanoma-study 2025-12-16T01:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/e18ec5351beeec94/organogenesis-initiates-rolling-bla-submission-for-renu-knee-osteoarthritis-treatment-following-fda-approval 2025-12-16T01:28:34+00:00 hourly 0.9 https://trial.medpath.com/news/932bedd6d0ddac60/mochida-and-duchesnay-partner-to-bring-first-pregnancy-nausea-treatment-to-japan 2025-12-16T01:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/a5e6b54d8da2d3d0/fda-eliminates-real-world-data-barriers-to-accelerate-drug-and-device-approvals 2025-12-16T01:26:49+00:00 hourly 0.9 https://trial.medpath.com/news/3e61f83bc51235a4/spruce-biosciences-adds-commercial-veteran-keli-walbert-to-board-ahead-of-sanfilippo-syndrome-therapy-bla 2025-12-15T21:36:14+00:00 hourly 0.9 https://trial.medpath.com/news/cb19d612f8d87bb4/ophidion-and-neuronasal-form-strategic-partnership-to-advance-cns-therapeutics-for-parkinson-s-disease-and-metabolic-disorders 2025-12-15T21:33:22+00:00 hourly 0.9 https://trial.medpath.com/news/376f6553d3366ca0/cure-rare-disease-secures-7-4-million-cirm-grant-for-novel-gene-therapy-targeting-lgmd2i-r9 2025-12-15T21:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/fca02c2a05badd64/supreme-court-declines-patent-case-that-could-impact-heart-failure-drug-entresto-and-pharmaceutical-innovation 2025-12-15T21:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/1793f5b3620563a7/jaguar-health-submits-abstract-for-crofelemer-trial-in-adult-short-bowel-syndrome-patients 2025-12-15T21:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/31b12aca24606854/pfizer-advances-two-phase-1-trials-targeting-kidney-disease-and-liver-cancer 2025-12-15T21:31:07+00:00 hourly 0.9 https://trial.medpath.com/news/7e82ebd34db25494/bright-minds-biosciences-raises-175-million-to-advance-epilepsy-drug-bmb-101-through-phase-ii-trials 2025-12-15T21:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/e57db5a9657bcf21/fda-approves-expanded-flibanserin-indication-for-postmenopausal-women-with-hypoactive-sexual-desire-disorder 2025-12-15T21:28:20+00:00 hourly 0.9 https://trial.medpath.com/news/01497b3f73f47a78/real-world-study-confirms-long-term-efficacy-of-luxturna-gene-therapy-for-inherited-retinal-disease 2025-12-15T19:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/660e2581b1019c36/alumis-raises-300-million-in-public-offering-following-planned-acelyrin-merger 2025-12-15T18:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/7a7f1b7e0453853e/zenas-biopharma-reports-positive-phase-3-indigo-data-for-obexelimab-in-igg4-related-disease 2025-12-15T17:43:10+00:00 hourly 0.9 https://trial.medpath.com/news/65444d7d342daf24/cofactor-genomics-validates-rna-based-biomarker-for-nsclc-immunotherapy-response-in-1400-patient-study 2025-12-15T17:41:21+00:00 hourly 0.9 https://trial.medpath.com/news/3a090a07521ceed5/pilatus-biosciences-receives-fda-clearance-for-first-in-class-anti-cd36-metabolic-checkpoint-antibody-plt012 2025-12-15T17:38:52+00:00 hourly 0.9 https://trial.medpath.com/news/7ac9b97a294eb51f/geovax-s-covid-19-vaccine-shows-superior-t-cell-response-in-cll-patients-prompts-trial-design-change 2025-12-15T17:38:28+00:00 hourly 0.9 https://trial.medpath.com/news/84476cd57044f104/sofie-biosciences-initiates-phase-3-trials-for-18f-fapi-74-pet-tracer-in-gastroesophageal-and-pancreatic-cancers 2025-12-15T17:36:45+00:00 hourly 0.9 https://trial.medpath.com/news/8cf2d2ca7b022f8d/sanofi-expands-dren-bio-partnership-with-1-7b-autoimmune-collaboration 2025-12-15T17:36:39+00:00 hourly 0.9 https://trial.medpath.com/news/96eb71eeaa8fbbb8/aviceda-s-avd-104-shows-31-reduction-in-geographic-atrophy-lesion-growth-in-phase-2b-trial 2025-12-15T17:36:17+00:00 hourly 0.9 https://trial.medpath.com/news/95b0791e72bf0d18/noom-launches-microdose-glp-1-program-for-preventive-health-and-longevity 2025-12-15T17:36:14+00:00 hourly 0.9 https://trial.medpath.com/news/735381e9d995e031/ankyra-therapeutics-appoints-sailaja-battula-as-chief-scientific-officer-to-lead-immuno-oncology-pipeline 2025-12-15T17:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/7eec5808c04bbdd1/abpro-and-celltrion-submit-ind-application-for-her2-targeting-t-cell-engager-abp-102-ct-p72 2025-12-15T17:35:41+00:00 hourly 0.9 https://trial.medpath.com/news/6b53a9702c21951a/gene-therapy-shows-promise-for-hereditary-spastic-paraplegia-in-preclinical-study 2025-12-15T17:34:58+00:00 hourly 0.9 https://trial.medpath.com/news/75e6c00531faf49c/algia-pharma-receives-fda-support-for-non-opioid-pain-treatment-algiapak-to-enter-phase-2-trials 2025-12-15T17:34:52+00:00 hourly 0.9 https://trial.medpath.com/news/eb5f45e5d176d6a4/cgt-catapult-launches-recell-consortium-to-develop-universal-safety-tests-for-cell-therapies 2025-12-15T17:34:38+00:00 hourly 0.9 https://trial.medpath.com/news/7b46c3c04e1ef1dc/fda-grants-orphan-drug-designation-to-roxadustat-for-myelodysplastic-syndromes-treatment 2025-12-15T17:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/605be11c17bc6f6e/immusoft-receives-fda-orphan-drug-designation-for-engineered-b-cell-therapy-isp-002-in-hunter-syndrome 2025-12-15T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/d24410d6d815d534/netramark-secures-phase-3-contract-following-fda-milestone-for-ai-powered-clinical-trial-platform 2025-12-15T17:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/57a25eafa48d5d01/cannabis-compounds-cbd-and-thc-show-promise-against-ovarian-cancer-in-laboratory-study 2025-12-15T17:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/5f9a8c48da2e93c3/adaptive-biotechnologies-partners-with-pfizer-in-890m-tcr-discovery-deal-for-rheumatoid-arthritis 2025-12-15T17:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/19e8e8c5cac5fcb6/chai-discovery-raises-130m-series-b-to-accelerate-ai-driven-drug-discovery-platform 2025-12-15T17:30:50+00:00 hourly 0.9 https://trial.medpath.com/news/56ca84fd59a28caf/rona-therapeutics-completes-first-cohort-of-phase-1-trial-for-novel-inhbe-targeting-sirna-obesity-treatment 2025-12-15T17:30:16+00:00 hourly 0.9 https://trial.medpath.com/news/842fc14b9619c774/actuate-therapeutics-reports-positive-phase-ii-results-for-elraglusib-in-advanced-salivary-gland-cancers 2025-12-15T17:29:40+00:00 hourly 0.9 https://trial.medpath.com/news/612384f74dcffe9e/dyadic-applied-biosolutions-expands-strategic-partnerships-to-accelerate-commercial-growth-of-recombinant-protein-portfolio 2025-12-15T17:29:38+00:00 hourly 0.9 https://trial.medpath.com/news/c62b45560de8d18e/pixelgen-technologies-expands-protein-interactomics-platform-to-south-korea-through-strategic-distribution-partnership 2025-12-15T17:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/5d8bccd4fe2af2d4/china-medical-system-s-jak1-inhibitor-povorcitinib-receives-breakthrough-therapy-designation-for-vitiligo-treatment 2025-12-15T17:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/d2aec326a9ae5ad9/kenai-therapeutics-initiates-first-in-human-trial-of-rndp-001-neuron-replacement-therapy-for-parkinson-s-disease 2025-12-15T17:28:31+00:00 hourly 0.9 https://trial.medpath.com/news/aa8ede491ab240c2/medicus-pharma-completes-phase-2-enrollment-for-novel-microneedle-basal-cell-carcinoma-treatment 2025-12-15T17:28:28+00:00 hourly 0.9 https://trial.medpath.com/news/295962c4757d4a79/fda-approves-first-posterior-motion-preserving-spinal-device-for-degenerative-disc-disease 2025-12-15T17:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/012db21b5ade0d2a/fda-grants-breakthrough-device-designation-to-nephrodite-s-holly-implantable-dialysis-system 2025-12-15T17:28:23+00:00 hourly 0.9 https://trial.medpath.com/news/bf8b910c9228db36/redhill-s-opaganib-shows-promise-in-overcoming-venetoclax-resistance-in-chronic-lymphocytic-leukemia 2025-12-15T17:27:33+00:00 hourly 0.9 https://trial.medpath.com/news/b317b739fb29175d/vanda-pharmaceuticals-submits-bla-for-imsidolimab-to-treat-rare-generalized-pustular-psoriasis 2025-12-15T17:27:27+00:00 hourly 0.9 https://trial.medpath.com/news/a02bbf98f8382af3/fda-approves-lerodalcibep-liga-lerochol-as-third-generation-pcsk9-inhibitor-for-cholesterol-management 2025-12-15T17:27:18+00:00 hourly 0.9 https://trial.medpath.com/news/1bc8f57ab2962f6c/link-cell-therapies-emerges-from-stealth-with-60m-series-a-to-advance-logic-gated-car-t-platform 2025-12-15T17:26:47+00:00 hourly 0.9 https://trial.medpath.com/news/f7492eb1d4b04cf9/pharmanovia-launches-first-in-class-korjuny-catumaxomab-in-germany-for-malignant-ascites-treatment 2025-12-15T17:26:44+00:00 hourly 0.9 https://trial.medpath.com/news/409122d25542221b/kyongbo-pharmaceutical-opens-korea-s-first-end-to-end-adc-cdmo-center 2025-12-15T14:42:59+00:00 hourly 0.9 https://trial.medpath.com/news/b9283d00f8757148/novel-mrna-lnp-platform-delivers-liver-targeted-t-cell-engager-for-hepatocellular-carcinoma-treatment 2025-12-15T14:42:17+00:00 hourly 0.9 https://trial.medpath.com/news/334d4dace92a546f/macro-trial-challenges-long-standing-chronic-rhinosinusitis-treatment-paradigms 2025-12-15T14:41:31+00:00 hourly 0.9 https://trial.medpath.com/news/99ab52b7af227ecb/biovica-secures-commercial-agreement-with-leading-nci-cancer-center-for-divitum-tka-biomarker-test 2025-12-15T14:41:16+00:00 hourly 0.9 https://trial.medpath.com/news/c02a31ee64f85223/novadip-initiates-pivotal-phase-3-trial-of-nvd003-for-rare-pediatric-bone-condition 2025-12-15T14:41:11+00:00 hourly 0.9 https://trial.medpath.com/news/f333a616edb1a6b4/atelerix-and-cherry-biotech-partner-to-enable-global-shipping-of-organoid-models-using-hydrogel-preservation-technology 2025-12-15T14:40:31+00:00 hourly 0.9 https://trial.medpath.com/news/da8e06bba9228db6/bristol-myers-squibb-gains-fda-priority-review-for-opdivo-in-hodgkin-lymphoma 2025-12-15T14:40:22+00:00 hourly 0.9 https://trial.medpath.com/news/7f1195fece863891/amphastar-receives-fda-approval-for-generic-teriparatide-injection-challenging-eli-lilly-s-forteo-in-585m-osteoporosis-market 2025-12-15T14:40:20+00:00 hourly 0.9 https://trial.medpath.com/news/f664ed4702cc4c99/ausperbio-completes-phase-iii-enrollment-for-ahb-137-hepatitis-b-therapy-following-30-functional-cure-rate 2025-12-15T14:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/85f972cf183191a6/believer-meats-ceases-operations-despite-achieving-fda-and-usda-regulatory-approvals-for-cultivated-chicken 2025-12-15T14:38:11+00:00 hourly 0.9 https://trial.medpath.com/news/4dd2ecebecd06ac0/large-scale-drug-screen-reveals-common-medicines-can-enhance-crispr-therapy-and-target-dna-repair-deficient-cancers 2025-12-15T14:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/19a1aa098d6479ad/akums-launches-enhanced-gabapentin-er-tablets-with-retenex-technology-for-postherpetic-neuralgia-management 2025-12-15T14:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/32017c345870df54/minghui-pharmaceutical-receives-fda-clearance-for-phase-iii-trials-of-novel-thyroid-eye-disease-treatment 2025-12-15T14:36:24+00:00 hourly 0.9 https://trial.medpath.com/news/de0abfeba8ccde2f/gene-therapy-trial-death-raises-safety-concerns-for-brain-targeted-aav-treatments 2025-12-15T14:35:33+00:00 hourly 0.9 https://trial.medpath.com/news/7de7d3faa3e5079e/enveric-biosciences-raises-3-1-million-through-warrant-exercise-to-advance-neuroplastogenic-therapeutics 2025-12-15T09:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/50a294f8fc45ea99/argenx-discontinues-phase-3-uplighted-studies-of-efgartigimod-sc-in-thyroid-eye-disease-following-futility-analysis 2025-12-15T09:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/d58b1c2896f07e48/gc-biopharma-selected-for-korea-s-covid-19-mrna-vaccine-phase-1-clinical-trial-support-program 2025-12-15T09:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/ce655b2ae0814269/sanofi-s-tolebrutinib-fails-phase-3-trial-in-primary-progressive-multiple-sclerosis 2025-12-15T09:30:21+00:00 hourly 0.9 https://trial.medpath.com/news/db78949e6fa69494/prescient-therapeutics-receives-european-approval-for-ptx-100-phase-2a-trial-in-rare-t-cell-lymphoma 2025-12-15T09:30:19+00:00 hourly 0.9 https://trial.medpath.com/news/ffc20b3be3632433/fda-approves-first-crispr-cas13-rna-editing-trial-for-wet-age-related-macular-degeneration 2025-12-15T09:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/75415502b6190dcf/kaist-researchers-develop-ai-engineered-interferon-lambda-nasal-spray-for-broad-spectrum-respiratory-virus-protection 2025-12-15T09:28:59+00:00 hourly 0.9 https://trial.medpath.com/news/804a164d88d3471c/dimerix-completes-recruitment-for-phase-3-trial-of-dmx-200-in-rare-kidney-disease-fsgs 2025-12-15T09:27:46+00:00 hourly 0.9 https://trial.medpath.com/news/60cffacb2050e6b6/indupro-therapeutics-secures-strategic-investment-from-sanofi-for-novel-bispecific-pd-1-agonist-program 2025-12-15T09:27:04+00:00 hourly 0.9 https://trial.medpath.com/news/b538a463aa20b300/china-mandates-rigorous-clinical-trials-for-traditional-medicine-injections-in-historic-regulatory-overhaul 2025-12-15T09:26:44+00:00 hourly 0.9 https://trial.medpath.com/news/c6d9880b00d5d830/fda-faces-growing-dilemma-as-10-of-approved-drugs-fail-primary-endpoints-in-pivotal-trials 2025-12-15T09:26:41+00:00 hourly 0.9 https://trial.medpath.com/news/8a659f63298de015/biocon-launches-glp-1-liraglutide-in-netherlands-marking-first-eu-direct-brand-launch 2025-12-15T09:26:09+00:00 hourly 0.9 https://trial.medpath.com/news/c072f63f1b51e850/cynata-therapeutics-completes-enrollment-in-phase-2-trial-of-cyp-001-for-acute-graft-versus-host-disease 2025-12-15T05:26:40+00:00 hourly 0.9 https://trial.medpath.com/news/68c86956132bfea8/immunome-prepares-to-release-phase-3-ringside-trial-results-for-varegacestat-in-desmoid-tumors 2025-12-15T01:27:20+00:00 hourly 0.9 https://trial.medpath.com/news/82ab14b1371fe811/hyperfine-initiates-clinical-study-to-expand-portable-mri-capabilities-with-contrast-enhancement 2025-12-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ed547ce177161856/cencora-expands-rare-disease-services-through-strategic-partnership-with-curant-health 2025-12-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ba923eff2db6b22f/kyverna-therapeutics-to-report-phase-2-trial-results-for-car-t-cell-therapy-in-stiff-person-syndrome 2025-12-14T21:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/9bf972b148c80818/allegria-therapeutics-raises-5-1-million-to-advance-mast-cell-targeted-therapies-for-allergic-diseases 2025-12-14T21:30:37+00:00 hourly 0.9 https://trial.medpath.com/news/1f9abfeb344481f4/bioretec-receives-fda-breakthrough-device-designation-for-biodegradable-remeos-drillpin 2025-12-14T21:30:34+00:00 hourly 0.9 https://trial.medpath.com/news/d9b864b18e111df7/vaxcyte-initiates-phase-3-opus-trial-for-vax-31-pneumococcal-vaccine-with-strong-institutional-backing 2025-12-14T17:26:01+00:00 hourly 0.9 https://trial.medpath.com/news/b3b71decd3ea32e5/forskolin-shows-dual-mechanism-against-aggressive-kmt2a-rearranged-acute-myeloid-leukemia 2025-12-14T17:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/db230a5d55973ec3/vaxxas-secures-tga-manufacturing-license-for-revolutionary-microarray-patch-vaccine-technology 2025-12-14T17:25:47+00:00 hourly 0.9 https://trial.medpath.com/news/219cca780df8c6be/ai-powered-discovery-identifies-novel-monkeypox-virus-drug-target-opg153 2025-12-14T13:28:02+00:00 hourly 0.9 https://trial.medpath.com/news/36e805479a574f4f/phase-2-trial-shows-promise-for-glp-1-receptor-agonists-in-large-vessel-occlusion-stroke-treatment 2025-12-14T13:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/d3365fd3908b767c/novel-lrba-targeting-approach-enhances-cancer-immunotherapy-by-inducing-ctla-4-degradation 2025-12-14T09:28:37+00:00 hourly 0.9 https://trial.medpath.com/news/febbeca8d1d9075a/fda-mandated-to-streamline-prescription-to-otc-drug-switch-process-under-new-congressional-legislation 2025-12-14T01:28:22+00:00 hourly 0.9 https://trial.medpath.com/news/6890c8d7df111593/theralase-completes-enrollment-of-90-patients-in-phase-ii-bladder-cancer-study-for-light-activated-ruvidar 2025-12-13T21:30:04+00:00 hourly 0.9 https://trial.medpath.com/news/e776edc3947bfad3/d3-bio-raises-108-million-series-b-to-advance-global-phase-iii-trials-for-kras-g12c-inhibitor-elisrasib 2025-12-13T21:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/5ef7d2ab0ba6259b/schizophrenia-drug-pipeline-surges-with-60-therapies-from-55-companies-as-novel-mechanisms-enter-late-stage-development 2025-12-13T21:27:58+00:00 hourly 0.9 https://trial.medpath.com/news/5c12f316cb60cd3d/sobi-acquires-arthrosi-therapeutics-for-950m-to-advance-next-generation-gout-treatment 2025-12-13T21:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/60121318bb621800/fda-prepares-major-clinical-trial-reform-to-accelerate-drug-approvals-through-single-pivotal-studies 2025-12-13T21:26:48+00:00 hourly 0.9 https://trial.medpath.com/news/2edb7b36c725e68f/quebec-and-netherlands-reject-public-coverage-of-alzheimer-s-drug-lecanemab-despite-health-canada-approval 2025-12-13T21:25:59+00:00 hourly 0.9 https://trial.medpath.com/news/a352a2fe77ec81b0/multi-component-intranasal-covid-19-vaccine-shows-promise-in-preclinical-and-early-human-studies 2025-12-13T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/845399227f7a8eb8/nurexone-advances-exopten-manufacturing-for-first-in-human-studies-in-spinal-cord-and-optic-nerve-injuries 2025-12-13T14:27:51+00:00 hourly 0.9 https://trial.medpath.com/news/b9afe8be73a92972/biocon-biologics-secures-global-settlement-for-aflibercept-biosimilar-enabling-worldwide-commercialization 2025-12-13T14:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/d93afcfde7669149/aiims-delhi-completes-india-s-first-brain-stent-clinical-trial-achieves-regulatory-approval-for-stroke-treatment 2025-12-13T09:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/f02ecff2d70f1347/radiomedix-secures-5-year-thorium-228-supply-deal-to-advance-targeted-alpha-therapy-pipeline 2025-12-13T09:27:31+00:00 hourly 0.9 https://trial.medpath.com/news/0c344bee84035cd4/long-term-arpi-data-reinforces-survival-benefits-in-metastatic-prostate-cancer-while-real-world-evidence-gaps-persist 2025-12-13T09:27:06+00:00 hourly 0.9 https://trial.medpath.com/news/b58bcc68dfed025d/sereneuro-s-sn101-pain-sponge-therapy-shows-promise-for-non-opioid-osteoarthritis-treatment 2025-12-13T09:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/e7336fca5fafc26f/anixa-biosciences-breast-cancer-vaccine-shows-74-immune-response-rate-in-phase-1-trial 2025-12-13T05:29:22+00:00 hourly 0.9 https://trial.medpath.com/news/ec21cd647803f03a/eu-drugs-regulator-backs-higher-dose-of-novo-nordisk-s-wegovy-for-weight-management 2025-12-13T05:27:20+00:00 hourly 0.9 https://trial.medpath.com/news/36c1777a2c74bd9b/fda-approves-cardamyst-nasal-spray-as-first-self-administered-treatment-for-psvt-in-over-30-years 2025-12-13T05:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/3ed7956e6b44789c/tiziana-life-sciences-initiates-phase-2-trial-testing-intranasal-foralumab-for-alzheimer-s-disease-neuroinflammation 2025-12-13T01:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/ca74f54475dcd52c/alphyn-biologics-raises-25m-series-b-to-advance-zabalafin-hydrogel-through-phase-iib-trials-for-atopic-dermatitis 2025-12-13T01:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/22e7367167b12617/zelluna-achieves-manufacturing-milestone-for-first-in-class-mage-a4-tcr-nk-cell-therapy 2025-12-13T01:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/b7282c4cca6cef67/blood-test-using-ctdna-identifies-colon-cancer-patients-who-benefit-from-celecoxib-anti-inflammatory-therapy 2025-12-13T01:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/efa8c1216f3dcb39/edesa-biotech-advances-eb06-anti-cxcl10-antibody-toward-phase-2-vitiligo-trial-in-mid-2026 2025-12-13T01:27:09+00:00 hourly 0.9 https://trial.medpath.com/news/460fdd1bc388b5ce/canada-s-drug-agency-reports-10-rise-in-drug-submissions-despite-15-drop-in-approvals-for-2024 2025-12-13T01:26:34+00:00 hourly 0.9 https://trial.medpath.com/news/760f9d65c27ccecb/circulating-tumor-dna-emerges-as-powerful-prognostic-tool-for-triple-negative-breast-cancer-recurrence-risk 2025-12-12T21:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/334ed9ab83544563/mineralys-therapeutics-lorundrostat-trial-recognized-in-jama-s-inaugural-research-of-the-year-for-treatment-resistant-hypertension 2025-12-12T21:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/5e76d41673192de5/tenaya-therapeutics-reports-positive-gene-therapy-data-for-rare-heart-disease-despite-stock-decline-following-60m-offering 2025-12-12T21:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/a289c30424d28c20/relay-therapeutics-zovegalisib-shows-consistent-efficacy-across-breast-cancer-patient-subgroups-in-sabcs-analysis 2025-12-12T21:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/276ff3dc70fe1b4a/uc-irvine-receives-12-million-grant-for-first-in-human-huntington-s-disease-stem-cell-trial 2025-12-12T21:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/12ac53af0fb2242e/vutrisiran-demonstrates-consistent-cardiovascular-benefits-across-all-age-groups-in-attr-cm-patients 2025-12-12T21:30:45+00:00 hourly 0.9 https://trial.medpath.com/news/14a2fc91ce964697/sms-pharmaceuticals-passes-usfda-inspection-at-vizag-api-facility-with-minor-observation 2025-12-12T21:30:34+00:00 hourly 0.9 https://trial.medpath.com/news/60e04ff3232e7670/parse-biosciences-partners-with-tahoe-therapeutics-and-codebreaker-labs-for-massive-single-cell-sequencing-projects 2025-12-12T21:29:50+00:00 hourly 0.9 https://trial.medpath.com/news/5f26edcdf5a86f6a/arcus-and-gilead-discontinue-tigit-therapy-after-phase-iii-gastric-cancer-trial-failure 2025-12-12T21:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/a4d9346e92a51134/ema-recommends-conditional-approval-for-immunitybio-s-anktiva-in-bcg-unresponsive-bladder-cancer 2025-12-12T21:28:02+00:00 hourly 0.9 https://trial.medpath.com/news/1c21b15d2f566d61/nimacimab-plus-semaglutide-achieves-superior-weight-loss-in-phase-2a-trial 2025-12-12T17:38:48+00:00 hourly 0.9 https://trial.medpath.com/news/c8b936bc9962ba54/biomarin-awaits-pivotal-inz-701-trial-results-following-270m-inozyme-acquisition 2025-12-12T17:36:21+00:00 hourly 0.9 https://trial.medpath.com/news/4681a1f85d2df3e1/sanofi-loses-key-patent-protection-for-cancer-drug-cabazitaxel-at-european-court 2025-12-12T17:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/4c566f7a417bb8c2/sanyou-bio-and-kanrybio-form-strategic-partnership-to-advance-biomarker-assay-kit-development 2025-12-12T17:33:55+00:00 hourly 0.9 https://trial.medpath.com/news/de24acf90bc8e4fa/biotech-sector-sees-record-3-5-billion-fundraising-surge-following-ash-conference 2025-12-12T17:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/8ae0941d64025fdf/neuexcell-s-gene-therapy-nxl-004-shows-promising-results-in-first-in-human-trial-for-recurrent-malignant-glioma 2025-12-12T17:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/338f6ca029b53077/apremilast-demonstrates-sustained-efficacy-in-moderate-to-severe-genital-psoriasis-through-32-weeks 2025-12-12T17:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/4c00a29f118f3ded/ractigen-therapeutics-initiates-first-in-human-trial-of-rag-18-for-duchenne-muscular-dystrophy 2025-12-12T17:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/c89516de809d0690/peijia-medical-receives-nmpa-approval-for-taurustrio-transcatheter-aortic-valve-system-for-aortic-regurgitation-treatment 2025-12-12T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/1cf310565222d7ff/ema-committee-recommends-expanding-gsk-s-rsv-vaccine-to-all-adults-18-and-over 2025-12-12T17:30:52+00:00 hourly 0.9 https://trial.medpath.com/news/3b3230c69d0694c9/glp-1-drugs-show-16-reduction-in-epilepsy-risk-among-diabetes-patients-in-large-scale-study 2025-12-12T17:30:49+00:00 hourly 0.9 https://trial.medpath.com/news/f902356652bb7c63/insilico-medicine-partners-with-taigen-for-ai-driven-anemia-treatment-in-greater-china 2025-12-12T17:30:47+00:00 hourly 0.9 https://trial.medpath.com/news/7a3b8d389537dd75/ema-approves-seven-new-medicines-including-covid-19-vaccine-and-cancer-treatments 2025-12-12T17:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/5dff26c6826f7822/cytokinetics-receives-positive-european-regulatory-opinion-for-myqorzo-in-obstructive-hypertrophic-cardiomyopathy 2025-12-12T17:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/8c70a4449abdbf08/csir-and-promptbio-partner-to-advance-ai-driven-precision-medicine-for-african-populations 2025-12-12T17:28:28+00:00 hourly 0.9 https://trial.medpath.com/news/ddbe0fc2cf1bac17/emergent-biosolutions-secures-fda-approval-for-raxibacumab-manufacturing-at-winnipeg-facility 2025-12-12T17:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/b6f649886e47f1ac/fda-approves-new-powder-formulation-of-trofinetide-for-enhanced-rett-syndrome-treatment-flexibility 2025-12-12T17:27:30+00:00 hourly 0.9 https://trial.medpath.com/news/a2f3a678d03dec81/suven-life-sciences-completes-phase-2b-enrollment-for-novel-depression-drug-ropanicant-two-months-ahead-of-schedule 2025-12-12T17:27:27+00:00 hourly 0.9 https://trial.medpath.com/news/180e5e8d254aba7b/mass-general-brigham-spins-out-aiwithcare-to-revolutionize-clinical-trial-patient-matching-with-ai 2025-12-12T17:26:50+00:00 hourly 0.9 https://trial.medpath.com/news/f0b87a494cb48b79/acupuncture-shows-promise-for-treating-cognitive-impairment-in-breast-cancer-survivors 2025-12-12T17:26:22+00:00 hourly 0.9 https://trial.medpath.com/news/bdcb56c417871f55/fda-plans-black-box-warning-for-covid-19-vaccines-amid-safety-concerns 2025-12-12T13:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/4d153b01313cda6d/uk-and-singapore-launch-first-of-its-kind-regulatory-innovation-corridor-to-accelerate-breakthrough-health-technologies 2025-12-12T13:29:13+00:00 hourly 0.9 https://trial.medpath.com/news/4128c37e5344c025/zepbound-weight-loss-drug-enters-clinical-testing-for-long-covid-treatment 2025-12-12T13:28:23+00:00 hourly 0.9 https://trial.medpath.com/news/10e5023fa0607edc/fda-plans-black-box-warning-for-covid-19-vaccines-amid-scientific-controversy 2025-12-12T13:28:05+00:00 hourly 0.9 https://trial.medpath.com/news/656b326a11fe90a7/elicio-therapeutics-eli-002-7p-demonstrates-antigen-spreading-in-87-of-phase-2-patients 2025-12-12T13:27:24+00:00 hourly 0.9 https://trial.medpath.com/news/3f4680aad06e70fa/taysha-gene-therapies-advances-tsha-102-to-phase-3-development-for-rett-syndrome-treatment 2025-12-12T13:27:22+00:00 hourly 0.9 https://trial.medpath.com/news/c03cecb901be4e13/medline-completes-6-26-billion-ipo-becomes-largest-healthcare-public-offering-of-2025 2025-12-12T13:27:16+00:00 hourly 0.9 https://trial.medpath.com/news/ae0c44dc6807da39/stada-and-bio-thera-s-golimumab-biosimilar-gotenfia-receives-positive-chmp-opinion-for-multiple-autoimmune-conditions 2025-12-12T13:27:11+00:00 hourly 0.9 https://trial.medpath.com/news/c4c3d999dbc138ff/celltrion-s-autoimmune-biosimilar-avtozma-gains-preferred-status-with-major-u-s-pharmacy-benefit-manager 2025-12-12T13:27:08+00:00 hourly 0.9 https://trial.medpath.com/news/5405a593a6ec0060/major-pharmaceutical-companies-push-fda-to-decouple-facility-inspections-from-drug-approval-timeline 2025-12-12T13:27:05+00:00 hourly 0.9 https://trial.medpath.com/news/916f5a7541e6a354/orphalan-acquires-orphelia-pharma-to-strengthen-rare-disease-portfolio-in-pediatric-neurology-and-oncology 2025-12-12T13:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/37a02edd54fe5bfe/nyu-abu-dhabi-develops-spheromatrix-platform-to-accelerate-cancer-drug-testing-with-freezable-3d-tumor-models 2025-12-12T13:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/e236d147ac53651f/ptc-therapeutics-secures-global-approvals-for-sephience-in-pku-treatment-across-canada-and-japan 2025-12-12T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/5fb091b4aaf1cc85/moderna-reports-strong-q3-2025-performance-with-mnexspike-capturing-24-of-us-covid-vaccine-market 2025-12-12T09:29:18+00:00 hourly 0.9 https://trial.medpath.com/news/a1293ddfab9118a3/south-australia-to-launch-car-t-cell-therapy-service-at-royal-adelaide-hospital-by-mid-2026 2025-12-12T09:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/c990e3d7dc61e586/first-commercial-gene-therapy-for-hemophilia-a-administered-in-michigan-outside-clinical-trials 2025-12-12T09:27:36+00:00 hourly 0.9 https://trial.medpath.com/news/308cab83885c5c24/revolution-medicines-receives-fda-breakthrough-therapy-designation-for-daraxonrasib-in-kras-g12-mutant-pancreatic-cancer 2025-12-12T09:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/f49324676c8e36e2/republican-led-states-challenge-fda-approval-of-generic-mifepristone-in-federal-lawsuits 2025-12-12T09:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/543a51bbd4cee558/xofluza-demonstrates-superior-efficacy-over-tamiflu-in-reducing-hospitalizations-and-emergency-department-visits 2025-12-12T09:25:45+00:00 hourly 0.9 https://trial.medpath.com/news/9158463416f3e967/eli-lilly-explores-acquisition-of-french-biotech-abivax-for-ulcerative-colitis-drug 2025-12-12T05:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/8b6a0f8e367f479e/proton-therapy-demonstrates-10-survival-advantage-over-traditional-radiation-in-landmark-head-and-neck-cancer-trial 2025-12-12T05:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/fbd7cfbe3e597bdf/aprogen-s-herceptin-biosimilar-ap-063-advances-to-regulatory-approval-without-phase-3-trials 2025-12-12T05:26:04+00:00 hourly 0.9 https://trial.medpath.com/news/92b6e775117e458b/cdc-study-shows-covid-19-vaccines-reduce-emergency-visits-in-children-by-up-to-76-amid-fda-safety-investigation 2025-12-12T01:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/36941cea9fe0508e/tenaya-therapeutics-reports-promising-early-results-for-tn-401-gene-therapy-in-rare-heart-disease 2025-12-12T01:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/08c2f8e6c94ac3cf/cycle-pharmaceuticals-acquires-applied-therapeutics-in-0-088-per-share-deal-to-advance-rare-disease-pipeline 2025-12-12T01:30:37+00:00 hourly 0.9 https://trial.medpath.com/news/a88cc704e304e7f4/bristol-myers-squibb-s-opdivo-plus-yervoy-receives-positive-reimbursement-recommendation-for-msi-h-dmmr-colorectal-cancer-in-canada 2025-12-12T01:30:01+00:00 hourly 0.9 https://trial.medpath.com/news/906f5a6d3e45752e/anixa-s-alpha-lactalbumin-breast-cancer-vaccine-shows-74-immune-response-rate-in-phase-1-trial 2025-12-12T01:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/612c9b814a78b125/fda-lifts-clinical-hold-on-tenaya-s-tn-201-gene-therapy-for-genetic-heart-disease 2025-12-12T01:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/260c637742d98677/belzutifan-shows-sustained-efficacy-in-heavily-pretreated-clear-cell-renal-cell-carcinoma-patients 2025-12-12T01:28:38+00:00 hourly 0.9 https://trial.medpath.com/news/a6eb0d8cd06caea2/crinetics-initiates-phase-3-trial-of-atumelnant-for-congenital-adrenal-hyperplasia 2025-12-12T01:28:30+00:00 hourly 0.9 https://trial.medpath.com/news/a8f51943c3ab77a1/evommune-advances-two-novel-inflammatory-disease-programs-following-172-5m-ipo 2025-12-12T01:28:24+00:00 hourly 0.9 https://trial.medpath.com/news/e92e5b2e3ad0e023/fda-approves-uplizna-as-first-cd19-targeted-b-cell-therapy-for-generalized-myasthenia-gravis 2025-12-12T01:27:19+00:00 hourly 0.9 https://trial.medpath.com/news/7e79f42abcb17cb2/long-term-juliet-trial-data-shows-car-t-therapy-delivers-durable-survival-in-relapsed-b-cell-lymphoma 2025-12-12T01:26:04+00:00 hourly 0.9 https://trial.medpath.com/news/3c1076ed16f340cd/cleveland-clinic-s-triple-negative-breast-cancer-vaccine-shows-74-immune-response-rate-in-phase-1-trial 2025-12-12T01:25:48+00:00 hourly 0.9 https://trial.medpath.com/news/fc678b207318c229/geron-projects-strong-2026-revenue-growth-for-rytelo-following-strategic-restructuring 2025-12-11T21:40:05+00:00 hourly 0.9 https://trial.medpath.com/news/3ad95d5df1af5698/basilea-and-phare-bio-partner-to-develop-ai-designed-broad-spectrum-antibiotic 2025-12-11T21:38:45+00:00 hourly 0.9 https://trial.medpath.com/news/1579330f160b6ea7/beyondspring-s-plinabulin-shows-consistent-survival-benefit-in-egfr-wild-type-nsclc-after-anti-pd-l-1-failure 2025-12-11T21:38:21+00:00 hourly 0.9 https://trial.medpath.com/news/76d454de3e32f613/rezolute-s-ersodetug-fails-phase-3-trial-for-congenital-hyperinsulinism-stock-plunges-88 2025-12-11T21:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/2ce4fe669e8fbfdd/accenture-invests-in-ryght-ai-to-accelerate-clinical-trial-execution-through-agentic-ai-platform 2025-12-11T21:37:15+00:00 hourly 0.9 https://trial.medpath.com/news/49ac511f607f8214/innocare-s-next-generation-trk-inhibitor-zurletrectinib-receives-nmpa-approval-in-china-for-ntrk-fusion-positive-solid-tumors 2025-12-11T21:37:01+00:00 hourly 0.9 https://trial.medpath.com/news/788de6133e08e7c9/immunewalk-therapeutics-reports-positive-phase-1-results-for-iw-601-novel-myeloid-cell-inhibitor-for-inflammatory-diseases 2025-12-11T21:36:14+00:00 hourly 0.9 https://trial.medpath.com/news/a7f10f88791fd933/valinor-secures-13-million-seed-funding-to-advance-ai-driven-patient-selection-platform-for-clinical-trials 2025-12-11T21:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/1b34a9e400a1aff6/less-invasive-axillary-staging-procedures-show-noninferiority-to-standard-lymph-node-dissection-in-breast-cancer 2025-12-11T21:35:08+00:00 hourly 0.9 https://trial.medpath.com/news/4dfafeb7b01a5fb1/intensity-therapeutics-reports-improved-safety-profile-for-int230-6-in-triple-negative-breast-cancer-trial 2025-12-11T21:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/bdab5332fcc8acb6/roswell-park-researchers-develop-il-36-gamma-armored-car-t-cells-to-eradicate-solid-tumors 2025-12-11T21:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/ca4cbdf7937c3e3f/two-novel-therapies-show-promise-for-neovascular-amd-duravyu-insert-and-ixo-vec-gene-therapy-demonstrate-safety-and-efficacy-in-phase-2-trials 2025-12-11T21:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/36782ca92b3c9f7b/preoperative-radiation-enhances-immune-response-in-hr-positive-breast-cancer-when-combined-with-pembrolizumab 2025-12-11T21:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/7fa942880aa1f498/corbus-and-eli-lilly-report-positive-obesity-drug-trial-results-driving-stock-gains 2025-12-11T21:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/1f75093436f54ae0/novartis-announces-771-million-manufacturing-expansion-in-north-carolina-creating-700-jobs 2025-12-11T21:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/fb6ed0ab2967164a/novo-nordisk-s-cagrisema-falls-short-against-eli-lilly-s-tirzepatide-in-obesity-trial 2025-12-11T21:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/249d99561978f0f6/roivant-accelerates-pipeline-timelines-with-multiple-late-stage-programs-advancing-toward-market 2025-12-11T21:31:07+00:00 hourly 0.9 https://trial.medpath.com/news/57c7b5a52fe9b449/everest-medicines-secures-exclusive-greater-china-rights-to-novel-pcsk9-inhibitor-lerodalcibep 2025-12-11T21:29:38+00:00 hourly 0.9 https://trial.medpath.com/news/33ff9b1e9e77ac18/quantum-computing-breakthroughs-promise-to-transform-drug-discovery-by-2028 2025-12-11T21:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/c6ccf931edababe0/ivosidenib-combination-demonstrates-real-world-efficacy-in-idh1-mutated-aml-matching-clinical-trial-results 2025-12-11T21:28:47+00:00 hourly 0.9 https://trial.medpath.com/news/6ea96724968f0439/phase-iii-trial-finds-no-oncologic-benefit-from-routine-preoperative-mri-in-early-stage-breast-cancer 2025-12-11T21:27:42+00:00 hourly 0.9 https://trial.medpath.com/news/37edbfcd8a454be6/baseline-therapeutics-launches-with-novel-glp-1-approach-for-substance-use-disorders 2025-12-11T21:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/6aa6c201d4869795/tivic-health-acquires-manufacturing-assets-to-accelerate-entolimod-development-with-90m-financing-package 2025-12-11T17:44:31+00:00 hourly 0.9 https://trial.medpath.com/news/b92da1252a5fe4bb/avenzo-s-cdk2-inhibitor-avzo-021-shows-promising-activity-in-breast-and-ovarian-cancer-patients 2025-12-11T17:43:29+00:00 hourly 0.9 https://trial.medpath.com/news/c7f791c1943585d4/renovorx-presents-promising-pharmacokinetic-data-for-tamp-therapy-platform-at-asco-gi-2026 2025-12-11T17:42:50+00:00 hourly 0.9 https://trial.medpath.com/news/9824597c5e7e99b9/purple-biotech-s-captn-3-platform-shows-promise-against-treatment-resistant-cancers-with-dual-tri-specific-antibodies 2025-12-11T17:41:25+00:00 hourly 0.9 https://trial.medpath.com/news/e398e5604d1ade2e/tuhura-biosciences-advances-multi-platform-cancer-immunotherapy-pipeline-with-15-6m-financing 2025-12-11T17:38:33+00:00 hourly 0.9 https://trial.medpath.com/news/10234b143956dedc/china-s-nmpa-accepts-nda-for-novel-brain-cytoprotectant-y-3-for-acute-ischemic-stroke-treatment 2025-12-11T17:37:38+00:00 hourly 0.9 https://trial.medpath.com/news/b9a8380870c3f63d/alembic-pharmaceuticals-secures-fda-approval-for-generic-zylet-ophthalmic-suspension-with-cgt-exclusivity 2025-12-11T17:37:32+00:00 hourly 0.9 https://trial.medpath.com/news/4a168513bcf177c4/fda-proposes-first-new-sunscreen-active-ingredient-approval-in-25-years-with-bemotrizinol 2025-12-11T17:37:26+00:00 hourly 0.9 https://trial.medpath.com/news/d24c33d02872ed0a/prolynx-raises-70-million-to-develop-extended-release-obesity-drugs-with-monthly-and-quarterly-dosing 2025-12-11T17:37:24+00:00 hourly 0.9 https://trial.medpath.com/news/ae968e499965346c/proteonic-s-2g-unic-technology-licensed-by-ginkgo-bioworks-for-22-2m-barda-funded-anti-filovirus-antibody-manufacturing-project 2025-12-11T17:37:12+00:00 hourly 0.9 https://trial.medpath.com/news/e14bd058c26d1f72/china-advances-ai-driven-drug-development-with-first-phase-3-trial-and-new-platform-launch 2025-12-11T17:37:09+00:00 hourly 0.9 https://trial.medpath.com/news/459443d6b306a7ee/rezolute-s-phase-3-trial-for-congenital-hyperinsulinism-drug-fails-to-meet-primary-endpoints 2025-12-11T17:37:04+00:00 hourly 0.9 https://trial.medpath.com/news/445d6939f5dc1995/autobahn-labs-and-astellas-form-strategic-partnership-to-accelerate-academic-drug-discovery 2025-12-11T17:37:01+00:00 hourly 0.9 https://trial.medpath.com/news/45cd78b300772544/eu-reaches-landmark-deal-on-pharmaceutical-legislation-reform-after-three-years-of-negotiations 2025-12-11T17:36:59+00:00 hourly 0.9 https://trial.medpath.com/news/619e3d2783e16060/medra-secures-52-million-series-a-to-develop-ai-powered-autonomous-drug-discovery-platform 2025-12-11T17:36:56+00:00 hourly 0.9 https://trial.medpath.com/news/3b069dca88459ad4/inotiv-partners-with-vugene-to-advance-ai-driven-drug-discovery-through-multi-omics-platform-integration 2025-12-11T17:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/707e3ee58757ee69/ophirex-advances-varespladib-for-snakebite-treatment-under-fda-animal-rule-pathway 2025-12-11T17:36:28+00:00 hourly 0.9 https://trial.medpath.com/news/a95b5908f5c89820/cadrenal-therapeutics-acquires-first-in-class-12-lox-inhibitor-vlx-1005-for-heparin-induced-thrombocytopenia-treatment 2025-12-11T17:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/4959467633174980/ataibeckley-secures-key-u-s-patent-for-emp-01-psychedelic-therapy-extending-exclusivity-through-2043 2025-12-11T17:34:47+00:00 hourly 0.9 https://trial.medpath.com/news/983d63a5133fe990/enliven-therapeutics-appoints-rick-fair-as-ceo-to-lead-elvn-001-through-phase-3-trial 2025-12-11T17:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/55dd3c3076c2f785/viromissile-initiates-first-in-human-trial-of-idov-immune-oncolytic-virus-therapy-for-advanced-solid-tumors 2025-12-11T17:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/f794f9c94071cae0/corbus-pharmaceuticals-crb-913-shows-promising-weight-loss-results-in-phase-1a-obesity-trial 2025-12-11T17:33:45+00:00 hourly 0.9 https://trial.medpath.com/news/df642ab51dc302a3/quanterix-and-emocog-partner-to-bring-ultra-sensitive-alzheimer-s-blood-testing-to-korea 2025-12-11T17:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/29462a8dfa6ba25b/trogenix-secures-95m-series-a-to-advance-trojan-horse-gene-therapy-for-glioblastoma 2025-12-11T17:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/66ed90a7c7147a56/gerosynth-labs-secures-fda-veterinary-approval-for-multi-species-oncology-drug-trials 2025-12-11T17:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/9f26a4dab5150d83/nanology-advances-novel-intratumoral-cisplatin-formulation-for-fatal-pediatric-brain-cancer-dipg 2025-12-11T17:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/97e399b928503681/sen-jam-pharmaceutical-secures-equity-backed-partnership-for-phase-3-trial-of-first-in-category-hangover-prevention-therapy 2025-12-11T17:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/f78262a369594aca/her2-negative-breast-cancer-pipeline-expands-with-75-therapies-from-70-companies 2025-12-11T17:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/05ab665134d32fdd/baxter-smart-infusion-pump-emr-integration-reduces-safety-alerts-by-up-to-50-in-real-world-study 2025-12-11T17:32:28+00:00 hourly 0.9 https://trial.medpath.com/news/0d9fd8f7a71d686b/biohaven-s-bhv-1510-shows-promising-efficacy-in-phase-1-trial-combining-trop2-adc-with-cemiplimab 2025-12-11T17:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/ed1667b1acb9d4c4/tempramed-launches-vivi-cap-smart-first-digital-temperature-protection-device-for-insulin-and-glp-1-medications 2025-12-11T17:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/a4d6d1ac47f50e1a/major-pharma-giants-return-to-neuroscience-with-26-6-billion-in-strategic-acquisitions 2025-12-11T17:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/d791ef8913bdf20e/galderma-initiates-phase-ii-trial-of-nemolizumab-for-chronic-pruritus-of-unknown-origin 2025-12-11T17:29:46+00:00 hourly 0.9 https://trial.medpath.com/news/7a67473b3683881d/disco-pharmaceuticals-secures-eur36m-seed-financing-and-appoints-new-ceo-to-advance-surfaceome-targeted-cancer-therapies 2025-12-11T17:29:43+00:00 hourly 0.9 https://trial.medpath.com/news/8f8a1bd1e807c817/ac-immune-s-alpha-synuclein-immunotherapy-shows-promise-in-slowing-parkinson-s-disease-progression 2025-12-11T17:29:22+00:00 hourly 0.9 https://trial.medpath.com/news/bfd600d642705c13/guardant-health-partners-with-trial-library-to-expand-cancer-clinical-trial-access-using-ai-and-genomic-data 2025-12-11T17:28:07+00:00 hourly 0.9 https://trial.medpath.com/news/55025bebd0b7da2b/fda-approves-first-at-home-brain-stimulation-device-for-major-depression-treatment 2025-12-11T17:28:01+00:00 hourly 0.9 https://trial.medpath.com/news/94f9d443f5c3cbc0/uk-achieves-global-first-patient-recruitment-in-novel-copd-treatment-trial 2025-12-11T17:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/8cce9db953540602/60-degrees-pharmaceuticals-expands-arakoda-sales-strategy-following-positive-commercial-pilot-results 2025-12-11T17:27:30+00:00 hourly 0.9 https://trial.medpath.com/news/f52be89ce595021b/transcode-therapeutics-advances-ttx-mc138-to-phase-2a-trial-for-minimal-residual-disease-in-colorectal-cancer 2025-12-11T17:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/682757f67c8e39ae/atossa-therapeutics-receives-fda-rare-pediatric-disease-designation-for-z-endoxifen-in-duchenne-muscular-dystrophy 2025-12-11T17:26:02+00:00 hourly 0.9 https://trial.medpath.com/news/ca51859f200e4be4/modified-water-vapor-therapy-shows-promise-for-large-volume-benign-prostatic-hyperplasia-treatment 2025-12-11T16:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/7979e118d7a824b4/medicines-for-malaria-venture-joins-iicon-consortium-to-accelerate-infectious-disease-drug-discovery 2025-12-11T13:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/c7848608b93c2565/chinese-scientists-develop-novel-cancer-therapy-using-reprogrammed-mast-cells-to-convert-cold-tumors-into-hot-targets 2025-12-11T13:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/2db5af504aa3324d/mabylon-initiates-first-in-human-trial-of-novel-tri-specific-antibody-my006-for-peanut-allergy-prevention 2025-12-11T13:27:26+00:00 hourly 0.9 https://trial.medpath.com/news/d32706ffd6d20990/ideaya-biosciences-completes-enrollment-in-pivotal-trial-for-darovasertib-combination-in-metastatic-uveal-melanoma 2025-12-11T13:25:30+00:00 hourly 0.9 https://trial.medpath.com/news/a194562f63ccd117/bioversys-initiates-phase-3-trial-for-bv100-antibiotic-following-50-mortality-reduction-in-phase-2 2025-12-11T13:25:27+00:00 hourly 0.9 https://trial.medpath.com/news/48e041810b18d01d/centessa-pharmaceuticals-advances-orexin-agonist-pipeline-with-leadership-transition-and-promising-clinical-data 2025-12-11T12:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/af1dcedd81340397/rhythm-pharmaceuticals-reports-positive-phase-2-results-for-setmelanotide-in-prader-willi-syndrome 2025-12-11T09:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/4ebf9234a4d00059/zealand-pharma-unveils-metabolic-frontier-2030-strategy-with-otr-therapeutics-partnership 2025-12-11T09:26:44+00:00 hourly 0.9 https://trial.medpath.com/news/b9069df543cd4415/sanofi-secures-chinese-approval-for-two-rare-blood-disorder-therapies-qfitlia-and-cablivi 2025-12-11T09:26:35+00:00 hourly 0.9 https://trial.medpath.com/news/ffff32b44543195b/deep-intelligent-pharma-secures-50m-series-d-to-expand-ai-powered-clinical-documentation-platform 2025-12-11T09:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/55040ac8fdfdb1a2/cell-and-gene-therapy-market-projected-to-reach-105-billion-by-2033-as-clinical-pipeline-expands 2025-12-11T09:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/60d4e188f086ee65/chugai-pharmaceutical-establishes-u-s-partnering-office-to-accelerate-global-open-innovation-strategy 2025-12-11T09:25:28+00:00 hourly 0.9 https://trial.medpath.com/news/9ad5e8f9551f97b7/pll-therapeutics-advances-gut-targeting-als-therapy-to-phase-ii-after-positive-safety-results 2025-12-11T05:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/210ca0867575c90e/heartbeam-receives-fda-clearance-for-first-cable-free-12-lead-ecg-device-for-home-arrhythmia-assessment 2025-12-11T05:27:21+00:00 hourly 0.9 https://trial.medpath.com/news/41119efa9ded81e2/blood-tests-show-promise-for-personalized-breast-cancer-treatment-selection 2025-12-11T05:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/7a3e869ca48257a7/senator-hawley-challenges-fda-over-alleged-delay-in-mifepristone-safety-review 2025-12-11T05:26:14+00:00 hourly 0.9 https://trial.medpath.com/news/7e16ecf5320b1359/natera-s-signatera-mrd-test-shows-powerful-prognostic-value-in-phase-iii-pallas-breast-cancer-study 2025-12-11T05:25:28+00:00 hourly 0.9 https://trial.medpath.com/news/6b3fbd95d2e55ff0/ro-telehealth-platform-demonstrates-clinical-trial-level-semaglutide-outcomes-in-real-world-study 2025-12-11T05:25:22+00:00 hourly 0.9 https://trial.medpath.com/news/c41237d17bd3b949/bbot-presents-first-in-class-ras-pi3ka-breaker-bbo-10203-data-at-sabcs-launches-phase-1-trial 2025-12-11T01:33:40+00:00 hourly 0.9 https://trial.medpath.com/news/6241978831f87acc/gri-bio-s-gri-0621-shows-promise-in-phase-2a-ipf-trial-with-disease-modifying-potential 2025-12-11T01:30:14+00:00 hourly 0.9 https://trial.medpath.com/news/f2c7b22c9bd96e11/moderna-partners-with-nanexa-on-pharmashell-drug-delivery-technology-in-500m-deal 2025-12-11T01:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/3eac599039fb425e/aardvark-therapeutics-initiates-international-expansion-of-phase-3-hero-trial-for-prader-willi-syndrome-treatment 2025-12-11T01:28:39+00:00 hourly 0.9 https://trial.medpath.com/news/1f3091df38efaeb3/fda-expert-panel-calls-for-testosterone-therapy-label-revisions-following-cardiovascular-safety-data 2025-12-11T01:28:22+00:00 hourly 0.9 https://trial.medpath.com/news/1a35d215293c59b9/lir-life-sciences-advances-needle-free-obesity-treatment-with-novel-transdermal-glp-gip-delivery-platform 2025-12-11T01:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/a21d19faf693951b/serina-therapeutics-responds-to-fda-clinical-hold-on-ser-252-parkinson-s-disease-treatment 2025-12-11T01:28:17+00:00 hourly 0.9 https://trial.medpath.com/news/8329e0599dd1f7b3/mediwound-s-nexobrid-r-demonstrates-92-5-reduction-in-traumatic-tattoos-from-blast-and-abrasion-injuries 2025-12-11T01:26:36+00:00 hourly 0.9 https://trial.medpath.com/news/bd5a020a234afbbf/karyopharm-prepares-for-pivotal-2026-with-phase-3-myelofibrosis-data-expected-in-march 2025-12-11T01:26:02+00:00 hourly 0.9 https://trial.medpath.com/news/e1e581c1edbbff60/ai-powered-multimodal-models-show-superior-breast-cancer-recurrence-risk-prediction-in-tailorx-validation-study 2025-12-11T01:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/71b4bd1fab272b73/medinatura-issues-nationwide-recall-of-reboost-nasal-spray-due-to-life-threatening-microbial-contamination 2025-12-10T21:40:36+00:00 hourly 0.9 https://trial.medpath.com/news/fdee048ddbf8c3d4/carrick-therapeutics-reports-promising-phase-2-results-for-cdk7-inhibitor-samuraciclib-in-advanced-breast-cancer 2025-12-10T21:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/4ac9b4f741614e6a/fda-launches-tempo-digital-health-pilot-to-accelerate-access-to-chronic-disease-management-technologies 2025-12-10T21:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/f03d9fa6d88195ed/fibrobiologics-files-patent-for-novel-fibroblast-based-chondrocyte-spheroid-platform-targeting-orthopedic-conditions 2025-12-10T21:36:19+00:00 hourly 0.9 https://trial.medpath.com/news/dd9a75fc1e1646ac/johnson-johnson-reports-100-procedural-success-in-atrial-fibrillation-study-and-durable-remissions-in-multiple-myeloma-trial 2025-12-10T21:36:16+00:00 hourly 0.9 https://trial.medpath.com/news/30dc5fd7d281ca55/romosozumab-demonstrates-superior-fracture-reduction-compared-to-pth-analogs-in-real-world-study 2025-12-10T21:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/bf7508883b310cf1/trispecific-antibody-shows-promise-for-immunotherapy-resistant-tumors-through-multi-target-approach 2025-12-10T21:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/a953cce8f05dbdbd/indivumed-partners-with-university-of-rochester-to-accelerate-precision-cancer-therapeutic-discovery 2025-12-10T21:33:25+00:00 hourly 0.9 https://trial.medpath.com/news/2bba462694f4faf2/bioxodes-secures-eur5-5-million-to-advance-first-in-class-stroke-treatment-toward-pivotal-trial 2025-12-10T21:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/fbc8b0396178bafd/children-s-health-defense-petitions-fda-to-revoke-covid-19-vaccine-licenses-over-regulatory-compliance-concerns 2025-12-10T21:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/d78ac3fee4654268/researchers-identify-fdx2-as-potential-drug-target-for-friedreich-s-ataxia-treatment 2025-12-10T21:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/e58ff7e3051e0952/maia-biotechnology-advances-first-in-class-telomere-targeting-therapy-ateganosine-into-phase-3-for-treatment-resistant-nsclc 2025-12-10T21:27:17+00:00 hourly 0.9 https://trial.medpath.com/news/2d28c1674c9011d3/stanford-study-identifies-biological-mechanism-behind-mrna-covid-19-vaccine-associated-myocarditis 2025-12-10T21:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/9c5f8cbccdafba28/genfit-s-gns561-combination-therapy-shows-disease-stabilization-in-advanced-cholangiocarcinoma-patients 2025-12-10T21:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/e7686450072c2882/sentynl-therapeutics-partners-with-mytomorrows-to-expand-global-access-to-rare-disease-treatments 2025-12-10T21:26:32+00:00 hourly 0.9 https://trial.medpath.com/news/60978c6ba7917eef/van-andel-institute-and-cure-parkinson-s-renew-1-5m-annual-funding-for-world-s-largest-parkinson-s-drug-repurposing-initiative 2025-12-10T21:25:59+00:00 hourly 0.9 https://trial.medpath.com/news/0f2a26196fa2a3f0/curis-secures-20-2-million-funding-to-advance-emavusertib-cancer-pipeline-following-positive-aml-trial-results 2025-12-10T17:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/937b019536396f61/staar-surgical-shareholders-reject-alcon-s-1-6-billion-acquisition-offer-deal-terminated 2025-12-10T17:37:06+00:00 hourly 0.9 https://trial.medpath.com/news/c7ea5b6b4525f3a3/azura-ophthalmics-receives-positive-fda-feedback-for-first-in-class-dry-eye-treatment-targeting-meibomian-gland-dysfunction 2025-12-10T17:35:42+00:00 hourly 0.9 https://trial.medpath.com/news/73f0133fe6650449/pfizer-allocates-6-billion-for-strategic-acquisitions-in-internal-medicine-and-immunology-following-metsera-deal 2025-12-10T17:35:31+00:00 hourly 0.9 https://trial.medpath.com/news/1029c09863206fe4/psithera-raises-47-5-million-series-a-to-develop-oral-drugs-for-tnf-superfamily-targets 2025-12-10T17:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/8f628c852dc7aed3/northwestern-scientists-develop-15-minute-hepatitis-c-test-enabling-same-day-treatment 2025-12-10T17:35:17+00:00 hourly 0.9 https://trial.medpath.com/news/5ec1177dacbc72ce/dare-bioscience-launches-first-evidence-based-topical-sildenafil-cream-for-women-s-sexual-health 2025-12-10T17:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/d2b4d9f4ac52a6a5/russia-completes-first-production-batches-of-personalized-mrna-cancer-vaccine 2025-12-10T17:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/5e9bea20d4aa31f2/fda-approves-five-novel-lung-cancer-therapies-in-2025-advancing-precision-medicine-and-immunotherapy 2025-12-10T17:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/3c738d3bc5220ae8/igyxos-biotherapeutics-reports-positive-phase-1-results-for-igx12-first-in-class-monoclonal-antibody-targeting-male-and-female-infertility 2025-12-10T17:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/f0693c1943ec7929/bantam-pharmaceutical-initiates-first-in-class-btm-3566-phase-1-trial-for-aggressive-cancers 2025-12-10T17:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/a5139b7d8c08f3c6/barinthus-bio-s-vtp-1000-shows-promising-safety-and-dose-dependent-effects-in-phase-1-celiac-disease-trial 2025-12-10T17:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/0ccd06ff53717fb8/diakonos-oncology-secures-7-million-cprit-grant-to-advance-doc1021-dendritic-cell-therapy-in-refractory-melanoma 2025-12-10T17:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/756616305e0298cc/ventus-therapeutics-doses-first-patient-in-phase-2-trial-of-vent-03-cgas-inhibitor-for-lupus 2025-12-10T17:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/72cc78acd81511c2/epilepsygtx-secures-33-million-series-a-to-advance-single-dose-gene-therapy-for-focal-refractory-epilepsy 2025-12-10T17:29:56+00:00 hourly 0.9 https://trial.medpath.com/news/5f6423c3bac6a7b8/tildrakizumab-demonstrates-sustained-safety-profile-over-four-years-in-psoriatic-arthritis-extension-study 2025-12-10T17:29:53+00:00 hourly 0.9 https://trial.medpath.com/news/e4fac4385857ca67/ontario-launches-fast-program-with-scemblix-as-first-priority-cancer-therapy-for-cml-patients 2025-12-10T17:28:50+00:00 hourly 0.9 https://trial.medpath.com/news/8439df29ee924978/kazia-s-paxalisib-shows-promise-in-advanced-breast-cancer-with-76-tumor-reduction-and-immune-system-reinvigoration 2025-12-10T17:28:01+00:00 hourly 0.9 https://trial.medpath.com/news/a0ecff3fe55b8f2a/cellenkos-ck0804-regulatory-t-cell-therapy-shows-promise-in-jak-inhibitor-resistant-myelofibrosis 2025-12-10T17:27:43+00:00 hourly 0.9 https://trial.medpath.com/news/1b984202e91eab58/landmark-rsi-trial-reveals-etomidate-safer-than-ketamine-for-emergency-intubation 2025-12-10T17:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/9cf06fc70ee25f99/ideaya-biosciences-submits-ind-for-first-in-class-kat6-7-dual-inhibitor-ide574-targeting-breast-and-lung-cancers 2025-12-10T17:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/3c45acd1eb270816/allonnia-raises-20-million-to-advance-biotechnology-platform-for-critical-mineral-recovery 2025-12-10T17:26:31+00:00 hourly 0.9 https://trial.medpath.com/news/80dfa45ff003e177/journey-medical-reports-positive-phase-1-results-for-emrosi-rosacea-treatment-showing-no-impact-on-microbiome 2025-12-10T17:26:06+00:00 hourly 0.9 https://trial.medpath.com/news/3f97c77e9925e746/nitinotes-initiates-pivotal-ease-trial-for-automated-endoscopic-sleeve-gastroplasty-system 2025-12-10T17:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/03a828f853ac5a71/trial-library-secures-10-million-series-a-to-democratize-clinical-trial-access-through-ai-enabled-community-platform 2025-12-10T17:24:50+00:00 hourly 0.9 https://trial.medpath.com/news/1b36de1e1632a3dd/hemostemix-receives-fda-support-for-basket-protocol-approach-in-stem-cell-therapy-development 2025-12-10T16:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/e65577c50e6aaf00/blossomhill-therapeutics-secures-84-million-to-advance-first-in-class-egfr-inhibitor-for-lung-cancer 2025-12-10T13:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/7de2653e44b08e32/mmi-achieves-major-milestones-with-fda-clearance-for-robotic-microsurgical-instruments-and-new-cpt-reimbursement-code 2025-12-10T13:37:11+00:00 hourly 0.9 https://trial.medpath.com/news/6b3ae94e92906e6f/glp-1-drugs-show-no-increased-cancer-risk-in-large-meta-analysis-of-94000-patients 2025-12-10T13:37:02+00:00 hourly 0.9 https://trial.medpath.com/news/fae163d4f319b5d3/pharmala-biotech-advances-mdma-manufacturing-and-novel-ala-002-development-for-clinical-trials 2025-12-10T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/1fd082439cae69c5/oxford-biotherapeutics-partners-with-gsk-in-multi-target-cancer-drug-discovery-collaboration 2025-12-10T13:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/7c87e3fe338b6833/physiomics-expands-biometrics-services-with-gardp-partnership-for-antibiotic-trial-optimization 2025-12-10T13:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/e4223081e3971de1/cytiva-and-fida-biosystems-partner-to-accelerate-drug-discovery-through-combined-analytical-platform 2025-12-10T13:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/dc358862b3f2f0e9/biotechnology-sector-experiences-market-volatility-following-december-2025-clinical-trial-results 2025-12-10T13:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/ade4a1d78974a999/fda-approves-first-gene-therapy-for-wiskott-aldrich-syndrome-marking-historic-milestone-for-non-profit-drug-development 2025-12-10T13:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/ed8ee76370657dc7/bendit-technologies-receives-fda-clearance-for-world-s-smallest-steerable-microcatheter 2025-12-10T13:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/954de32e17e05735/vortex-launches-clinical-study-to-transform-cancer-monitoring-with-live-cell-liquid-biopsy-technology 2025-12-10T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/efd699ec82a8cecf/polpharma-biologics-partners-with-libbs-farmaceutica-to-bring-autoimmune-biosimilar-to-brazilian-market 2025-12-10T09:26:06+00:00 hourly 0.9 https://trial.medpath.com/news/dcc319bba3ee953b/fda-grants-orphan-drug-designation-to-gsk-s-b7-h3-targeted-adc-for-small-cell-lung-cancer 2025-12-10T09:25:29+00:00 hourly 0.9 https://trial.medpath.com/news/df2b50b2728d59eb/lunai-bioworks-launches-ai-driven-drug-discovery-programs-for-alcohol-use-disorder-and-parkinson-s-disease 2025-12-10T05:29:15+00:00 hourly 0.9 https://trial.medpath.com/news/e12aa1005ff5d1e5/medicenna-s-mdna11-shows-promising-anti-tumor-activity-in-advanced-solid-tumors-at-esmo-io-congress-2025 2025-12-10T05:28:02+00:00 hourly 0.9 https://trial.medpath.com/news/76de43dd40b558b7/cleveland-clinic-researchers-identify-distinct-biomarkers-for-predicting-car-t-cell-therapy-response-in-b-cell-lymphoma 2025-12-10T05:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/0e5f7d4d663230e7/uspto-introduces-subject-matter-eligibility-declarations-to-streamline-patent-protection-for-life-sciences-innovations 2025-12-10T05:27:28+00:00 hourly 0.9 https://trial.medpath.com/news/789acb6846842c4c/innovent-initiates-first-in-human-trial-of-ibi3011-novel-anti-il-1rap-monoclonal-antibody-for-gout-treatment 2025-12-10T05:26:43+00:00 hourly 0.9 https://trial.medpath.com/news/5a5b5590bd455eda/fda-reverses-course-on-nmn-reinstates-dietary-supplement-status-after-legal-challenge 2025-12-10T05:26:35+00:00 hourly 0.9 https://trial.medpath.com/news/cdba75b145227875/fda-approves-first-gene-therapy-for-wiskott-aldrich-syndrome 2025-12-10T05:26:30+00:00 hourly 0.9 https://trial.medpath.com/news/468202f3fc8b8462/fda-approves-provee-system-first-next-generation-prostatic-urethral-stent-for-benign-prostatic-hyperplasia 2025-12-10T05:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/bd3ac79ee65b2323/akari-therapeutics-reports-promising-preclinical-data-for-aktx-101-in-k-ras-mutant-pancreatic-cancer 2025-12-10T03:21:37+00:00 hourly 0.9 https://trial.medpath.com/news/8f3a38b9e996d6fe/hhs-adds-duchenne-muscular-dystrophy-to-newborn-screening-panel-boosting-sarepta-s-market-prospects 2025-12-10T03:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/20b509cdaf4eb384/thermo-fisher-scientific-launches-integrated-drug-development-platform-to-address-industry-fragmentation 2025-12-10T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/76d4577d8cac30b7/fda-grants-breakthrough-therapy-designation-to-adrabetadex-for-infantile-onset-niemann-pick-disease-type-c 2025-12-10T00:17:56+00:00 hourly 0.9 https://trial.medpath.com/news/e9856a10ebfa2780/idorsia-s-dual-orexin-receptor-antagonist-wins-inaugural-prix-galien-bridges-award-for-insomnia-treatment-innovation 2025-12-10T00:17:54+00:00 hourly 0.9 https://trial.medpath.com/news/aca0cff88cd9bd72/eli-lilly-announces-6-billion-alabama-manufacturing-facility-for-glp-1-and-small-molecule-medicines 2025-12-10T00:17:14+00:00 hourly 0.9 https://trial.medpath.com/news/84e89e50f3b52f4f/hothouse-therapeutics-emerges-with-ps2-9m-to-revolutionize-plant-based-drug-manufacturing-using-ai 2025-12-10T00:17:03+00:00 hourly 0.9 https://trial.medpath.com/news/49983c0bbcdcb277/magnus-medical-enrolls-first-patient-in-11-6m-dod-funded-trial-of-saint-therapy-for-postpartum-depression 2025-12-10T00:16:54+00:00 hourly 0.9 https://trial.medpath.com/news/a9cb91ec1415e6ba/lexicon-pharmaceuticals-advances-multiple-late-stage-programs-with-key-2026-2027-milestones 2025-12-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/98b93956cd7b9d14/cardiff-oncology-s-plk1-inhibitor-onvansertib-shows-promise-in-cmml-trial-and-advances-toward-phase-iii-in-colorectal-cancer 2025-12-09T21:39:14+00:00 hourly 0.9 https://trial.medpath.com/news/5cb0a6cb428f67f1/forensic-review-reveals-undisclosed-deaths-and-data-discrepancies-in-pfizer-covid-19-vaccine-trial 2025-12-09T21:35:51+00:00 hourly 0.9 https://trial.medpath.com/news/165bd783c5e09721/pfizer-biontech-lp-8-1-adapted-covid-19-vaccine-receives-regulatory-approval-in-australia-and-new-zealand 2025-12-09T21:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/cbd8f44ae097bec6/dexamethasone-prophylaxis-reduces-severe-neurotoxicity-in-car-t-therapy-without-compromising-efficacy 2025-12-09T21:34:25+00:00 hourly 0.9 https://trial.medpath.com/news/beb260a03aea6b74/regenerative-patch-technologies-initiates-phase-iib-trial-for-stem-cell-based-retinal-implant-in-geographic-atrophy 2025-12-09T21:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/3940e0031c8785f5/cytoagents-to-present-cto1681-data-demonstrating-reduced-car-t-toxicity-without-compromising-efficacy-at-esmo-2025 2025-12-09T21:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/2decbbf5b11c83e2/real-world-data-and-ai-transform-rare-disease-clinical-trial-design-through-synthetic-control-arms 2025-12-09T21:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/b7bfadf552d79b9a/fda-accepts-nda-for-trn-257-first-once-nightly-low-sodium-oxybate-for-narcolepsy-and-idiopathic-hypersomnia 2025-12-09T21:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/e573a2a3d2ec9585/phanes-therapeutics-to-present-first-clinical-data-for-spevatamig-in-metastatic-pancreatic-cancer-at-asco-gi-2026 2025-12-09T21:29:09+00:00 hourly 0.9 https://trial.medpath.com/news/65b7fc2a2242afa1/ucla-researchers-develop-first-small-molecule-inhibitor-for-undruggable-cancer-protein-igf2bp3 2025-12-09T21:28:32+00:00 hourly 0.9 https://trial.medpath.com/news/f0a8fddacf12ac6f/ensysce-biosciences-enrolls-first-patient-in-pivotal-phase-3-trial-for-abuse-resistant-opioid-pf614 2025-12-09T21:28:07+00:00 hourly 0.9 https://trial.medpath.com/news/2a02406804b312b5/celldex-advances-barzolvolimab-into-phase-3-trials-for-cold-urticaria-and-symptomatic-dermographism 2025-12-09T21:28:04+00:00 hourly 0.9 https://trial.medpath.com/news/77a76f43130c1619/pds-biotechnology-secures-new-japanese-patent-for-cancer-immunotherapy-pds0101-extending-protection-into-2040s 2025-12-09T21:28:01+00:00 hourly 0.9 https://trial.medpath.com/news/df56338fcf4eb39e/airiver-medical-receives-fda-ide-approval-for-pivotal-trial-of-drug-coated-balloon-in-chronic-rhinosinusitis 2025-12-09T21:27:21+00:00 hourly 0.9 https://trial.medpath.com/news/329a20ed3c2be55c/pulse-biosciences-advances-nanosecond-pulsed-field-ablation-technology-with-fda-approvals-for-cardiac-and-thyroid-cancer-studies 2025-12-09T21:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/844743d2a746e29f/new-mexico-accelerates-psilocybin-therapy-program-launch-to-december-2026-new-jersey-approves-hospital-based-pilot 2025-12-09T21:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/f59f3dce810eb8b1/health-canada-approves-first-postpartum-depression-specific-drug-zurzuvae 2025-12-09T21:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/f9156fd2a9da5218/enveda-advances-first-in-class-oral-therapy-env-294-to-phase-2-trials-for-atopic-dermatitis-and-asthma 2025-12-09T21:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/a561bd97e3d9aff7/myriad-genetics-advances-ultrasensitive-mrd-testing-with-march-2026-clinical-launch 2025-12-09T17:42:31+00:00 hourly 0.9 https://trial.medpath.com/news/c4c9f8ac3ca193c3/pfizer-secures-2-1-billion-deal-for-yaopharma-s-oral-glp-1-obesity-drug 2025-12-09T17:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/ea30efd46637abd2/epivax-and-fda-scientists-identify-immunogenicity-risks-in-generic-teriparatide-impurities 2025-12-09T17:41:22+00:00 hourly 0.9 https://trial.medpath.com/news/55f9101bb280f170/fda-initiates-safety-review-of-infant-rsv-drugs-beyfortus-and-enflonsia-amid-kennedy-administration-scrutiny 2025-12-09T17:39:44+00:00 hourly 0.9 https://trial.medpath.com/news/ec5a7f23215c2617/sonothera-s-ultrasound-gene-therapy-achieves-65-normal-factor-viii-levels-in-hemophilia-a-primate-study 2025-12-09T17:38:02+00:00 hourly 0.9 https://trial.medpath.com/news/f62f67ed1f0524cb/pfizer-secures-exclusive-rights-to-yaopharma-s-oral-glp-1-agonist-yp05002-in-2-1-billion-deal 2025-12-09T17:36:56+00:00 hourly 0.9 https://trial.medpath.com/news/b777aa9287d09e10/vincere-cancer-center-launches-clinical-study-for-syantra-s-immune-based-breast-cancer-screening-test 2025-12-09T17:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/2494a1d053a2065f/experimental-narcolepsy-drug-oveporexton-shows-cognitive-benefits-in-phase-2-trial 2025-12-09T17:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/ae865002104f3d14/probiogen-partners-with-spica-therapeutics-to-advance-first-in-class-anti-cd163-antibody-st101-for-cancer-immunotherapy 2025-12-09T17:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/0d18feb945de8055/phillips-medisize-showcases-advanced-inhaled-drug-delivery-platforms-at-ddl-2025-following-vectura-acquisition 2025-12-09T17:34:34+00:00 hourly 0.9 https://trial.medpath.com/news/a4a9cd32d480fed2/verismo-s-novel-kir-car-platform-shows-superior-tumor-control-with-reduced-toxicity-in-preclinical-studies 2025-12-09T17:34:12+00:00 hourly 0.9 https://trial.medpath.com/news/96132c082ad9eb48/create-medicines-initiates-first-in-class-frontline-hcc-trial-combining-in-vivo-car-therapy-mt-303-with-standard-immunotherapy 2025-12-09T17:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/40130ced0e03e0cf/destiny-ovarian01-phase-3-trial-launches-to-test-enhertu-as-first-line-maintenance-therapy-for-her2-expressing-ovarian-cancer 2025-12-09T17:34:07+00:00 hourly 0.9 https://trial.medpath.com/news/3b95594f41bd96bb/enterprise-therapeutics-etd001-shows-promise-as-novel-inhaled-enac-blocker-for-cystic-fibrosis-treatment 2025-12-09T17:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/e18e6079a73d5563/xinnate-advances-tcp-25-for-epidermolysis-bullosa-with-fda-ind-approval-and-first-clinical-publication 2025-12-09T17:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/0867ea893cd14be4/traction-trial-shows-tranexamic-acid-reduces-blood-transfusions-by-31-in-non-cardiac-surgery-without-increasing-clot-risk 2025-12-09T17:32:20+00:00 hourly 0.9 https://trial.medpath.com/news/ffb4b1ec51fd97ef/real-world-safety-data-confirms-long-term-tolerability-of-enjaymo-in-cold-agglutinin-disease-patients 2025-12-09T17:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/4318fcf22725b544/benchsci-extends-ai-partnership-with-merck-for-preclinical-disease-biology-research 2025-12-09T17:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/61a27b82eaa9449d/actimed-therapeutics-advances-novel-muscle-preserving-therapies-for-cancer-cachexia-and-glp-1-associated-muscle-loss 2025-12-09T17:30:04+00:00 hourly 0.9 https://trial.medpath.com/news/58b1fe5f90cc8425/saol-therapeutics-secures-fda-type-a-meeting-to-advance-sl1009-for-rare-pediatric-mitochondrial-disease 2025-12-09T17:28:58+00:00 hourly 0.9 https://trial.medpath.com/news/6ae7dde86a5e4855/curis-reports-62-5-undetectable-mrd-rate-in-aml-triplet-therapy-study-at-ash-2025 2025-12-09T17:28:11+00:00 hourly 0.9 https://trial.medpath.com/news/f53d1c0eb3a34a18/lee-s-pharmaceutical-acquires-staccato-inhalation-technology-platform-in-strategic-deal-with-ucb-partnership 2025-12-09T17:27:32+00:00 hourly 0.9 https://trial.medpath.com/news/b5edf3f261e26eee/moleculin-advances-miracle-phase-3-aml-trial-with-78-enrollment-first-data-readout-expected-q1-2026 2025-12-09T17:27:29+00:00 hourly 0.9 https://trial.medpath.com/news/84e34685d87c28e8/sibel-health-advances-digital-health-innovation-with-fda-recognition-for-cough-and-scratch-monitoring-technologies 2025-12-09T17:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/5874caceb496d00d/seqtor-phase-iii-trial-shows-equivalent-survival-for-streptozotocin-5-fu-and-everolimus-sequencing-in-pancreatic-nets 2025-12-09T17:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/1fb9d65ad29f7ae1/askbio-s-gene-therapies-ab-1005-and-ab-1002-receive-japan-s-pioneering-regenerative-medical-product-designation 2025-12-09T17:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/a4dd214d9c48d317/century-therapeutics-strengthens-board-with-biotech-veterans-to-advance-ipsc-cell-therapy-pipeline 2025-12-09T17:26:05+00:00 hourly 0.9 https://trial.medpath.com/news/e58e4fc4185f41dc/novartis-kisqali-shows-exceptional-long-term-efficacy-with-25-of-metastatic-breast-cancer-patients-remaining-progression-free-beyond-four-years 2025-12-09T17:26:02+00:00 hourly 0.9 https://trial.medpath.com/news/41452633b8516abe/novartis-commits-1-7-billion-to-ai-driven-allergy-drug-discovery-partnership-with-relation-therapeutics 2025-12-09T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/ed67315ae913d51b/relation-therapeutics-secures-55-million-novartis-partnership-for-ai-driven-atopic-disease-target-discovery 2025-12-09T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/d8f83aff6c290a00/curifylabs-launches-3d-printed-veterinary-medicine-platform-to-address-pet-medication-compliance-challenges 2025-12-09T17:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/4642084355c26ad4/federal-study-launches-to-evaluate-oregon-s-legal-psilocybin-program-for-substance-use-disorders 2025-12-09T17:25:23+00:00 hourly 0.9 https://trial.medpath.com/news/e288506a510b2804/fda-tightens-car-t-approval-standards-mandating-randomized-controlled-trials-for-future-therapies 2025-12-09T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/6c638e65ffca84b6/cannabix-technologies-marijuana-breath-test-device-passes-fcc-emissions-testing-advances-toward-u-s-and-canadian-market-entry 2025-12-09T14:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/49e166a7f8ae7943/generic-drug-industry-shows-strong-growth-as-biosimilar-launches-drive-revenue-expansion 2025-12-09T13:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/90d9bacf54933cd2/senti-bio-s-senti-202-car-nk-therapy-achieves-50-response-rate-in-relapsed-refractory-aml-receives-fda-rmat-designation 2025-12-09T13:30:54+00:00 hourly 0.9 https://trial.medpath.com/news/8ed17007b0214031/ose-immunotherapeutics-expands-lusvertikimab-program-with-new-autoimmune-indications-in-2026-2028-strategic-plan 2025-12-09T13:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/55934390ddf67b65/terns-pharmaceuticals-closes-747-5-million-public-offering-to-advance-bcr-abl-inhibitor-tern-701 2025-12-09T13:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/c7038843c9f1a9c0/cepi-awards-16m-to-korean-consortium-for-first-ever-sfts-mrna-vaccine-development 2025-12-09T13:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/b6ca34288c08a18e/enterome-s-eo2463-achieves-100-response-rate-in-follicular-lymphoma-phase-2-trial 2025-12-09T13:28:37+00:00 hourly 0.9 https://trial.medpath.com/news/4ba57aba3f244596/dizal-reports-promising-hematology-data-at-ash-2025-with-jak1-inhibitor-golidocitinib-and-dual-btk-lyn-inhibitor-birelentinib 2025-12-09T13:27:47+00:00 hourly 0.9 https://trial.medpath.com/news/2cdf7d6e1f6b3fd2/precision-immunotherapy-shows-promise-for-sepsis-treatment-through-targeted-patient-selection 2025-12-09T13:27:39+00:00 hourly 0.9 https://trial.medpath.com/news/d4c396aea6eeb24e/sk-biopharmaceuticals-cenobamate-and-solriamfetol-receive-nmpa-approval-for-china-market 2025-12-09T13:26:29+00:00 hourly 0.9 https://trial.medpath.com/news/72d34986c6d03ac5/scancell-s-iscib1-shows-74-progression-free-survival-at-16-months-in-advanced-melanoma-phase-2-trial 2025-12-09T13:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/ea5494b7f9ee20c6/cellular-origins-raises-40m-series-a-to-scale-cell-therapy-manufacturing-platform 2025-12-09T13:25:37+00:00 hourly 0.9 https://trial.medpath.com/news/5563f9f921060880/university-of-oxford-launches-world-s-first-phase-ii-nipah-virus-vaccine-trial-in-bangladesh 2025-12-09T13:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/377b0e9c01a47c39/castle-biosciences-gene-expression-tests-show-superior-survival-prediction-in-melanoma-patients 2025-12-09T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/002d19e355e68830/guinea-bissau-suspends-trump-backed-hepatitis-b-vaccine-study-amid-ethical-concerns 2025-12-09T09:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/98a5b1c53555836c/global-pharma-companies-seek-r-d-efficiency-lessons-from-china-s-clinical-trial-success 2025-12-09T09:25:31+00:00 hourly 0.9 https://trial.medpath.com/news/731624713f84b264/fox-chase-cancer-center-demonstrates-safe-home-monitoring-for-t-cell-redirecting-therapies 2025-12-09T09:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/7189f8ec1c3e904c/greenyn-biotechnology-s-insumate-r-mcirbp-19-bitter-melon-peptide-achieves-triple-certification-for-metabolic-health 2025-12-09T09:24:49+00:00 hourly 0.9 https://trial.medpath.com/news/dd7a4e171bd51ec0/mercury-bio-partners-with-meta-flux-to-accelerate-cns-therapeutics-using-ai-powered-disease-modeling-and-novel-delivery-platform 2025-12-09T05:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/ef9f9532b5d9b34a/genfit-s-g1090n-shows-promising-phase-1-results-for-acute-on-chronic-liver-failure-treatment 2025-12-09T05:28:16+00:00 hourly 0.9 https://trial.medpath.com/news/a6968e2bf19d74d5/ptab-pendulum-swings-back-as-patent-enforcement-landscape-shifts-toward-stronger-ip-protection 2025-12-09T05:26:34+00:00 hourly 0.9 https://trial.medpath.com/news/4ca66ff55a4e7003/kymera-therapeutics-closes-upsized-602-million-public-offering-to-advance-targeted-protein-degradation-pipeline 2025-12-09T05:26:29+00:00 hourly 0.9 https://trial.medpath.com/news/d30e7ee966066431/vera-therapeutics-raises-300-million-in-public-offering-to-advance-immunologic-disease-pipeline 2025-12-09T05:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/86d66790bba91c1f/pathai-expands-european-presence-with-major-academic-medical-center-partnerships-for-ai-powered-pathology-solutions 2025-12-09T01:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/f063981de76da956/casi-pharmaceuticals-cid-103-shows-73-response-rate-in-phase-1-immune-thrombocytopenia-trial 2025-12-09T01:35:03+00:00 hourly 0.9 https://trial.medpath.com/news/3a62e4fcc73571bc/aleta-001-shows-promise-in-phase-i-ii-trial-for-relapsed-b-cell-malignancies-after-car-t-therapy 2025-12-09T01:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/a7ce7eb48b496a45/assembly-biosciences-herpes-drugs-show-98-reduction-in-viral-shedding-in-phase-i-studies 2025-12-09T01:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/b1bd40baf408338b/qihan-biotech-initiates-phase-i-iia-trial-of-off-the-shelf-car-t-therapy-for-refractory-lupus 2025-12-09T01:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/5f6e27299c63899b/wave-life-sciences-wve-007-shows-superior-fat-loss-in-phase-1-trial-stock-surges-146 2025-12-09T01:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/87f77e99e0f40d49/pfizer-s-mrna-flu-vaccine-shows-30-superior-effectiveness-in-phase-3-trial 2025-12-09T01:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/7b8a0515abab288a/imviva-biotech-reports-promising-car-t-cell-therapy-data-at-ash-2025-meeting 2025-12-09T01:31:04+00:00 hourly 0.9 https://trial.medpath.com/news/1bf1b3e7f934dd3d/covid-19-mrna-vaccines-show-promise-in-boosting-cancer-immunotherapy-effectiveness 2025-12-09T01:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/6485a9c7fb5b56d5/morning-immunotherapy-administration-reduces-death-risk-by-63-in-small-cell-lung-cancer-patients 2025-12-09T01:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/dcb766f49e3a0cc3/world-first-base-edited-car-t-therapy-shows-64-disease-free-survival-in-previously-untreatable-t-cell-leukemia 2025-12-09T01:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/1c377c5b5c7fbeb6/anova-achieves-rapid-clinical-trial-enrollment-using-ai-powered-platform-enrolling-550-cancer-patients-in-six-months 2025-12-09T01:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/f751e2c0e57aee26/hk-innoen-s-k-cab-receives-brazilian-gmp-certification-advances-global-market-expansion 2025-12-09T01:27:33+00:00 hourly 0.9 https://trial.medpath.com/news/8c6e381eb01dff63/hikma-launches-first-room-temperature-stable-vancomycin-injection-for-critical-sepsis-treatment 2025-12-09T01:26:04+00:00 hourly 0.9 https://trial.medpath.com/news/7024cdfec13d7174/jackson-laboratory-receives-30-million-arpa-h-award-to-develop-ai-powered-virtual-hearts-for-drug-safety-testing 2025-12-09T01:26:01+00:00 hourly 0.9 https://trial.medpath.com/news/933db9ec635c77b9/opna-bio-s-zavabresib-receives-fda-orphan-drug-designation-for-myelofibrosis-treatment 2025-12-08T21:39:16+00:00 hourly 0.9 https://trial.medpath.com/news/f50b479f0ede4367/restem-initiates-first-in-human-trial-of-umbilical-cell-therapy-for-facioscapulohumeral-muscular-dystrophy 2025-12-08T21:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/674c121e731f2c40/seabelife-partners-with-unither-pharmaceuticals-to-advance-sbl03-ophthalmic-formulation-for-retinal-degenerative-disorders 2025-12-08T21:35:17+00:00 hourly 0.9 https://trial.medpath.com/news/72a03b6eadaccb55/nfl-biosciences-raises-efficacy-targets-for-smoking-cessation-drug-candidates-with-novel-mechanism-discovery 2025-12-08T21:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/1f7809f96445c770/geovax-s-gedeptin-shows-disease-stability-in-heavily-pretreated-head-and-neck-cancer-patients 2025-12-08T21:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/e89d9897cb8e51c0/us-government-backs-hikma-s-supreme-court-appeal-in-vascepa-generic-patent-dispute 2025-12-08T21:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/a051eca27723ec08/routine-blood-test-predicts-car-t-therapy-success-in-non-hodgkin-lymphoma-patients 2025-12-08T21:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/015579a59a608284/reveal-genomics-unveils-breakthrough-cns-progression-score-for-her2-breast-cancer-brain-metastasis-prediction-at-sabcs-2025 2025-12-08T21:30:43+00:00 hourly 0.9 https://trial.medpath.com/news/37aaa80a7b3c9956/novel-astatine-211-targeted-alpha-therapy-shows-promise-for-radioactive-iodine-refractory-thyroid-cancer 2025-12-08T21:30:07+00:00 hourly 0.9 https://trial.medpath.com/news/345ee62990d0d7d9/subcutaneous-cevostamab-shows-promise-in-relapsed-refractory-multiple-myeloma-with-38-8-response-rate 2025-12-08T21:29:56+00:00 hourly 0.9 https://trial.medpath.com/news/7a887dc68103fe0b/saskatchewan-adds-merck-s-capvaxive-to-publicly-funded-adult-immunization-program 2025-12-08T21:29:15+00:00 hourly 0.9 https://trial.medpath.com/news/15ee0596488ea757/terns-tern-701-shows-superior-molecular-response-rates-in-chronic-myeloid-leukemia-challenging-novartis-scemblix-dominance 2025-12-08T21:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/a49a3e64de20740a/eczema-drug-development-pipeline-surges-with-100-companies-advancing-novel-therapies 2025-12-08T21:28:23+00:00 hourly 0.9 https://trial.medpath.com/news/c517f5640c1cb2c1/kamada-discontinues-phase-3-inhaled-aat-trial-following-futility-analysis-maintains-strong-financial-outlook 2025-12-08T21:27:29+00:00 hourly 0.9 https://trial.medpath.com/news/df43f0864112bf8c/fda-clears-enhanced-omnipod-5-algorithm-with-lower-glucose-target-for-improved-diabetes-management 2025-12-08T21:26:53+00:00 hourly 0.9 https://trial.medpath.com/news/ab3af80711549aa2/fda-approves-first-bioequivalent-injectable-antiemetic-solution-for-veterinary-use 2025-12-08T21:26:28+00:00 hourly 0.9 https://trial.medpath.com/news/caf75f5e78becd55/intellicule-receives-217941-nih-grant-to-develop-ai-powered-cryo-em-software-for-drug-discovery 2025-12-08T21:26:25+00:00 hourly 0.9 https://trial.medpath.com/news/1bbeb8f582c49d2b/baylor-college-of-medicine-leads-21m-ai-driven-cardiac-drug-safety-initiative-to-reduce-clinical-trial-failures 2025-12-08T21:25:42+00:00 hourly 0.9 https://trial.medpath.com/news/0aec96c05d71735f/spinogenix-s-tazbentetol-shows-rapid-cognitive-improvement-in-alzheimer-s-disease-phase-2-trial 2025-12-08T21:24:35+00:00 hourly 0.9 https://trial.medpath.com/news/e0c4ab5a6de16d3b/elacestrant-combination-therapy-shows-promising-progression-free-survival-results-in-er-metastatic-breast-cancer 2025-12-08T17:48:07+00:00 hourly 0.9 https://trial.medpath.com/news/d520501e2b10e145/ernexa-therapeutics-advances-erna-101-cell-therapy-for-ovarian-cancer-following-fda-alignment-and-promising-preclinical-data 2025-12-08T17:47:17+00:00 hourly 0.9 https://trial.medpath.com/news/758572e441ee4c54/pan-cancer-t-secures-eur10-million-to-advance-tcr-t-cell-therapy-for-triple-negative-breast-cancer 2025-12-08T17:47:15+00:00 hourly 0.9 https://trial.medpath.com/news/f42010032ab4c816/pillar-biosciences-and-astrazeneca-expand-liquid-biopsy-partnership-to-china-amid-high-cancer-burden 2025-12-08T17:45:27+00:00 hourly 0.9 https://trial.medpath.com/news/70fc513c6029ad05/autolus-reports-promising-car-t-results-for-severe-lupus-and-pediatric-leukemia-at-ash-2025 2025-12-08T17:45:19+00:00 hourly 0.9 https://trial.medpath.com/news/280c2ed9c0347c1f/march-biosciences-reports-100-complete-response-rate-with-mb-105-car-t-therapy-in-relapsed-t-cell-lymphoma 2025-12-08T17:45:16+00:00 hourly 0.9 https://trial.medpath.com/news/7d4a78fc9c1d0b92/gsk-terminates-five-year-cancer-partnership-with-ideaya-biosciences-returns-two-synthetic-lethality-programs 2025-12-08T17:44:26+00:00 hourly 0.9 https://trial.medpath.com/news/5e37cc71e10548b0/vyome-s-vt-1953-achieves-primary-endpoints-in-phase-2-trial-for-malignant-fungating-wounds 2025-12-08T17:43:33+00:00 hourly 0.9 https://trial.medpath.com/news/0befa1a62fb60a09/novel-car-t-regulatory-cell-therapy-shows-promise-in-refractory-rheumatoid-arthritis 2025-12-08T17:43:06+00:00 hourly 0.9 https://trial.medpath.com/news/8da6d334c44d89b1/fda-extends-review-timeline-for-agios-mitapivat-thalassemia-application-beyond-pdufa-date 2025-12-08T17:37:04+00:00 hourly 0.9 https://trial.medpath.com/news/369191d313575a92/alr-technologies-prepares-january-2026-relaunch-of-glucurve-pet-cgm-following-successful-manufacturing-tests 2025-12-08T17:37:02+00:00 hourly 0.9 https://trial.medpath.com/news/3c3a4390e936c17f/mirum-pharmaceuticals-acquires-bluejay-therapeutics-for-620m-to-advance-breakthrough-hdv-treatment 2025-12-08T17:36:56+00:00 hourly 0.9 https://trial.medpath.com/news/c788bbaedaa3b187/biomx-discontinues-phase-2b-cystic-fibrosis-trial-due-to-safety-concerns 2025-12-08T17:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/636e9b7887a4c611/fate-therapeutics-reports-promising-phase-1-results-for-off-the-shelf-car-t-therapy-ft819-in-systemic-lupus-erythematosus 2025-12-08T17:35:41+00:00 hourly 0.9 https://trial.medpath.com/news/f2cbaabbc4b6a4a1/scottish-medicines-consortium-approves-rybrevant-combination-for-first-line-egfr-exon-20-insertion-nsclc-treatment 2025-12-08T17:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/9e644399b429eb1e/cytomed-therapeutics-partners-with-malaysian-medical-center-for-first-in-human-gamma-delta-t-cell-cancer-trial 2025-12-08T17:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/ea6269020e7eebbe/citryll-doses-first-patient-in-phase-iia-trial-of-cit-013-for-hidradenitis-suppurativa 2025-12-08T17:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/f0dcd14c55458182/tutor-phase-1-trial-combines-stereotactic-radiosurgery-with-triple-her2-targeted-therapy-for-brain-metastases 2025-12-08T17:31:50+00:00 hourly 0.9 https://trial.medpath.com/news/0fe4bf248c58556b/solid-biosciences-advances-gene-therapy-pipeline-with-next-generation-capsid-technology-and-regulatory-milestones 2025-12-08T17:31:11+00:00 hourly 0.9 https://trial.medpath.com/news/60d1d9fd98b8a42f/convergen-raises-10-million-to-advance-novel-trimtac-platform-targeting-neurodegenerative-disease-protein-aggregates 2025-12-08T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/ad5d1d6f68e249cb/recordati-presents-breakthrough-ai-technology-and-real-world-evidence-for-castleman-disease-at-ash-2025 2025-12-08T17:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/48abd88f4cb65bf7/ss-innovations-files-510-k-submission-for-ssi-mantra-surgical-robot-with-fda 2025-12-08T17:30:27+00:00 hourly 0.9 https://trial.medpath.com/news/f30f2396b7a3123c/vaxcyte-initiates-phase-3-trial-for-vax-31-pneumococcal-vaccine-with-potential-to-expand-disease-coverage-by-34 2025-12-08T17:29:43+00:00 hourly 0.9 https://trial.medpath.com/news/56e115fc559a391b/fda-updates-expanded-access-guidance-to-streamline-investigational-drug-access-for-patients 2025-12-08T17:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/be8b6799c506b4be/moleculin-partners-with-cic-biomagune-to-evaluate-annamycin-for-glioblastoma-treatment 2025-12-08T17:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/7df13c588a5a0dc6/ouro-medicines-gamgertamig-receives-second-fda-orphan-drug-designation-for-immune-thrombocytopenia 2025-12-08T17:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/c7eae266dd37b57a/recursion-s-rec-4881-shows-durable-polyp-reduction-in-familial-adenomatous-polyposis-phase-2-trial 2025-12-08T17:28:58+00:00 hourly 0.9 https://trial.medpath.com/news/56a61d43b3555aff/spinogenix-s-tazbentetol-shows-rapid-cognitive-improvement-in-phase-2a-alzheimer-s-trial 2025-12-08T17:28:55+00:00 hourly 0.9 https://trial.medpath.com/news/b31807e821eae9b3/agora-open-science-trust-selects-m4k2009-as-lead-candidate-for-rare-pediatric-brain-cancer-treatment 2025-12-08T17:28:10+00:00 hourly 0.9 https://trial.medpath.com/news/457c89010b512876/galmed-s-aramchol-shows-promise-in-hepatocellular-carcinoma-combination-therapy-prompting-phase-1-2-trial 2025-12-08T17:28:04+00:00 hourly 0.9 https://trial.medpath.com/news/586f890ad25007fb/dyne-therapeutics-advances-duchenne-drug-to-regulatory-filing-as-biotech-stocks-surge-on-promising-trial-data 2025-12-08T17:28:01+00:00 hourly 0.9 https://trial.medpath.com/news/9978fc2a26e4ef8c/eli-lilly-s-retatrutide-achieves-record-28-7-weight-loss-in-phase-3-trial-despite-high-discontinuation-rates 2025-12-08T17:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/8482307f2b7a7a0d/pierre-fabre-s-tabelecleucel-shows-47-7-response-rate-in-phase-3-trial-for-rare-post-transplant-cancer 2025-12-08T17:27:35+00:00 hourly 0.9 https://trial.medpath.com/news/c4743b42bdd3faa6/puretech-health-shares-rise-following-fda-meeting-after-phase-ii-trial-completion 2025-12-08T17:26:54+00:00 hourly 0.9 https://trial.medpath.com/news/b53e0883b998f34c/glyconex-partners-with-change-cure-to-advance-first-in-class-hmgb1-targeted-antibody-for-frontotemporal-lobar-degeneration 2025-12-08T17:26:12+00:00 hourly 0.9 https://trial.medpath.com/news/be9be3505bd38859/sana-biotechnology-achieves-breakthrough-in-in-vivo-gene-editing-of-hematopoietic-stem-cells-using-fusogen-technology 2025-12-08T17:26:09+00:00 hourly 0.9 https://trial.medpath.com/news/aa787dc02cb8f99f/her2-amplification-linked-to-worse-outcomes-in-first-line-metastatic-colorectal-cancer-treatment 2025-12-08T17:26:03+00:00 hourly 0.9 https://trial.medpath.com/news/49f7111aa42448ab/fda-grants-ide-approval-for-first-synthetic-corneal-endothelial-layer-to-treat-chronic-corneal-edema 2025-12-08T17:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/b4610a377bd8005e/avacta-s-faridoxorubicin-shows-promising-tumor-shrinkage-in-salivary-gland-cancer-phase-1b-trial 2025-12-08T17:25:27+00:00 hourly 0.9 https://trial.medpath.com/news/f65efe12c6d19090/wellgistics-health-launches-diabetes-drug-brenzavvy-through-6500-pharmacy-network-targeting-cost-effective-sglt-2-treatment 2025-12-08T17:25:24+00:00 hourly 0.9 https://trial.medpath.com/news/871e9f02c95f2a97/neuropace-files-fda-application-for-rns-system-expansion-to-treat-drug-resistant-generalized-epilepsy 2025-12-08T17:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/c12ddada1cc7d63a/dechra-receives-fda-approval-for-emeprev-injectable-solution-first-bioequivalent-maropitant-for-veterinary-use 2025-12-08T17:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/4e232e6e144c0308/cirrhosis-reshapes-immune-microenvironment-limiting-hepatocellular-carcinoma-immunotherapy-efficacy 2025-12-08T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c24bc197c3ec7057/ose-immunotherapeutics-regains-control-of-abbv-230-early-development-in-strategic-partnership-amendment-with-abbvie 2025-12-08T13:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/d1a5624054470eae/dyne-therapeutics-reports-breakthrough-results-for-duchenne-muscular-dystrophy-gene-therapy 2025-12-08T13:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/036c2017fdfc86e9/scancell-s-iscib1-immunotherapy-shows-74-progression-free-survival-in-phase-ii-melanoma-trial 2025-12-08T13:30:36+00:00 hourly 0.9 https://trial.medpath.com/news/9dcb940a96531959/dr-reddy-s-secures-370m-licensing-deal-for-immutep-s-cancer-immunotherapy 2025-12-08T13:29:27+00:00 hourly 0.9 https://trial.medpath.com/news/d0e3c5adfc47ee52/newron-initiates-enigma-trs-2-phase-iii-trial-for-treatment-resistant-schizophrenia-in-us 2025-12-08T13:26:54+00:00 hourly 0.9 https://trial.medpath.com/news/5d888d784e110202/genmab-discontinues-phase-iii-lung-cancer-bispecific-antibody-acasunlimab-to-focus-on-late-stage-pipeline 2025-12-08T13:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/2b90daa3a667fc18/poolbeg-pharma-s-polb-001-takes-center-stage-in-ps3-4-million-crs-prevention-research-programme 2025-12-08T13:26:39+00:00 hourly 0.9 https://trial.medpath.com/news/0f55da2a58cfc14c/anuh-pharma-secures-european-regulatory-approval-for-veterinary-antibiotic-sulfadimethoxine 2025-12-08T13:26:20+00:00 hourly 0.9 https://trial.medpath.com/news/d3a116553a9c3aa7/cloudbreak-therapeutics-advances-cbt-004-to-phase-3-trials-following-successful-fda-meeting-for-vascularized-pinguecula-treatment 2025-12-08T09:29:46+00:00 hourly 0.9 https://trial.medpath.com/news/43ba3687851d7bd2/aprea-therapeutics-secures-3-1-million-private-placement-to-advance-cancer-targeting-drug-development 2025-12-08T09:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/56bdb6c705804171/sensorion-s-gene-therapy-sens-501-shows-early-efficacy-signals-in-pediatric-congenital-deafness-trial 2025-12-08T09:28:21+00:00 hourly 0.9 https://trial.medpath.com/news/9197a3c873f57830/fanss-study-demonstrates-promising-lung-cancer-detection-rates-in-non-smoking-asian-women 2025-12-08T09:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/61be5fb3235424e9/victorian-researchers-develop-rna-prime-editing-therapy-for-fanconi-anemia-and-rare-blood-disorders 2025-12-08T09:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/bd838943575b2af6/epiendo-s-glasmacinal-shows-promise-in-first-copd-clinical-trial-reduces-neutrophilic-inflammation-without-antimicrobial-resistance 2025-12-08T09:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/0028c47e573add07/ucb-s-fenfluramine-shows-significant-seizure-reduction-in-phase-3-trial-for-cdkl5-deficiency-disorder 2025-12-08T09:26:10+00:00 hourly 0.9 https://trial.medpath.com/news/02ee9d12790c61be/iaso-bio-s-car-t-therapy-shows-93-8-complete-response-rate-in-high-risk-multiple-myeloma-patients 2025-12-08T09:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/2c30cc6106337f88/puretech-s-deupirfenidone-receives-fda-backing-for-phase-3-trial-in-idiopathic-pulmonary-fibrosis 2025-12-08T09:25:18+00:00 hourly 0.9 https://trial.medpath.com/news/366a2fc8454fc3bb/chugai-s-vabysmo-demonstrates-sustained-vision-improvements-in-48-week-angioid-streaks-trial 2025-12-08T09:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/8c45481a76932135/celltrion-internalizes-hyaluronidase-based-subcutaneous-formulation-technology-to-expand-biosimilar-pipeline 2025-12-08T05:27:56+00:00 hourly 0.9 https://trial.medpath.com/news/671ba3d5d1c2af75/lower-dose-ipilimumab-shows-superior-efficacy-and-safety-in-advanced-melanoma-treatment 2025-12-08T05:27:47+00:00 hourly 0.9 https://trial.medpath.com/news/5a1295717c851ca6/imugene-receives-fda-support-for-azer-cel-car-t-therapy-registration-pathway-in-lymphoma 2025-12-08T05:27:12+00:00 hourly 0.9 https://trial.medpath.com/news/c93092860d0cfed9/ghit-fund-invests-460000-in-novel-mpox-diagnostic-test-development-to-address-african-outbreak 2025-12-08T05:26:48+00:00 hourly 0.9 https://trial.medpath.com/news/765d744d6d2cc104/chimeric-therapeutics-receives-fda-orphan-drug-designation-for-chm-cdh17-car-t-therapy-in-gastric-cancer 2025-12-08T05:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/4c8bc60ad84918bf/leads-biolabs-lbl-034-demonstrates-82-5-response-rate-in-relapsed-refractory-multiple-myeloma-at-ash-2025 2025-12-08T05:25:50+00:00 hourly 0.9 https://trial.medpath.com/news/8b792fa229368bf3/innovent-s-trispecific-antibody-ibi3003-shows-83-3-response-rate-in-heavily-pretreated-multiple-myeloma-patients 2025-12-08T05:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/6dec19a80cedf8b6/iktos-secures-eur1-billion-partnership-with-servier-to-bridge-ai-drug-discovery-with-wet-lab-operations 2025-12-08T03:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/2c0817b9c8ef703d/hutchmed-secures-continued-nrdl-coverage-for-three-cancer-drugs-and-gains-commercial-insurance-access-for-tazemetostat-in-china 2025-12-08T01:30:26+00:00 hourly 0.9 https://trial.medpath.com/news/3ea116df34140504/fda-expands-pitolisant-label-to-include-cataplexy-treatment-in-pediatric-narcolepsy-patients 2025-12-08T01:29:40+00:00 hourly 0.9 https://trial.medpath.com/news/2a943a90d5b53eb1/dual-bispecific-antibody-combination-achieves-79-response-rate-in-relapsed-refractory-multiple-myeloma-with-extramedullary-disease 2025-12-08T01:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/5f06a3bbeab1715a/miltenyi-s-dual-target-car-t-therapy-shows-superior-efficacy-in-pivotal-trial-for-relapsed-large-b-cell-lymphoma 2025-12-08T01:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/cea7b4d68347ca25/smart-stop-trial-shows-targeted-therapy-first-strategy-reduces-chemotherapy-need-in-large-b-cell-lymphoma 2025-12-08T01:29:18+00:00 hourly 0.9 https://trial.medpath.com/news/1fcdd9971685eb79/lynozyfic-monotherapy-shows-promising-efficacy-in-newly-diagnosed-multiple-myeloma-patients 2025-12-08T01:27:24+00:00 hourly 0.9 https://trial.medpath.com/news/8663e15d8e897403/structure-therapeutics-to-release-pivotal-data-for-oral-glp-1-obesity-drug-aleniglipron 2025-12-08T01:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/caa6b3a807310a9f/triple-therapy-combination-shows-promise-for-rare-blood-cancer-bpdcn-with-high-response-rates 2025-12-08T01:26:46+00:00 hourly 0.9 https://trial.medpath.com/news/56baf8fe32d73a19/telix-pharmaceuticals-advances-prostact-global-phase-3-trial-with-first-patient-dosed-in-randomized-expansion 2025-12-08T01:26:43+00:00 hourly 0.9 https://trial.medpath.com/news/6b0cb120b1e0e550/lyell-s-ronde-cel-shows-93-response-rate-in-large-b-cell-lymphoma-with-enhanced-safety-profile 2025-12-08T01:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/d3827a1d03fa59ae/grace-and-molecule-one-partner-to-revolutionize-peptide-manufacturing-with-ai-driven-synthesis-platform 2025-12-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ca074f520527666d/faron-pharmaceuticals-advances-bexmarilimab-with-new-phase-ii-trial-and-promising-ash-data-in-blood-cancers 2025-12-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/565f8012d016d51a/isatuximab-based-therapy-shows-sustained-efficacy-across-age-groups-in-transplant-ineligible-multiple-myeloma 2025-12-07T21:30:03+00:00 hourly 0.9 https://trial.medpath.com/news/67c85609ac60890b/aop-health-presents-new-clinical-data-for-ropeginterferon-alfa-2b-in-rare-blood-cancers-at-ash-2025 2025-12-07T21:29:28+00:00 hourly 0.9 https://trial.medpath.com/news/600405f9c67b5506/dyne-therapeutics-stock-plunges-17-following-300-million-secondary-offering-despite-dmd-trial-success 2025-12-07T21:29:19+00:00 hourly 0.9 https://trial.medpath.com/news/501ce4fec4bf8828/cenobamate-demonstrates-sustained-efficacy-in-asian-and-chinese-patients-with-focal-seizures 2025-12-07T21:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/71ef478bdf29a58c/msd-pharma-receives-conditional-approval-for-phase-iii-trial-of-sacituzumab-tirumotecan-in-india 2025-12-07T21:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/72dd6cc966c0b0e6/ideaya-biosciences-completes-enrollment-in-pivotal-uveal-melanoma-trial-advances-novel-adc-program 2025-12-07T21:27:39+00:00 hourly 0.9 https://trial.medpath.com/news/63813b5b12981539/five-day-azacitidine-regimen-shows-superior-survival-outcomes-in-lower-risk-mds-patients 2025-12-07T21:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/539580bfb6dd6db9/hemgenix-gene-therapy-shows-sustained-five-year-efficacy-in-hemophilia-b-patients 2025-12-07T21:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/f73bca709bbffbb0/secura-bio-reports-sustained-efficacy-of-duvelisib-in-heavily-pretreated-peripheral-t-cell-lymphoma-patients 2025-12-07T17:29:45+00:00 hourly 0.9 https://trial.medpath.com/news/b4b671c9a4d24179/zai-lab-secures-reimbursement-renewal-for-three-key-therapies-in-china-s-2025-national-drug-list 2025-12-07T17:28:12+00:00 hourly 0.9 https://trial.medpath.com/news/322fa0a6f27757f5/cellcentric-s-inobrodib-shows-60-75-response-rates-in-heavily-pretreated-multiple-myeloma-patients 2025-12-07T17:25:23+00:00 hourly 0.9 https://trial.medpath.com/news/dab1fbaf77d61ad2/alx-oncology-s-evorpacept-combination-achieves-92-complete-response-rate-in-frontline-indolent-non-hodgkin-lymphoma-trial 2025-12-07T17:25:12+00:00 hourly 0.9 https://trial.medpath.com/news/c56e2e2871c8b463/bioinvent-s-bi-1808-shows-46-response-rate-in-cutaneous-t-cell-lymphoma-phase-2a-trial 2025-12-07T17:25:06+00:00 hourly 0.9 https://trial.medpath.com/news/9fe80c622e8e992d/prime-medicine-reports-first-in-human-prime-editing-success-for-chronic-granulomatous-disease-in-nejm 2025-12-07T17:25:03+00:00 hourly 0.9 https://trial.medpath.com/news/8b8eaefff872e78d/fda-grants-breakthrough-therapy-designation-to-incyte-s-first-in-class-mutcalr-targeted-antibody-for-essential-thrombocythemia 2025-12-07T17:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/b5f2fc72dc4e32e1/fda-grants-breakthrough-therapy-designation-to-incyte-s-inca033989-for-rare-blood-cancer 2025-12-07T17:24:18+00:00 hourly 0.9 https://trial.medpath.com/news/d6d8d5dac0119408/rigel-s-r289-shows-promise-in-lower-risk-mds-with-33-transfusion-independence-rate-at-ash-2025 2025-12-07T17:23:42+00:00 hourly 0.9 https://trial.medpath.com/news/04c21a7103cd8b6a/formosa-pharmaceuticals-expands-global-reach-of-fda-approved-eye-surgery-treatment-through-asean-partnership 2025-12-07T13:30:32+00:00 hourly 0.9 https://trial.medpath.com/news/5b26794712e8a443/carsgen-s-car-t-therapy-zevor-cel-gains-coverage-under-china-s-new-commercial-health-insurance-catalogue 2025-12-07T13:29:44+00:00 hourly 0.9 https://trial.medpath.com/news/21518b6449708245/china-s-2025-national-drug-list-adds-114-medicines-with-historic-commercial-insurance-breakthrough 2025-12-07T13:28:53+00:00 hourly 0.9 https://trial.medpath.com/news/6484d7ecc3ecb26b/china-expands-national-medical-insurance-coverage-with-114-new-drugs-including-50-innovative-pharmaceuticals 2025-12-07T09:26:53+00:00 hourly 0.9 https://trial.medpath.com/news/f0cc723824e6b47f/cdsco-approves-levim-lifetech-s-phase-i-iii-trial-for-teriparatide-biosimilar-in-osteoporosis 2025-12-07T09:26:47+00:00 hourly 0.9 https://trial.medpath.com/news/ffe19f3597adf290/neurocrine-biosciences-initiates-phase-2a-trial-for-schizophrenia-treatment-following-depression-drug-setback 2025-12-07T09:26:35+00:00 hourly 0.9 https://trial.medpath.com/news/75218b81ea765dd7/akeso-achieves-complete-nrdl-coverage-for-five-innovative-drugs-in-china-including-first-in-class-bispecifics 2025-12-07T09:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/2ab5e9875f9d840e/innovent-secures-nrdl-inclusion-for-seven-innovative-therapies-expanding-access-to-cancer-and-rare-disease-treatments-in-china 2025-12-07T09:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/0f169089e1e73b2a/csl-seqirus-opens-1-billion-cell-based-vaccine-manufacturing-facility-in-melbourne 2025-12-07T05:26:55+00:00 hourly 0.9 https://trial.medpath.com/news/6485cca0b5937fd5/ctdna-testing-outperforms-pet-ct-in-predicting-lymphoma-patient-outcomes 2025-12-07T05:26:46+00:00 hourly 0.9 https://trial.medpath.com/news/041c9491550826bf/akari-therapeutics-initiates-gmp-manufacturing-for-novel-adc-aktx-101-with-wuxi-xdc-partnership 2025-12-07T03:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/35040b425b6843df/once-weekly-oral-hiv-therapy-shows-promise-in-phase-2-trial-maintaining-viral-suppression-through-48-weeks 2025-12-07T01:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/dfbc1c555a181ee1/axatilimab-monthly-dosing-shows-promise-for-chronic-gvhd-treatment-convenience 2025-12-07T01:29:42+00:00 hourly 0.9 https://trial.medpath.com/news/e3a184079ccafe61/star-therapeutics-reports-promising-phase-1-2-data-for-vga039-in-von-willebrand-disease-showing-73-100-reduction-in-bleeding-episodes 2025-12-07T01:26:50+00:00 hourly 0.9 https://trial.medpath.com/news/674989b95a333daa/biontech-and-oncoc4-report-54-reduction-in-death-risk-with-gotistobart-in-advanced-squamous-lung-cancer 2025-12-07T01:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/bcd50371d4575cd2/zenocutuzumab-shows-superior-efficacy-in-treatment-naive-nrg1-nsclc-patients 2025-12-07T01:26:39+00:00 hourly 0.9 https://trial.medpath.com/news/bdf180cf52e5a8f7/biogen-and-eisai-advance-leqembi-subcutaneous-formulation-with-china-regulatory-milestone 2025-12-07T00:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/5f132a2698103773/glp-1-receptor-agonists-linked-to-12-higher-risk-of-chronic-cough-in-large-scale-study 2025-12-06T21:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/dca01ae0d128ec67/fda-recalls-over-11000-bottles-of-blood-pressure-drug-due-to-cholesterol-medication-cross-contamination 2025-12-06T21:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/2ee31a7c50bfa161/iv-iron-treatment-improves-survival-in-anemic-patients-with-acute-bacterial-infections-large-scale-study-shows 2025-12-06T21:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/4498c959df31c095/elranatamab-plus-iberdomide-combination-achieves-95-5-response-rate-in-relapsed-refractory-multiple-myeloma 2025-12-06T21:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/093bfc421932edb4/disc-medicine-s-disc-0974-shows-promising-results-for-myelofibrosis-anemia-in-phase-2-trial 2025-12-06T21:30:15+00:00 hourly 0.9 https://trial.medpath.com/news/d6d6755b026ff8dd/novel-btk-degrader-bgb-16673-demonstrates-85-response-rate-in-heavily-pretreated-cll-sll-patients 2025-12-06T21:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/c92232ed9c613e0b/ash-2025-reveals-critical-gaps-in-sickle-cell-emergency-care-and-promising-gene-therapy-advances 2025-12-06T21:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/05fdf352e41c90db/prelude-therapeutics-unveils-novel-jak2v617f-selective-inhibitor-and-mcalr-targeted-therapy-for-myeloproliferative-neoplasms 2025-12-06T21:29:50+00:00 hourly 0.9 https://trial.medpath.com/news/c2b375b3d95a95d9/lundbeck-s-bexicaserin-shows-sustained-seizure-reduction-in-rare-childhood-epilepsies-after-two-years-of-treatment 2025-12-06T21:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/e05c032c75715c41/phase-2-endrad-study-shows-non-tbi-conditioning-maintains-efficacy-in-pediatric-b-all-transplant 2025-12-06T21:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/3d4f06eaa594ab9c/kite-s-anito-cel-shows-96-response-rate-in-pivotal-multiple-myeloma-trial-supporting-2026-launch-plans 2025-12-06T21:28:54+00:00 hourly 0.9 https://trial.medpath.com/news/549b082ce59d1fcf/natera-acquires-foresight-diagnostics-for-275-million-to-advance-molecular-residual-disease-detection 2025-12-06T21:27:36+00:00 hourly 0.9 https://trial.medpath.com/news/967fbd08810d7803/sapablursen-shows-promising-results-in-phase-2a-trial-for-polycythemia-vera-significantly-reducing-phlebotomy-burden 2025-12-06T21:26:08+00:00 hourly 0.9 https://trial.medpath.com/news/abf0614ba3734aa9/states-push-for-fda-approval-of-ibogaine-clinical-trials-to-treat-ptsd-and-opioid-addiction 2025-12-06T21:25:45+00:00 hourly 0.9 https://trial.medpath.com/news/aa935811539c01b3/measurable-residual-disease-validated-as-strong-predictor-of-survival-in-aml-patients 2025-12-06T21:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/511e958e5d2d68bf/verona-trial-shows-mixed-results-for-venetoclax-azacitidine-combination-in-high-risk-mds 2025-12-06T21:25:37+00:00 hourly 0.9 https://trial.medpath.com/news/30a473514dbe97f6/orca-bio-reports-promising-results-for-orca-t-cell-therapy-in-older-blood-cancer-patients-at-ash-2025 2025-12-06T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/a012a180b78051f9/lisaftoclax-demonstrates-62-5-response-rate-in-btk-refractory-cll-sll-patients 2025-12-06T17:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/c7296626e45b4798/large-scale-indian-study-validates-ai-enhanced-smile-laser-technology-for-myopia-correction 2025-12-06T17:35:08+00:00 hourly 0.9 https://trial.medpath.com/news/158f5d5ee5f861eb/viatris-divests-815-million-biocon-biologics-stake-to-accelerate-biosimilars-market-re-entry 2025-12-06T17:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/cda7357c491449a4/beam-therapeutics-reports-promising-long-term-data-for-base-edited-sickle-cell-therapy-risto-cel 2025-12-06T17:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/a18c1b8d41486c24/kala-bio-completes-10-million-funding-round-to-advance-rare-eye-disease-therapies 2025-12-06T17:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/d724e67d7c86aafb/tirzepatide-demonstrates-94-reduction-in-type-2-diabetes-risk-in-landmark-prevention-trial 2025-12-06T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/6ab0bab945ef1699/large-french-study-links-mrna-covid-19-vaccination-to-25-reduction-in-long-term-mortality 2025-12-06T17:29:46+00:00 hourly 0.9 https://trial.medpath.com/news/6fa2cba326d8b9b0/io-therapeutics-reports-synergistic-activity-of-rxr-agonist-irx4204-with-car-t-therapy-in-multiple-myeloma 2025-12-06T17:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/1d0ea713ca001ae3/sync-t-therapy-shows-54-complete-bone-metastasis-resolution-in-phase-1-prostate-cancer-trial 2025-12-06T17:28:35+00:00 hourly 0.9 https://trial.medpath.com/news/2c716035ef7a9327/arvinas-reports-promising-preclinical-data-for-arv-393-and-glofitamab-combination-in-b-cell-lymphoma 2025-12-06T17:28:30+00:00 hourly 0.9 https://trial.medpath.com/news/50008ef6c66ca744/real-world-gene-therapy-implementation-shows-promise-for-blood-disorders-despite-timeline-challenges 2025-12-06T17:27:14+00:00 hourly 0.9 https://trial.medpath.com/news/9db2970dec06b857/vertex-s-crispr-therapy-casgevy-shows-promise-in-children-as-young-as-5-with-blood-disorders 2025-12-06T17:26:32+00:00 hourly 0.9 https://trial.medpath.com/news/44d98d4c062606a8/atara-biotherapeutics-approaches-critical-fda-decision-for-tab-cel-as-company-implements-strategic-restructuring 2025-12-06T17:26:29+00:00 hourly 0.9 https://trial.medpath.com/news/a45ee0862ce15ead/cqdm-awards-500000-to-develop-fut8-inhibitors-for-enhanced-cancer-antibody-therapies 2025-12-06T17:25:25+00:00 hourly 0.9 https://trial.medpath.com/news/591ed05de24bbb05/realta-reports-promising-phase-2-results-for-pegtarazimod-in-steroid-refractory-acute-graft-versus-host-disease 2025-12-06T17:25:23+00:00 hourly 0.9 https://trial.medpath.com/news/89ef6e344ae42e0d/deucravacitinib-shows-efficacy-in-psoriasis-patients-who-failed-apremilast-treatment 2025-12-06T17:25:20+00:00 hourly 0.9 https://trial.medpath.com/news/22ddf5eba70c01b4/carvykti-shows-durable-treatment-free-remissions-at-2-5-years-in-earlier-line-multiple-myeloma 2025-12-06T17:25:18+00:00 hourly 0.9 https://trial.medpath.com/news/5f1d5c4717d5ad8b/nmdp-access-trial-shows-80-survival-with-mismatched-donor-transplants-expanding-access-for-blood-cancer-patients 2025-12-06T17:25:15+00:00 hourly 0.9 https://trial.medpath.com/news/2abcc00c76eed3c6/rusfertide-demonstrates-sustained-efficacy-in-52-week-polycythemia-vera-study-supporting-regulatory-filing 2025-12-06T17:25:10+00:00 hourly 0.9 https://trial.medpath.com/news/3160d64212d860f2/genmab-s-epcoritamab-shows-promising-results-in-first-line-lymphoma-treatment-with-fixed-duration-therapy 2025-12-06T17:22:57+00:00 hourly 0.9 https://trial.medpath.com/news/c88e702f832828c2/painreform-advances-ocuring-k-phase-2-trial-for-drop-free-post-cataract-surgery-pain-management 2025-12-06T13:25:19+00:00 hourly 0.9 https://trial.medpath.com/news/26f4d588ecb32693/abbvie-reports-positive-phase-3-results-for-migraine-drug-atogepant-in-eclipse-trial 2025-12-06T13:25:17+00:00 hourly 0.9 https://trial.medpath.com/news/260c78de4204eae6/lebrikizumab-shows-comparable-efficacy-to-dupilumab-in-moderate-to-severe-atopic-dermatitis-treatment 2025-12-06T13:25:09+00:00 hourly 0.9 https://trial.medpath.com/news/8fa315fe3c612c0a/world-s-first-lung-cancer-prevention-vaccine-lungvax-enters-clinical-trials-in-2026 2025-12-06T12:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/8fb4f2958bd7d420/toripalimab-achieves-record-breaking-long-term-survival-in-advanced-nasopharyngeal-and-esophageal-cancers 2025-12-06T10:25:30+00:00 hourly 0.9 https://trial.medpath.com/news/772b857642fe6831/uk-launches-controversial-puberty-blocker-trial-following-national-ban 2025-12-06T06:27:44+00:00 hourly 0.9 https://trial.medpath.com/news/6a1acb507a3bb544/india-reopens-pli-applications-for-critical-antibiotic-and-antiviral-drug-manufacturing 2025-12-06T06:25:17+00:00 hourly 0.9 https://trial.medpath.com/news/159ac264457d4c78/al-s-pharma-s-ap-101-shows-promising-survival-benefits-in-phase-2-als-trial-advancing-to-phase-3 2025-12-06T04:25:36+00:00 hourly 0.9 https://trial.medpath.com/news/3ec880a3025ebbc7/tempramed-expands-temperature-controlled-medication-storage-solutions-across-europe-and-north-america 2025-12-06T04:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/d9735dce80078602/french-study-validates-long-term-safety-and-efficacy-of-moderna-s-covid-19-mrna-vaccine 2025-12-06T01:27:03+00:00 hourly 0.9 https://trial.medpath.com/news/4d7abd52f85aa943/novel-treatment-combinations-show-promise-in-mantle-cell-lymphoma-trials 2025-12-06T01:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/2292cf315e8700e9/gemcitabine-intravesical-system-shows-promise-in-bcg-unresponsive-bladder-cancer-reducing-need-for-radical-cystectomy 2025-12-06T01:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/22a72021c4329cbb/berenson-cancer-center-reports-record-13-year-survival-for-multiple-myeloma-patients-without-standard-transplant-therapy 2025-12-06T01:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/09c655cb738607a9/fda-approves-omisirge-as-first-cell-therapy-for-severe-aplastic-anemia 2025-12-06T01:24:36+00:00 hourly 0.9 https://trial.medpath.com/news/83dd0a7a56f0b9eb/hims-hers-enters-canadian-market-through-livewell-acquisition-targeting-generic-semaglutide-launch 2025-12-06T01:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/e1fb1c611ee7221a/boehringer-ingelheim-s-digital-therapeutic-ct-155-shows-efficacy-for-schizophrenia-negative-symptoms-in-pivotal-trial 2025-12-06T01:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/5bee42150e84f27b/amneal-s-crexont-shows-significant-clinical-benefits-in-phase-4-parkinson-s-disease-study 2025-12-05T21:35:45+00:00 hourly 0.9 https://trial.medpath.com/news/ab3868a11d489a30/perspective-therapeutics-reports-sustained-tumor-response-with-lead-212-radiopharmaceutical-in-neuroendocrine-tumors 2025-12-05T21:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/6a65aa8c3c1052fe/blueprint-medicines-reports-long-term-efficacy-data-for-ayvakit-in-systemic-mastocytosis-at-ash-2025 2025-12-05T21:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/8403b15382950fcd/inmune-bio-s-cordstrom-platform-featured-in-peer-reviewed-study-on-mesenchymal-stromal-cell-therapies 2025-12-05T21:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/3956ce88e450d8eb/apeiron-s-gta182-shows-57-response-rate-in-mtap-deleted-lung-cancer-phase-1-trial 2025-12-05T21:34:07+00:00 hourly 0.9 https://trial.medpath.com/news/7defcef41801f9bf/freenome-secures-330-million-spac-deal-to-advance-multi-cancer-blood-detection-tests 2025-12-05T21:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/3e88794595d86a94/amylyx-reports-positive-safety-data-for-amx0114-in-first-in-human-als-trial 2025-12-05T21:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/96faaafa162b2f17/imcheck-therapeutics-to-present-promising-ict01-aml-data-at-ash-2025-showing-high-remission-rates-in-first-line-treatment 2025-12-05T21:29:43+00:00 hourly 0.9 https://trial.medpath.com/news/f64df9c4abad4d14/fda-approves-eighth-denosumab-biosimilar-as-amgen-settles-patent-dispute-with-hikma-and-gedeon-richter 2025-12-05T21:29:38+00:00 hourly 0.9 https://trial.medpath.com/news/e2a7fc9fc34589e9/amicus-therapeutics-galafold-drives-strong-revenue-growth-amid-pending-4-8b-biomarin-acquisition 2025-12-05T21:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/4c47737c490ebc33/medicare-part-b-premiums-to-rise-9-7-in-2026-as-cms-negotiates-cancer-drug-price-reductions 2025-12-05T21:28:21+00:00 hourly 0.9 https://trial.medpath.com/news/0d167685c23641b2/start-opens-new-early-phase-cancer-clinical-trial-unit-in-new-york-long-island 2025-12-05T21:27:48+00:00 hourly 0.9 https://trial.medpath.com/news/93e20bf6f18b00f2/corrixr-therapeutics-partners-to-develop-first-inhaled-crispr-therapy-for-lung-cancer 2025-12-05T21:27:46+00:00 hourly 0.9 https://trial.medpath.com/news/0ff5758c79944a5c/encoded-therapeutics-reports-78-seizure-reduction-with-etx101-gene-therapy-in-dravet-syndrome-trial 2025-12-05T21:27:43+00:00 hourly 0.9 https://trial.medpath.com/news/7cf18a9e147a7281/prostate-cancer-pipeline-shows-robust-growth-with-150-therapies-in-development-across-multiple-companies 2025-12-05T21:27:41+00:00 hourly 0.9 https://trial.medpath.com/news/8b413391a7609eb4/senores-pharmaceuticals-secures-philippine-fda-approval-for-10-products-across-cardiovascular-cns-and-pain-management-therapies 2025-12-05T21:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/22af1cba8c6d0e7c/gallop-oncology-s-lyt-200-shows-promising-13-2-month-survival-in-relapsed-refractory-aml-phase-1b-trial 2025-12-05T21:27:03+00:00 hourly 0.9 https://trial.medpath.com/news/0758bf5a9e738181/spineguard-receives-nmpa-clearance-for-advanced-pediguard-models-in-china 2025-12-05T21:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/68cebefc9b83e456/oye-therapeutics-receives-fda-clearance-to-begin-clinical-testing-of-novel-caffeine-injection-for-anesthesia-recovery 2025-12-05T21:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/032100a53ef907c2/biomea-fusion-s-icovamenib-shows-durable-diabetes-benefits-nine-months-after-treatment-ends 2025-12-05T17:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/d122f759d7df76a1/medicare-drug-price-negotiations-deliver-major-savings-25-medications-to-see-reduced-costs-by-2027 2025-12-05T17:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/61c03dc1ea15a60c/long-term-follow-up-confirms-sustained-benefits-of-adjuvant-pembrolizumab-in-high-risk-clear-cell-renal-cell-carcinoma 2025-12-05T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/094248b65af97bcd/candel-therapeutics-reports-30-reduction-in-prostate-cancer-recurrence-risk-with-can-2409-in-phase-3-trial 2025-12-05T17:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/4eef389a275d3de0/first-in-class-mmset-inhibitor-gintemetostat-shows-clinical-activity-in-heavily-pretreated-multiple-myeloma 2025-12-05T17:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/ad4e133dca035515/first-ever-personalized-crispr-therapy-successfully-treats-baby-with-ultra-rare-metabolic-disorder 2025-12-05T17:30:33+00:00 hourly 0.9 https://trial.medpath.com/news/6bda856085867ada/regeneron-and-tessera-therapeutics-form-global-partnership-to-advance-tsra-196-gene-writing-therapy 2025-12-05T17:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/2d208801a9e16a7f/roche-advances-in-tigit-immunotherapy-and-ai-driven-biomarker-development-signal-strategic-shift-in-precision-oncology 2025-12-05T17:29:58+00:00 hourly 0.9 https://trial.medpath.com/news/faef2e4fcef162c0/novo-nordisk-receives-fda-approval-for-oral-wegovy-formulation-driving-pharmaceutical-sector-gains 2025-12-05T17:29:53+00:00 hourly 0.9 https://trial.medpath.com/news/bdc3000ddd5ac05e/revalia-bio-secures-26-7-million-arpa-h-award-to-revolutionize-drug-development-with-human-data-trials 2025-12-05T17:29:15+00:00 hourly 0.9 https://trial.medpath.com/news/40cb315c8c0e79a0/wugen-s-allogeneic-car-t-therapy-shows-promising-long-term-survival-data-in-t-cell-leukemia-patients 2025-12-05T17:29:13+00:00 hourly 0.9 https://trial.medpath.com/news/559c91f2c9c85bb8/stat3-inhibitor-safety-concerns-highlight-alternative-approaches-in-ipf-drug-development 2025-12-05T17:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/1ed0301984fb3064/palbociclib-triple-therapy-shows-significant-survival-benefit-in-her2-positive-breast-cancer-trial 2025-12-05T17:28:20+00:00 hourly 0.9 https://trial.medpath.com/news/c53e75487fb12810/fda-launches-commissioner-s-national-priority-voucher-program-to-accelerate-critical-drug-reviews 2025-12-05T17:26:50+00:00 hourly 0.9 https://trial.medpath.com/news/566154125b8c71e4/bristol-myers-squibb-s-breyanzi-becomes-first-car-t-therapy-approved-for-marginal-zone-lymphoma 2025-12-05T17:26:38+00:00 hourly 0.9 https://trial.medpath.com/news/6d5472af80124d85/b-braun-launches-piperacillin-tazobactam-in-duplex-drug-delivery-system-to-reduce-medication-errors 2025-12-05T17:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/5ca452065ee9cb2f/otr-therapeutics-secures-100-million-series-a-to-build-capital-efficient-r-d-platform-in-shanghai 2025-12-05T13:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/2b78d90f5b7b4bd4/transcenta-s-osemitamab-combination-shows-promising-16-6-month-median-pfs-in-first-line-gastric-cancer-trial 2025-12-05T13:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/cb4926f087c4cdc8/rocatinlimab-demonstrates-significant-efficacy-in-phase-3-trials-for-moderate-to-severe-atopic-dermatitis 2025-12-05T13:31:29+00:00 hourly 0.9 https://trial.medpath.com/news/41b5bb345d0f33a8/hanmi-pharmaceutical-s-efeglenatide-receives-fast-track-designation-for-obesity-treatment-in-south-korea 2025-12-05T13:30:13+00:00 hourly 0.9 https://trial.medpath.com/news/43561583534d2dd0/cumulus-neuroscience-demonstrates-superior-digital-endpoints-for-alzheimer-s-clinical-trials-at-ctad-2025 2025-12-05T13:30:08+00:00 hourly 0.9 https://trial.medpath.com/news/f806b313cddd23b7/alvotech-gains-european-approval-for-denosumab-biosimilar-avt03-opening-access-to-1-2-billion-market 2025-12-05T13:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/6ec480cf84c3d1fc/beigene-reports-record-1-4-billion-quarterly-revenue-as-brukinsa-surpasses-1-billion-milestone 2025-12-05T12:10:43+00:00 hourly 0.9 https://trial.medpath.com/news/c483a47e709866c6/annexin-pharmaceuticals-reports-promising-early-results-from-phase-2a-study-of-anxv-in-diabetic-retinopathy-and-retinal-vein-occlusion 2025-12-05T12:10:39+00:00 hourly 0.9 https://trial.medpath.com/news/ac908221c0a79b7e/gelteq-s-oral-gel-platform-shows-22-bioavailability-boost-for-medicinal-cannabinoids-in-preclinical-study 2025-12-05T10:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/7fba1bded0ada01a/us-fda-accepts-wockhardt-s-nda-for-novel-antibiotic-zaynich-marking-historic-first-for-indian-pharma 2025-12-05T09:52:16+00:00 hourly 0.9 https://trial.medpath.com/news/19890108f34618af/lupin-receives-tentative-fda-approval-for-generic-siponimod-multiple-sclerosis-treatment 2025-12-05T09:52:01+00:00 hourly 0.9 https://trial.medpath.com/news/ae35791571be2684/french-study-of-28-million-adults-confirms-long-term-safety-of-covid-19-mrna-vaccines 2025-12-05T06:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/6e505fc1119d200a/genentech-and-roche-secure-upc-evidence-orders-against-organon-s-pertuzumab-biosimilar 2025-12-05T06:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/041b856e9a6d1976/german-court-blocks-merck-s-subcutaneous-keytruda-launch-in-patent-dispute-with-halozyme 2025-12-05T06:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/2bec9930d80b07c4/fda-clears-first-in-class-bispecific-adc-ide034-for-phase-1-trial-in-multiple-solid-tumors 2025-12-05T06:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/c1b718b8cf264a8b/cell-and-gene-therapy-investment-plummets-66-as-industry-shifts-to-lower-risk-strategies 2025-12-05T06:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/710a6d6b41301a95/ipsc-therapy-for-parkinson-s-disease-receives-fda-rmat-designation-marking-regulatory-milestone 2025-12-05T06:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/7ba1e5f1f569d15d/cystic-fibrosis-patients-on-triple-drug-therapy-can-safely-reduce-daily-lung-treatments-multi-site-study-shows 2025-12-05T06:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/fac280d540aa517f/ascentage-pharma-receives-fda-and-ema-clearance-for-global-phase-iii-trial-of-olverembatinib-in-philadelphia-chromosome-positive-all 2025-12-05T04:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/06894c2d47558dda/pharmaceutical-industry-turns-to-ai-to-combat-236-billion-patent-cliff-crisis 2025-12-05T04:09:44+00:00 hourly 0.9 https://trial.medpath.com/news/7c073b9db4e58d71/ai-transforms-cancer-drug-development-from-discovery-to-clinical-management 2025-12-05T03:52:07+00:00 hourly 0.9 https://trial.medpath.com/news/961454890b55fbaa/sanofi-secures-dual-eu-approvals-dupixent-for-chronic-urticaria-and-first-ever-btk-inhibitor-wayrilz-for-immune-thrombocytopenia 2025-12-05T00:54:41+00:00 hourly 0.9 https://trial.medpath.com/news/b58ccffb0f819f5a/fda-lifts-clinical-hold-on-tradipitant-clearing-path-for-first-new-motion-sickness-treatment-in-40-years 2025-12-05T00:54:08+00:00 hourly 0.9 https://trial.medpath.com/news/c7aaee332320d705/immorta-bio-s-senovaxtm-shows-tumor-reduction-across-multiple-cancer-types-in-preclinical-study 2025-12-05T00:53:28+00:00 hourly 0.9 https://trial.medpath.com/news/4efdbea7bfd3d9dd/scineuro-pharmaceuticals-secures-53m-series-funding-to-advance-neurodegeneration-therapies 2025-12-05T00:51:02+00:00 hourly 0.9 https://trial.medpath.com/news/8c112a6709ee37e2/nikon-instruments-and-yamaha-motor-form-strategic-partnership-to-advance-drug-discovery-research 2025-12-05T00:50:56+00:00 hourly 0.9 https://trial.medpath.com/news/0eda67665d55ba2c/duchenne-muscular-dystrophy-market-reaches-2-15-billion-as-pipeline-shows-promise-with-75-active-therapies 2025-12-05T00:50:54+00:00 hourly 0.9 https://trial.medpath.com/news/bc20e421fd98df1c/belite-bio-raises-350-million-in-public-offering-to-advance-stargardt-disease-treatment 2025-12-05T00:50:50+00:00 hourly 0.9 https://trial.medpath.com/news/3784e020cb3c57b3/foundation-medicine-reaches-historic-100-companion-diagnostic-approvals-milestone 2025-12-05T00:50:39+00:00 hourly 0.9 https://trial.medpath.com/news/d74145f82c978293/praxis-precision-medicines-advances-two-cns-programs-with-positive-fda-meeting-and-phase-2-results 2025-12-05T00:50:36+00:00 hourly 0.9 https://trial.medpath.com/news/9f400a601b275d74/praxis-precision-medicines-reports-positive-embold-study-results-for-relutrigine-in-rare-epileptic-encephalopathies 2025-12-05T00:50:33+00:00 hourly 0.9 https://trial.medpath.com/news/96b44474179fb39e/immortal-dragons-invests-in-etheros-pharmaceuticals-catalytic-antioxidant-platform-for-age-related-diseases 2025-12-05T00:50:18+00:00 hourly 0.9 https://trial.medpath.com/news/5e05e4bc142f9138/fda-approves-breyanzi-car-t-cell-therapy-for-relapsed-refractory-marginal-zone-lymphoma 2025-12-05T00:48:28+00:00 hourly 0.9 https://trial.medpath.com/news/25d27379b0eca5f1/algorae-pharmaceuticals-validates-ai-drug-discovery-platform-and-identifies-90-new-cannabidiol-combination-candidates 2025-12-05T00:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/349211b41f3c5123/ossium-health-reports-promising-early-results-for-deceased-donor-bone-marrow-transplants-in-hematologic-malignancies 2025-12-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c33805507cd7a54d/fda-advisory-panel-unanimously-rejects-johnson-johnson-s-v-wave-heart-shunt-for-heart-failure 2025-12-04T21:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/fb084d310baf53ba/cdc-vaccine-advisory-committee-delays-vote-on-hepatitis-b-birth-dose-recommendation 2025-12-04T21:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/b6b42838bfbe9177/eli-lilly-s-mounjaro-gains-insurance-coverage-in-china-and-south-korea-expanding-global-access 2025-12-04T21:31:06+00:00 hourly 0.9 https://trial.medpath.com/news/645731e4d0da536b/sglt-2-inhibitors-and-glp-1-agonists-show-promise-in-slowing-frailty-progression-in-older-diabetic-adults 2025-12-04T21:31:03+00:00 hourly 0.9 https://trial.medpath.com/news/6ff4cceaade731bb/paxg-chemotherapy-shows-superior-event-free-survival-over-mfolfirinox-in-pancreatic-cancer-trial 2025-12-04T21:30:44+00:00 hourly 0.9 https://trial.medpath.com/news/f4619075664da342/dart-trial-shows-combination-immunotherapy-effective-in-rare-cancer-patients-with-brain-metastases 2025-12-04T21:30:08+00:00 hourly 0.9 https://trial.medpath.com/news/54c801e3e10e0288/absci-initiates-first-in-human-trial-of-ai-designed-antibody-abs-201-for-hair-loss-treatment 2025-12-04T21:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/d34141911c59a730/regeneration-biomedical-s-autologous-stem-cell-therapy-for-alzheimer-s-disease-advances-to-phase-2-following-positive-safety-data 2025-12-04T21:28:59+00:00 hourly 0.9 https://trial.medpath.com/news/0cb4cd379cedfec2/rare-pediatric-disease-voucher-program-faces-uncertain-future-as-congressional-reauthorization-stalls 2025-12-04T21:28:38+00:00 hourly 0.9 https://trial.medpath.com/news/3b28c522362acaf2/port-delivery-system-demonstrates-7-year-vision-preservation-in-wet-amd-patients 2025-12-04T21:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/5a077c5e62eee1f3/cedars-sinai-scientists-develop-first-in-class-rna-drug-ty1-to-repair-dna-and-regenerate-damaged-heart-tissue 2025-12-04T21:27:14+00:00 hourly 0.9 https://trial.medpath.com/news/ffa6c1ddf09043b7/quotient-sciences-and-intrepid-labs-form-strategic-partnership-to-accelerate-ai-guided-drug-formulation-development 2025-12-04T21:25:59+00:00 hourly 0.9 https://trial.medpath.com/news/f61e545d411f4f36/protara-s-tara-002-cell-therapy-achieves-72-complete-response-rate-in-bcg-naive-bladder-cancer-patients 2025-12-04T21:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/18562304c60e9555/sana-biotechnology-refocuses-pipeline-on-type-1-diabetes-treatment-sc451-and-car-t-platform 2025-12-04T21:25:46+00:00 hourly 0.9 https://trial.medpath.com/news/7bb46c842aecaad2/real-world-data-shows-lecanemab-could-delay-alzheimer-s-progression-by-8-3-years 2025-12-04T21:24:24+00:00 hourly 0.9 https://trial.medpath.com/news/9862f0ff1ab944c7/cu-anschutz-launches-first-in-class-phase-1-trial-combining-parp-inhibitor-with-novel-wnt-pathway-modulator-for-resistant-ovarian-cancer 2025-12-04T21:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/8b1e973021ab6da1/fda-grants-conditional-approval-to-merck-s-exzolt-cattle-ca1-for-new-world-screwworm-prevention-and-treatment 2025-12-04T21:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/47b683d92eb30a6d/als-association-awards-2-million-to-fund-phase-1-trials-of-two-novel-als-therapies 2025-12-04T21:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/0a2ab275f4518c0c/magnetically-controlled-microrobots-show-promise-for-precision-drug-delivery-in-preclinical-studies 2025-12-04T17:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/b22a9105bd6bdb0d/mission-bio-s-single-cell-platform-advances-biomarker-analysis-for-incyte-s-mpn-therapy-at-ash-2025 2025-12-04T17:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/7d71df6b433acaf7/fda-issues-updated-patient-focused-drug-development-guidance-on-clinical-outcome-assessments 2025-12-04T17:35:40+00:00 hourly 0.9 https://trial.medpath.com/news/5a8313b36da64d18/polyrizon-s-naloxone-hydrogel-shows-superior-nasal-adhesion-in-preclinical-study-potentially-improving-overdose-reversal 2025-12-04T17:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/47988839ff6b942d/debiopharm-initiates-phase-iii-trial-for-quarterly-acromegaly-treatment-debio-4126 2025-12-04T17:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/b27b2d8a63377e3b/engineered-herpes-virus-shows-promise-against-treatment-resistant-glioblastoma-in-preclinical-studies 2025-12-04T17:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/e2e4a892a28e6d2d/replicate-bioscience-partners-with-instituto-butantan-to-advance-self-replicating-rna-rabies-vaccine-in-latin-america 2025-12-04T17:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/f337a24f62ccf0c1/gt-biopharma-advances-gtb-3650-to-higher-dose-level-in-phase-1-blood-cancer-trial 2025-12-04T17:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/0761fb45ef60a817/galmed-secures-global-patent-protection-for-aramchol-rezdiffra-combination-therapy-in-mash-treatment 2025-12-04T17:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/7d724bc3b66b823e/luspatercept-shows-survival-advantage-over-esa-in-low-risk-mds-after-three-years 2025-12-04T17:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/80d69f970a62e648/breakthrough-strategy-overcomes-immunotherapy-resistance-in-estrogen-receptor-positive-breast-cancer 2025-12-04T17:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/1f00c99c6ef0e6b8/alpha-9-oncology-initiates-phase-1-trial-of-novel-actinium-225-radiotherapeutic-for-melanoma 2025-12-04T17:29:45+00:00 hourly 0.9 https://trial.medpath.com/news/932782161529d54d/volitionrx-s-sepsis-biomarker-selected-for-eur6-3-million-french-national-healthcare-initiative 2025-12-04T17:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/6295b6fefeae661f/jyong-biotech-signs-mou-with-vietnamese-distributor-to-explore-mcs-2-market-entry 2025-12-04T17:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/bd7b80a597d6032d/sctbio-and-fortrea-form-strategic-partnership-to-accelerate-cell-and-gene-therapy-development 2025-12-04T17:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/5ac06a0afee0bf1c/orano-med-and-roche-advance-novel-two-step-radioimmunotherapy-targeting-cea-positive-cancers 2025-12-04T17:27:26+00:00 hourly 0.9 https://trial.medpath.com/news/844b7353b70d8cc6/fda-approves-plozasiran-for-familial-chylomicronemia-syndrome-marking-breakthrough-in-rare-lipid-disorder-treatment 2025-12-04T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/7f6a2aa8f9ca65ce/esperare-secures-gates-foundation-grant-to-develop-novel-preeclampsia-therapy 2025-12-04T17:26:39+00:00 hourly 0.9 https://trial.medpath.com/news/e0c389ba0da934a2/bioage-labs-reports-positive-phase-1-data-for-brain-penetrant-nlrp3-inhibitor-bge-102 2025-12-04T17:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/82834df7f2804df8/j-d-pharmaceuticals-receives-fda-orphan-drug-designation-for-hepatocellular-carcinoma-treatment 2025-12-04T17:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/d70a2c59527ecd25/bd-and-chemoglo-partner-to-enhance-hazardous-drug-contamination-testing-in-healthcare-facilities 2025-12-04T17:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/04994ef9cd7c9be8/merakris-therapeutics-achieves-fda-alignment-on-mtx-001-development-pathway-for-chronic-venous-leg-ulcers 2025-12-04T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/f0c4187209eac726/italian-no-cut-trial-shows-nonoperative-management-safe-for-rectal-cancer-patients-after-complete-response 2025-12-04T17:24:56+00:00 hourly 0.9 https://trial.medpath.com/news/1a90e68972222fdb/microbiota-therapy-maat013-achieves-62-response-rate-in-refractory-gi-agvhd-phase-3-trial 2025-12-04T17:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/29dad002b2a910b5/fda-proposes-higher-user-fees-for-overseas-phase-i-trials-to-boost-domestic-drug-development 2025-12-04T17:24:23+00:00 hourly 0.9 https://trial.medpath.com/news/280e465e93f63e0c/malawi-becomes-fourth-african-nation-to-approve-lenacapavir-gilead-s-twice-yearly-hiv-prevention-injectable 2025-12-04T17:24:21+00:00 hourly 0.9 https://trial.medpath.com/news/6cb379dd3396696f/hope-medicine-s-hmi-115-receives-fda-fast-track-designation-for-endometriosis-pain-treatment 2025-12-04T17:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/37852e0ad1b1194c/paradigm-health-secures-78-million-series-b-to-expand-ai-powered-clinical-trial-platform-across-us-healthcare-systems 2025-12-04T17:21:59+00:00 hourly 0.9 https://trial.medpath.com/news/cf7d41c264a02611/terasaki-institute-develops-organ-on-chip-platform-to-test-cancer-vaccines-in-aging-populations 2025-12-04T14:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/603ddff22f9ffd37/oral-glp-1-obesity-drugs-set-to-transform-korean-market-as-eli-lilly-and-novo-nordisk-advance-next-generation-therapies 2025-12-04T13:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/bdf08170039e3e1d/brazil-approves-world-s-first-single-dose-dengue-vaccine-following-severe-2024-outbreak 2025-12-04T13:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/b7391d1f8a4e9812/denali-therapeutics-secures-275-million-royalty-deal-with-royalty-pharma-for-hunter-syndrome-therapy 2025-12-04T13:30:42+00:00 hourly 0.9 https://trial.medpath.com/news/610fcfdf96994468/labgenius-and-sanofi-expand-ai-driven-antibody-partnership-with-new-nanobody-optimization-collaboration 2025-12-04T13:30:36+00:00 hourly 0.9 https://trial.medpath.com/news/f1df1f707a40404e/kelun-biotech-and-crescent-biopharma-form-strategic-partnership-to-advance-novel-oncology-therapeutics 2025-12-04T13:30:31+00:00 hourly 0.9 https://trial.medpath.com/news/02e7d65b80daf3c6/formycon-partners-with-ms-pharma-for-keytruda-biosimilar-fyb206-commercialization-in-mena-region 2025-12-04T13:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/e8dadc9989de6099/mabxience-and-hp-develop-ai-powered-digital-twin-for-monoclonal-antibody-manufacturing 2025-12-04T13:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/88bd4503bf1ec155/iqvia-partners-with-aws-to-launch-agentic-ai-platform-for-clinical-trial-automation 2025-12-04T13:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/fee69f0ffd700f26/dupilumab-significantly-improves-quality-of-life-in-chronic-spontaneous-urticaria-patients 2025-12-04T13:29:18+00:00 hourly 0.9 https://trial.medpath.com/news/79ae60c2dd7ecfb5/sanofi-completes-acquisition-of-vicebio-expanding-respiratory-vaccine-portfolio-with-molecular-clamp-technology 2025-12-04T13:29:06+00:00 hourly 0.9 https://trial.medpath.com/news/ddb41b98b1f2c0f6/oxford-begins-first-in-human-trial-of-lassa-fever-vaccine-using-covid-19-platform-technology 2025-12-04T13:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/28b1e22fa0281025/laigo-bio-secures-eur11-5-million-to-advance-novel-protein-degradation-platform-for-cancer-and-autoimmune-diseases 2025-12-04T13:27:51+00:00 hourly 0.9 https://trial.medpath.com/news/b02cc215bc3bef03/actithera-appoints-radiopharmaceutical-veteran-dr-darshan-dalal-as-chief-medical-officer-to-lead-fap-targeting-therapy-development 2025-12-04T13:27:46+00:00 hourly 0.9 https://trial.medpath.com/news/79aa6bd15eef07ca/monte-rosa-therapeutics-reports-promising-mrt-8102-cardiovascular-data-and-prepares-updated-mrt-2359-cancer-results 2025-12-04T13:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/af62f5bc9094f124/lupin-partners-with-valorum-biologics-for-us-launch-of-cancer-biosimilar-armlupeg 2025-12-04T13:26:33+00:00 hourly 0.9 https://trial.medpath.com/news/a21c20ddc0278693/bayer-initiates-phase-iia-trial-for-novel-alport-syndrome-treatment-bay-3401016 2025-12-04T13:26:30+00:00 hourly 0.9 https://trial.medpath.com/news/7ed2625d1777d9e6/ionctura-initiates-phase-i-ii-trial-combining-roginolisib-with-ruxolitinib-for-jak-inhibitor-resistant-myelofibrosis 2025-12-04T13:26:05+00:00 hourly 0.9 https://trial.medpath.com/news/3f950e8759d3e74e/garsorasib-shows-45-5-response-rate-in-kras-g12c-mutated-pancreatic-cancer-patients 2025-12-04T13:26:02+00:00 hourly 0.9 https://trial.medpath.com/news/760eb2867dbbec3a/avencell-therapeutics-receives-fda-and-ema-clearance-for-phase-i-ii-trial-of-dual-target-allogeneic-car-t-therapy 2025-12-04T13:25:55+00:00 hourly 0.9 https://trial.medpath.com/news/c1c0ce7e10d7f1b0/fda-announces-shift-to-single-trial-standard-for-drug-approvals-under-new-commissioner-makary 2025-12-04T13:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/9b90af3cf943de04/atavistik-bio-unveils-novel-jak2-v617f-mutant-selective-inhibitors-for-myeloproliferative-neoplasms-at-ash-2025 2025-12-04T12:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/f4c941fa178e6a92/insilico-medicine-raises-295-million-in-hong-kong-ipo-as-ai-drug-discovery-gains-momentum 2025-12-04T11:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/93c8db7608fa252a/fda-advances-new-approach-methodologies-to-reduce-animal-testing-in-drug-development 2025-12-04T10:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/a95afb1641318d93/cms-proposes-major-medicare-advantage-and-part-d-reforms-for-2027-streamlining-star-ratings-and-drug-coverage-programs 2025-12-04T09:26:55+00:00 hourly 0.9 https://trial.medpath.com/news/eccb2b0d176d1c10/former-fda-and-cdc-leaders-warn-against-proposed-vaccine-policy-changes-amid-acip-deliberations 2025-12-04T09:26:28+00:00 hourly 0.9 https://trial.medpath.com/news/37178bd3da506025/federal-court-of-appeal-upholds-trademark-injunction-against-samsung-bioepis-byooviz-biosimilar 2025-12-04T09:25:50+00:00 hourly 0.9 https://trial.medpath.com/news/7e36c4b214f48ba6/hiropharmaconsulting-receives-japan-s-first-patent-for-ai-enabled-pharmacovigilance-system-validation 2025-12-04T09:25:44+00:00 hourly 0.9 https://trial.medpath.com/news/98c4e1cbfac03a63/argenica-s-arg-007-shows-promise-for-severe-stroke-patients-while-demonstrating-safety-compatibility-with-standard-clot-dissolving-therapies 2025-12-04T09:25:41+00:00 hourly 0.9 https://trial.medpath.com/news/2eefefce0f74d541/novartis-establishes-india-as-largest-r-d-hub-outside-switzerland-with-9000-strong-workforce 2025-12-04T09:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/60f1189fce2a5016/fda-proposes-major-overhaul-of-biosimilar-approval-process-eliminating-most-clinical-studies 2025-12-04T09:25:26+00:00 hourly 0.9 https://trial.medpath.com/news/384c0ad38e958101/liver-cirrhosis-pipeline-shows-strong-growth-with-30-companies-advancing-novel-therapies-through-clinical-trials 2025-12-04T07:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/f04ff6a29c712841/altimmune-announces-ceo-transition-as-pemvidutide-approaches-phase-3-readiness 2025-12-04T06:40:46+00:00 hourly 0.9 https://trial.medpath.com/news/9d41091d93b6b7af/biontech-completes-curevac-acquisition-with-81-74-shareholder-acceptance-consolidating-mrna-technology-portfolio 2025-12-04T06:39:09+00:00 hourly 0.9 https://trial.medpath.com/news/335a9bf26a631674/transthera-s-tinengotinib-receives-priority-review-status-in-china-for-advanced-cholangiocarcinoma-treatment 2025-12-04T06:39:06+00:00 hourly 0.9 https://trial.medpath.com/news/b28447c7d6264d37/novabridge-s-ragistomig-shows-promise-in-checkpoint-inhibitor-resistant-cancers-with-new-q6w-dosing-schedule 2025-12-04T06:38:47+00:00 hourly 0.9 https://trial.medpath.com/news/a9c6c9a41792c931/vera-therapeutics-reports-positive-phase-3-igan-data-prompting-valuation-reassessment 2025-12-04T06:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/4798abc79450c935/nona-biosciences-appoints-dr-hongjiang-miao-as-chief-ai-officer-to-advance-ai-driven-drug-discovery-strategy 2025-12-04T06:38:30+00:00 hourly 0.9 https://trial.medpath.com/news/ecc681bae50acac2/impact-biotech-reports-70-complete-response-rate-in-phase-3-enlighted-trial-of-padeliporfin-vtp-for-low-grade-upper-tract-urothelial-cancer 2025-12-04T06:38:22+00:00 hourly 0.9 https://trial.medpath.com/news/890525eeb2199c25/celltrion-s-ct-p70-adc-receives-fda-fast-track-designation-for-metastatic-lung-cancer 2025-12-04T06:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/eaf019b2c2c325b4/axogen-receives-fda-biologics-license-approval-for-avance-nerve-allograft-marking-regulatory-milestone 2025-12-04T06:37:47+00:00 hourly 0.9 https://trial.medpath.com/news/e1e905d4d398dbed/ucsf-study-shows-promise-for-hiv-functional-cure-through-triple-immunotherapy-approach 2025-12-04T06:37:29+00:00 hourly 0.9 https://trial.medpath.com/news/e4034ab5986fb5cf/janx007-demonstrates-promising-efficacy-and-manageable-safety-profile-in-phase-1-metastatic-prostate-cancer-trial 2025-12-04T06:36:58+00:00 hourly 0.9 https://trial.medpath.com/news/54a9a391c418ffd4/exmoor-pharma-and-ucl-form-strategic-partnership-to-accelerate-cell-and-gene-therapy-development 2025-12-04T06:36:24+00:00 hourly 0.9 https://trial.medpath.com/news/78a3c46ffd9f9f89/fda-accepts-mannkind-s-readyflow-autoinjector-application-for-rapid-furosemide-delivery-in-heart-failure 2025-12-04T06:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/60da5872ffb176fa/larkspur-biosciences-initiates-first-in-human-trial-of-novel-protein-degrader-lrk-4189-for-colorectal-cancer 2025-12-04T06:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/674178517f2f98aa/gensight-biologics-secures-french-regulatory-approvals-for-gs010-lumevoq-gene-therapy-in-rare-blindness-disease 2025-12-04T06:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/7c317e57693ea9e9/lyric-bio-raises-6-6m-to-revolutionize-ivig-production-with-ultra-high-density-bioreactors 2025-12-04T06:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/1aa02c9600a70aee/bayer-launches-phase-iii-trial-testing-mirena-iud-for-precancerous-uterine-condition-with-no-approved-treatments 2025-12-04T06:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/6ba3e38072984997/alpha-tau-receives-fda-approval-for-prostate-cancer-trial-and-presents-pancreatic-cancer-data-at-asco 2025-12-04T06:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/f20b0bfc8e9c238a/tscan-therapeutics-announces-two-year-relapse-data-for-tsc-101-cell-therapy-ahead-of-pivotal-trial-launch 2025-12-04T06:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/f6c01a799e6a66e0/dogwood-therapeutics-secures-26-8m-financing-and-files-new-ip-protection-for-synthetic-halneuron-through-2045 2025-12-04T06:30:35+00:00 hourly 0.9 https://trial.medpath.com/news/f6360c43abd86f6d/advanced-solid-dispersion-techniques-show-promise-for-improving-tegoprazan-bioavailability-in-gerd-treatment 2025-12-04T06:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/56c2576d03c08348/quralis-demonstrates-target-engagement-of-qrl-101-in-als-patients-advancing-precision-medicine-for-neurological-disorders 2025-12-04T06:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/77f16e27afa51ce4/soligenix-advances-hybryte-through-final-phase-3-trial-for-rare-cutaneous-t-cell-lymphoma 2025-12-04T06:27:28+00:00 hourly 0.9 https://trial.medpath.com/news/18d2e82d39bd9fcc/immutep-s-eftilagimod-alfa-shows-strong-response-rates-in-metastatic-breast-cancer-establishes-optimal-dose-for-future-trials 2025-12-04T06:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/9865ce3be5bdc578/scholar-rock-faces-manufacturing-setback-as-fda-issues-warning-letter-to-catalent-partner-ahead-of-apitegromab-launch 2025-12-04T06:26:02+00:00 hourly 0.9 https://trial.medpath.com/news/4aa208e1d6890b36/ventyx-expands-phase-2-recurrent-pericarditis-trial-internationally-adds-industry-veterans-to-advisory-board 2025-12-04T06:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/063b5c13d59333d8/australian-court-rules-formulation-patents-ineligible-for-patent-term-extensions-in-landmark-otsuka-decision 2025-12-04T06:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/7f8e5335ee2a2c27/major-mid-atlantic-insurer-expands-coverage-for-nerivio-migraine-device-providing-access-to-3-4-million-members 2025-12-04T06:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/2b6cec56f4b9012e/novo-nordisk-s-cagrisema-outperforms-ozempic-in-diabetes-trial-company-plans-pediatric-obesity-study 2025-12-04T06:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/f6d28cef03a83bc3/ovid-therapeutics-reports-first-in-human-safety-data-for-novel-kcc2-direct-activator-ov350 2025-12-04T06:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/d69fd6022042aaeb/next-generation-her2-targeted-adcs-show-promise-in-breast-cancer-trials 2025-12-04T06:20:15+00:00 hourly 0.9 https://trial.medpath.com/news/a23f04817fab1eb2/bayer-s-low-dose-mri-contrast-agent-gadoquatrane-shows-promise-in-pediatric-study 2025-12-04T06:20:04+00:00 hourly 0.9 https://trial.medpath.com/news/bc2463c2f444ceb0/lithium-shows-promise-in-suppressing-hiv-reactivation-through-novel-mechanism 2025-12-04T06:19:39+00:00 hourly 0.9 https://trial.medpath.com/news/9b5561fd04b3e517/junevity-raises-20m-to-advance-first-in-class-sirna-cell-reprogramming-therapy-for-metabolic-disorders 2025-12-04T06:16:54+00:00 hourly 0.9 https://trial.medpath.com/news/198da0de0b313e53/experimental-vaccine-provides-year-long-protection-against-deadly-allergic-reactions-in-mice 2025-12-04T06:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/86ee5a6ed1337f0a/aspire-biopharma-advances-sublingual-aspirin-for-heart-attack-treatment-with-fda-pre-ind-submission 2025-12-04T06:15:21+00:00 hourly 0.9 https://trial.medpath.com/news/828a6bc5c3b87465/ultragenyx-advances-multiple-gene-therapies-toward-regulatory-approval-with-dtx401-bla-submission 2025-12-04T06:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/ef4b8d4b6bf557b0/robust-aml-clinical-pipeline-shows-promise-with-100-companies-developing-novel-therapies 2025-12-04T06:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/d4acf20c1400ba0e/foresight-diagnostics-showcases-ultrasensitive-mrd-technology-in-multiple-lymphoma-studies-at-ash-2025 2025-12-04T06:14:18+00:00 hourly 0.9 https://trial.medpath.com/news/beb3c1a58b157f0c/ge-healthcare-and-mayo-clinic-launch-gemini-rt-initiative-to-transform-personalized-radiation-therapy 2025-12-04T06:14:16+00:00 hourly 0.9 https://trial.medpath.com/news/a24053392f613998/real-world-evidence-shows-adalimumab-biosimilars-maintain-efficacy-despite-injection-site-tolerability-concerns 2025-12-04T06:13:33+00:00 hourly 0.9 https://trial.medpath.com/news/8d0e9bc5e9485ad0/rentschler-biopharma-and-coriolis-pharma-form-strategic-alliance-to-deliver-integrated-biopharmaceutical-solutions 2025-12-04T06:11:49+00:00 hourly 0.9 https://trial.medpath.com/news/5d6f401249125d61/fda-clears-francis-medical-s-vanquish-water-vapor-system-for-intermediate-risk-prostate-cancer-treatment 2025-12-04T06:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/d3ba20e7673cad17/epcoritamab-demonstrates-strong-efficacy-in-elderly-dlbcl-and-follicular-lymphoma-patients-at-ash-2024 2025-12-04T06:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/74f6c22f6d1418fb/medtronic-receives-fda-clearance-for-hugo-robotic-surgery-system-in-urology-procedures 2025-12-04T06:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/c038ac4e4ece60af/novo-nordisk-to-launch-ozempic-in-india-this-december-as-competition-intensifies-in-150-billion-weight-loss-market 2025-12-04T06:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/db38270736f7ee33/uk-clinical-trial-recruitment-drops-25-despite-government-reform-efforts 2025-12-04T06:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/60fe722b1a1ef108/eli-lilly-commits-40-million-to-indiana-university-for-ai-enhanced-clinical-trial-infrastructure 2025-12-04T06:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/56bb0028b278c477/arrowhead-pharmaceuticals-receives-fda-breakthrough-therapy-designation-for-plozasiran-in-severe-hypertriglyceridemia 2025-12-04T06:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/1f2870709a2ed837/fda-reduces-surveillance-requirements-for-seastar-medical-s-pediatric-aki-therapy-following-promising-safety-data 2025-12-04T06:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/9aac947d8dad0962/novartis-advances-12-billion-acquisition-of-avidity-biosciences-for-rna-therapeutics-platform 2025-12-04T06:04:20+00:00 hourly 0.9